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CHOLESTEROL METABOLISM AND STATIN EFFECTS  
ON AN FH CLASS II LDL-RECEPTOR MUTATION 
 
Linda Omer 
November 9, 2018 
Familial hypercholesterolemia (FH) is a common genetic disease and has been 
studied with the aim of finding a curative measure for decades. FH is caused by 
mutations in the low-density lipoprotein receptor (LDLR) resulting in defects in LDL-
cholesterol (LDL-C)-receptor mediated endocytosis and development of premature 
cardiovascular disease (CVD). Here I describe the use of a corrected and non-corrected 
LDLR FH cell model to investigate receptor-mediated endocytosis and statin effects.   
For these studies, we reprogrammed FH fibroblast cells to induced pluripotent stem cells 
(iPSC) and confirmed their pluripotency and ability to differentiate to hepatocyte-like 
cells (HLC). A clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated 9 (Cas9) design was created and used to successfully 
correct a 3 base pair deletion in the class II LDLR FH iPSC. Western blot and 
immunocytochemistry analysis showed maturation and proper localization of the LDLR 
after correction in iPSC and HLC. We used internalization analyses to detect LDL-C 
receptor mediated endocytosis in non-corrected and corrected HLC. Real time PCR for 
ER stress markers showed that statin-induced accumulation of an immature LDLR in 
non-corrected FH cells did not activate the unfolded protein response. Together, this 
 vii 
work demonstrates the capacity to utilize the resources of CRISPR, iPSC, and HLC to 
study misfolded class II LDLR providing a physiologically relevant in vitro model for 
investigating the differential effects of mutant versus corrected LDLR-mediated 
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PART I: FAMILIAL HYPERCHOLESTEROLEMIA AND THE LDLR 
 
 
Familial Hypercholesterolemia (FH) 
 
 High serum cholesterol levels are correlated with an increased risk in the 
development of cardiovascular disease. A subset of the population cannot maintain 
cholesterol levels without medical interventions due to genetics.  
Familial hypercholesterolemia (FH) is the most common genetic disease in our 
population, affecting 1:250 people (heterozygous FH, HetFH) [1-3]. As early as 1938, Dr. 
Carl Muller observed “an inborn error of metabolism” or genetic mutation he used to 
describe young patients with both high cholesterol and myocardial infarctions [4]. He 
labeled FH as a single gene-determined autosomal dominant trait. Two decades later, 
researchers studying populations with high incidence of FH believed to be due to a 
founder’s affect confirmed clinically both the HetFH and homozygous FH (HoFH) disease. 
Still then, it was unknown what mutation was causing this hypercholesterolemia.  
Cholesterol is obtained by diet and liver synthesis [5]. Intestinal mucosal cells 
convert dietary cholesterol into lipoproteins. A lipoprotein is a micelle-like structure 
comprised of a nonpolar core containing triacyclglycerols and cholesterol esters 
surrounded by a amphiphilic proteins and cholesterol. There are five classes of lipoproteins 
categorized by density and function: chylomicrons, very low density lipoprotein (VLDL), 
  2 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and high density 
lipoprotein (HDL) [5]. The protein component of the lipoprotein is the apoprotein. Our 
lipoprotein of interest, LDL, contains a single apolipoprotein B-100 (apoB-100) molecule 
that covers half the particle surface [5]. Because LDL is the major carrier of cholesterol, it 
is commonly referred to as LDL-cholesterol (LDL-C).  
 The levels of cholesterol are tightly regulated to maintain balance between 
biosynthesis, utilization, and transport of cholesterol to prevent its accumulation and 
deposition in arteries [6]. Briefly, cholesterol biosynthesis begins when acetate (from 
acetyl-CoA) is converted to isoprene units containing a 5-carbon skeleton. These isoprene 
units will eventually condense to form a linear molecular with 30 carbons that cyclizes to 
form the cholesterol molecule [6].  The process begins in the liver where acetyl-CoA is 
converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase and 
thiolase. The next step is the rate-limiting step of cholesterol biosynthesis. HMG-CoA 
reductase will catalyze the reaction of HMG-CoA to mevalonic acid which will proceed 
through an additional 8-12 steps for the production of cholesterol  [6]. HMG-CoA-
reductase is the enzyme involved in the rate-limiting step in cholesterol synthesis, and is 
regulated through feedback control where the amount of enzyme present in the cell can 
increase or decrease based on the amount of cholesterol in the cell [7]. HMG-CoA is also 
controlled by competitive inhibition, allosteric effects, and covalent modifications that will 
change it from active and less active states [4]. Statins competitively inhibit HMG-CoA 
reductase activity with a greater Km than its HMG-CoA substrate [8, 9].   
In the early 1970s studies on human livers were nearly impossible making it 
difficult to study cholesterol metabolism [10]. To overcome this limitation, investigation 
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using skin fibroblast cells from patients with FH because they were known to express the 
inherited mutation. Normal and FH affected skin fibroblasts were treated with lipoprotein 
deficient serum (LPDS) with or without additional LDL-C [4, 11].  They HMG-CoA-
reductase activity to determine activity in FH patient fibroblasts [11, 12]. In the presence 
of serum, normal fibroblasts had low HMG-CoA-reductase activity while LPDS media 
resulted in a 50-fold increase in HMG-CoA-reductase activity. In addition, they noticed 
the addition of as low a concentration as 5 g/mL LDL would decrease HMG-CoA-
reductase activity [11]. These results allowed them to hypothesize that a receptor might be 
regulating cholesterol uptake since LDL and its concentration were necessary to see 
changes in enzymatic activity of HMG-CoA-reductase.  
In fibroblasts from HoFH patients, there was a 50-100-fold increase in HMG-CoA-
reductase activity even in the presence of lipoproteins [11], and the addition of LPDS with 
or without LDL had no effect on HMG-CoA-reductase activity. This led to their hypothesis 
that HMG-CoA-reductase may be the site of a mutation, causing a break in the feedback 
loop of LDL-C metabolism and hence FH. However, upon the addition of ethanol-
dissolved cholesterol to either normal or affected FH skin cells, enzymatic activity was 
suppressed uniformly [7, 11]. This indicated that HMG-CoA-reductase was not responsible 
for the phenotype of FH.  
To try to solve this mystery, Brown and Goldstein turned to the use of radioiodine 
labeled LDL-C (125I-LDL) and hypothesized that a cell surface receptor must be present 
and responsible for the uptake of LDL-C. Normal and FH fibroblasts were incubated in 
125I-LDL to measure binding [7, 13]. Normal human fibroblasts bound and degraded 125I-
LDL and at a high rate when 125I-LDL was present at a low concentration [7, 13]. This is 
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correlated with a high rate of degradation. However, upon incubation with high levels of 
125I-LDL, the binding decreased and the rate of bound/degraded was similar in both normal 
and FH fibroblasts. It was hypothesized this was due to receptor independent endocytosis. 
In the presence of low or high concentrations of 125I-LDL, HoFH fibroblasts had low 
binding and degradation [7, 13]. Further studies were done to differentiate between 
internalized or surface bound 125I-LDL. Techniques involved experiments at 4 C and 37 
C and the sequential use of buffers that would allow the measurement of bound versus 
internalized 125I-LDL. It was discovered that 125I-LDL-bound to a receptor and remained 
so for no more than 10 minutes [7, 13]. This followed with complete catabolism of 125I-
LDL into its components of amino acids and free fatty acids within an hour. With the 
chloroquine inhibitor and lysosomal defective patient fibroblasts, it was confirmed this 
rapid degradation occurred within the lysosomal vesicle [7, 13]. The free fatty acids 
released by the lysosome then went on to act as an inhibitor of HMG-Co-A reductase, 
inhibiting its activity and therefore cholesterol production [7, 13]. This data clearly 
demonstrated the definite presence of a cell surface receptor that was responsible for the 
binding and endocytosis of LDL-C [7, 13].  
Although most FH is caused by mutations of the low-density lipoprotein receptor 
(LDLR), defects in the apolipoprotein B (ApoB), proprotein convertase kinase 9 (PCSK9), 
and the low-density lipoprotein receptor adaptor protein 1 (ARH) genes are also 
responsible for this disease [14]. This inherited disease can be transmitted through due to 
a single (HetFH) or two defective alleles (HoFH) leading to a range in the development of 
cardiovascular disease. Normal cholesterol levels should be less than 100 mg/dL. As levels 
increase, a person can be considered hypercholesterolemic if levels reach between 150-200 
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mg/dL. HetFH patients are common (1:250) can have LDL-C levels from 200-500 mg/dL. 
The rarer HoFH is present in 1:250,000 people and leads to cholesterol levels as high as 
1000 mg/dL [1-3]. Because of the extremely elevated cholesterol levels, apparent 
symptoms can arise that include cutaneous xanthomas and corneal arcus [14]. HoFH 
patients especially present with murmurs of aortic stenosis and symptoms of ischemic heart 
disease in early childhood [15] which can result in death due to myocardial infraction 
before the age of 25 if left untreated [15-18].  
HetFH is treatable through strict lifestyle requirements such as exercising regularly, 
consuming a low saturated and trans-fat diet, taking medications, and using lipid apheresis 
[15, 19-21]. Several non-curative pharmacologic treatments are available, while new ones 
have been recently approved for FH patients [22-24]. The well-known and most prescribed 
drug is statin [25]. Statins are competitive inhibitors of HMG-CoA reductase and therefore 
(1) inhibit endogenous cholesterol production and (2) upregulate LDLR expression [25]. 
This process forces the cell to scavenge LDL-C that is present in circulation through the 
increased LDLR in a process called LDLR-mediated endocytosis resulting in decreased 
circulating LDL-C levels [9, 25].  
 Although statin treatment has a significant therapeutic benefit in HetFH patients, 
most HoFH patients receive minimal benefit [2, 15, 26]. A non-functional/receptor-
defective/negative patient will be required to supplement their diet with high dose statins 
along with other drugs and alternative treatments such as Mipomersin [2, 15, 26]. 
Mipomersin acts similarly to microRNAs [24]. It is an antisense oligonucleotide that binds 
to the mRNA sequence of ApoB-100, promoting ApoB’s mRNA degradation by 
ribonuclease H [24]. By reducing ApoB-100 production, very low-density lipoprotein 
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(VLDL) generation by the liver is also reduced, consequently decreasing circulating LDL-
C levels. An emerging therapy for FH is the use of monoclonal antibody to PCSK9. PCSK9 
binds to LDLR, accelerating its degradation [27-29]. Within the human population exist 
mutations for PCSK9 loss-of-function that leads to an 88% reduction in coronary artery 
disease (CAD) [27]. PCSK9 binds in the epidermal growth factor (EGF)-A domain of 
LDLR, and mutation of an aspartate residue (Asp310) in LDLR inhibits binding and 
subsequent degradation of LDLR by PCSK9 [28]. Monoclonal antibodies like Evolocumab 
target PCSK9 and are 70% more effective in lowering LDL-C than statins [30]. However, 
receptor negative HoFH patients did not respond to Evolocumab since there is no plasma 
membrane LDLR to target [23]. There was a large variation in response to Evolocumab in 
2 genetically identical homozygous receptor-defective patients. Both began with similar 
baseline LDL-C levels; one patient showed the largest decrease in LDL-C levels while the 
other had the smallest decrease in LDL-C post-clinical trial [22].  Furthermore, statins have 
been shown to upregulate PCSK9, reducing LDLR levels and decreasing statins’ efficacy 
in the more prevalent HetFH [31].  
An alternative treatment for HoFH patients that do not respond to medicinal 
treatments is the dialysis-like lipid apheresis [15, 19]. The aim of lipid apheresis is to 
reduce plasma LDL-C levels to prevent the progression of premature CAD. The technique 
involves “plasma exchange” in which plasma LDL-C is selectively removed without 
affecting other proteins present in the serum [19, 32]. Lipid apheresis is beneficial in having 
shown over a 60% decrease in LDL-C levels. However, upon removal from apheresis, the 
cholesterol levels rebound rapidly [19]. Although this can be the only standard of treatment 
for some patients with HoFH, it is limited in availability, requires frequent trips for dialysis 
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that can cost upwards of $250,000/year, and presents patient complication, such as venous 
access [19].  
 A liver transplant is the only currently definitive cure for FH, but also requires 
lifelong immunosuppressive drugs [3, 33, 34]. It is not the first treatment option, but rather 
a secondary prevention for patients with severe HoFH [34-36]. One study reported that 
after treating 36 FH patients with liver transplants the key to successful liver transplantation 
is timing of transplant [33]. In the study, the majority of patients had LDL-C levels greater 
than 500 mg/dL, and 11 of these patients were under 8 years old [33]. When treatment with 
high dose statins had failed to decrease LDL-C levels, a liver transplant was considered for 
treatment. After liver transplantation, the patients were followed up from six months to six 
years. Three patients under the age of four years died due to cardiac arrest or septicemia 
[33]. Most of the patients showed a regression of xanthomas and normalization of LDL-C 
levels. A seven-year-old boy with severe HoFH presented a drastic reduction in LDL-C 
from 946 mg/dL to 71 mg/dL post-liver transplant; however, he still required an aortic root 
replacement [37]. The current practice is to treat patients with the maximal dose of statins 
and monitor until the necessity for a liver transplant occurs because of the onset of CVD. 
This case helps argue that the timing of transplantation is key to a successful liver 
transplantation, rather than following the current practice [33, 37].  
 An experimental treatment approach for FH involves gene therapy that uses a 
vector to deliver a functional LDLR to the liver [3]. Gene delivery can be performed ex 
vivo, in vitro, and in vivo. Ex vivo gene therapy [38] was one of the first processes used for 
gene therapy [3] and included harvesting the liver resection tissue from an FH patient, 
isolating the autologous hepatocytes, growing the cells in vitro, introducing the LDLR into 
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the cells using a recombinant retrovirus, and delivering the now genetically modified cells 
back into the FH patient [39, 40].  Studies using the Watanabe heritable hyperlipidemic 
rabbit (WHHL), which is considered an authentic model of FH [41], demonstrated that 
transplantation of both normal or genetically altered allogenic hepatocytes could lower 
serum LDL-C in WHHL rabbits. However, the decrease was temporary with the high 
number of rejected allogenic cells likely due to an immune response [42-44]. Instead, 
Wilson and colleagues focused on using autologous retroviral-LDLR expressing 
hepatocytes transplanted back into the WHHL rabbit. The results were a prolonged 
improvement in serum cholesterol levels with liver tissue showing a high level of 
recombinant derived LDLR RNA expression throughout the duration of the six and a half-
month experiment [45].  
 The success of liver-based gene therapy is largely dependent on the method of gene 
delivery. The most efficient method used thus far has been through viral vectors [46-49]. 
Wilson’s group found that the delivery of 0.1 to 1 proviral copy of the LDLR-expressing 
retrovirus into isolated human hepatocytes resulted in LDLR protein levels exceeding the 
normal endogenous levels of the human hepatocytes [40].  In addition, the infection 
efficiency was highest when the cells were exposed to the virus 48 hours post plating, 
allowing gene transduction to be achieved within 72 hours after initial seeding, minimizing 
the time the hepatocytes were in culture prior to transplantation [40].  
When the technique appeared to be successful in the animal models, Wilson moved 
onto clinical trials with FH patients. The trial involved a receptor-defective HoFH patient 
who underwent liver resection followed by transplantation of the genetically modified 
autologous hepatocytes [50]. The patient had a 17% decrease in plasma LDL-C levels after 
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a 25% hepatectomy and re-infusion. She also did not show any immunogenic response to 
the viral vector. This study demonstrated the feasibility, safety, and potential efficacy for 
ex vivo gene therapy in humans [50]. After 2.5 years, the patient still maintained a 20% 
decrease in serum LDL-C levels. However, because the patient was receptor defective but 
had a partially functional LDLR to begin with, there were questions in regard to whether 
patients with different genotypes, including receptor negative LDLR, would respond to this 
treatment. The first pilot study for liver-directed gene therapy to be done in HoFH patients 
included patients ranging in age from 7 to 41 years old and with mutations that resulted in 
receptor defective and receptor negative phenotypes [51]. From the studies, a 12-year-old 
receptor negative HoFH patient showed a significant reduction in serum LDL-C levels post 
gene transfer. Another two patients also showed prolonged reduction in LDL-C levels 4 
months after therapy. However, two patients failed to show any significant changes in 
LDL-C levels. The variability in results led to a halt in the clinical trials [51]. Of 
importance, the isolation and survival of primary hepatocytes for this process was essential 
for the successes seen in the trials. Primary hepatocytes cannot be passaged; therefore, 
transduced cells cannot be selected and expanded [49, 52, 53]. The cells also remain 
differentiated and viable for only a short period of time; Wilson’s experiment showed that 
infecting cells within 48 hours of isolation showed an open window in which the cells were 
most susceptible to infection [54].  
There are still barriers preventing successful gene therapy including 1) vector 
genome persistence in which the expression can vary depending on if the DNA exists as 
an episomal molecule or integrative in the host, 2) loss of gene expression due to 
immunogenicity to the transduced cells or gene product, and 3) their uptake and transport 
  10 
requires tissue specificity but this can be influenced by the organ’s vascular supply and 
endothelial barriers [53, 55, 56]. In addition, their delivery usually requires the stimulation 
of hepatocyte proliferation through either hepatectomy or cytotoxic agents [57-60]. Gene 
correction through gene targeting could provide an alternative approach to correcting the 
mutation in vivo without affecting the rest of the genome.   
Statins 
With the link finally made between risk of heart disease and cholesterol levels, 
many researchers began their focus on finding a molecule inhibitor of any of the 30 steps 
involved in the synthesis of cholesterol [61, 62]. Of the many inhibitors synthesized and 
tested, only one made it to the market, Triparanol (MER/29). MER/29 inhibited 24-
dehydrocholesterol reductase preventing the conversion of desmosterol to cholesterol [63, 
64]. 
   Since MER/29 inhibited the enzyme that catalyzed the final step to cholesterol, it 
caused an accumulation of cholesterol intermediates resulting in severe side effects 
including vision loss due to irreversible cataracts, accelerated atherosclerosis, and even 
alopecia [65, 66].  At this time, other groups studying enzymes discovered the ability of 
antibiotics to inhibit enzymatic activity . An antibiotic that inhibits HMG-CoA-reductase 
in microbes could be lethal to them and successful in mammals. This led Akira Endo’s 
group to hypothesize that fungi like molds and mushrooms could potentially produce 
antibiotics that inhibit the rate-limiting step in cholesterol synthesis thru HMG-Co-A 
reductase and thus, be lethal to these microbes [67]. His group utilized radiolabeled 14C-
acetate active microbial culture broths. The concept was that broths that inhibited the 
incorporation of 14C-acetate into nonsaponifiable (or non-ester bonded) lipids could be 
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tested for their ability to inhibit lipid synthesis from 3H-mevalonate. If a culture broth was 
inactive, it was suspected to contain inhibitory compounds that prevented the early stages 
of cholesterol synthesis from acetate to mevalonate. The isolated compounds were tested 
on rat liver enzymes [67-69].  
Over one year and 3800 fungal strains later, Endo found a mold culture broth 
containing citrinin [70]. Citrinin inhibited HMG-CoA-reductase and even lowered serum 
cholesterol levels in rats [71]. However, the molecule also caused kidney toxicity [71]. 
Eventually, his group found an active culture of blue-green mold, Penicillium citrinum 
Pen51, isolated from a rice sample. They isolated 3 active metabolites through solvent 
extraction, silica gel chromatography, and crystallization [72].  Compactin (ML-236B) was 
the most active and structurally similar to HMG-CoA. Because of this, compactin was an 
extremely effective competitive inhibitor for HMG-CoA-reductase [8]. Unless cells were 
homogenized to dilute compactin in vitro, no HMG-CoA-reductase activity could be 
detected. However, when rats were fed compactin 7 days in a row, there was no reduction 
in serum cholesterol [73]. The caveat of compactin is its ability to lower cholesterol but 
only for 3 to 8 hours after a single dose. After 8 hours, an almost 10-fold induction of 
hepatic HMG-CoA-reductase activity would occur [67, 73]. Endo’s findings suggested 
compactin would still be beneficial but in experimental animals with elevated blood 
cholesterol levels. They showed that in chickens, dogs, and monkeys compactin treatment 
decreased plasma cholesterol levels after a month [67]. With the collaboration of Dr. Akira 
Yamamoto at Osaka University Hospital, compactin was used to treat an 18-year-old 
female FH patient who had serum cholesterol levels of 1000 mg/dL. Within two weeks of 
a daily dose of 500 mg compactin, her serum cholesterol levels dropped to 700 mg/dL. 
  12 
However, she developed muscular dystrophy like symptoms and elevated trans-aminase 
that were reversed upon discontinuation of the high dose of compactin [67, 74]. Reducing 
her dose to 200 mg still resulted in reduced tuberous and Achilles tendon xanthomatosis, 
but no reduction in serum cholesterol levels. Nevertheless, clinical trials continued with 5 
HetFH patients who showed an on average 30% reduction in serum cholesterol levels with 
no adverse side effects [67, 74].  
Many pharmaceutical industries set out to find molecular inhibitors similar to 
compactin. Merck, upon signing a confidentiality agreement with Sankyo, obtained both 
samples of compactin and the experimental data of Endo [67]. With this resource, Merck’s 
scientists developed a structurally similar drug to compactin called mevinolin from the 
fungus Aspergillus terreus [75]. The two compounds differed by only one methyl group 
and displayed similar biological properties [75, 76]. Endo continued his work at Tokyo 
Noko University and isolated another statin named monacolin K from Monascus ruber. 
Surprisingly, monacolin K and mevinolin were the same compound and would be renamed 
Lovastatin [77].  
Clinicians began treating patients with severe hypercholesterolemia with 
Lovastatin and saw their LDL cholesterol levels decrease dramatically with minor side 
effects [78]. In 1986, the Food and Drug Administration approved Lovastatin as the first 
commercially available statin [78]. Since then, another 6 statins have been developed. 
Simvastatin and Pravastatin are semi-synthetic statins that are Lovastatin with either an 
extra methyl group or hydroxyl group, respectively [25]. Four synthetic statins have 
subsequently been developed including Fluvastatin, Rosuvastatin, Pitavastatin, and the 
currently popular Atorvastatin [67]. Many large scale clinical trials, including a five-year 
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study, have all shown the ability of statins to lower LDL-cholesterol and decrease the 
incidence of CVD and stroke by 30% [67]. It is estimated that over 30 million people 
globally take statins generating over $25 billion in revenue [67]. Ideal for modern day 
medicine, a difficulty of statins is the ability to predict an individual’s response and genetic 
predispositions that cause adverse side effects. For example, a study has shown a 45-fold 
variability in plasma Atorvastatin and Rosuvastatin concentration, in patients receiving the 
same dose [9, 79]. Major genetic variants have been linked to both the variability in 
concentration as well as serious side effects seen in certain populations, requiring further 
research to determine statin efficacy and safety on a person-to-person level [9]. 
Interestingly, besides statins primary role in lowering lipids levels, it has also become an 
imperative treatment for the intervention in coronary artery and vascular disease [80, 81], 
rheumatoid arthritis, polycystic ovary syndrome, sepsis, and cancer [81-86].   
 
Low Density Lipoprotein-Receptor (LDLR)  
The LDLR is a cell-surface endocytic receptor responsible for the internalization 
and regulation of LDL-C [4, 87].  The mature LDLR is an 839-amono acid type I 
transmembrane glycoprotein encoded by 18 exons [88, 89]. These 18 exons code for 5 
functional domains (Figure 1).  
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Figure 1. Schematic Representation of the Human LDLR Promoter, Gene, Domain, and 
Protein Structure. The mature LDLR is made up of 18 exons that code for 5 functional 
domains to make up a cell surface endocytic receptor. Mutations have been found in the 
promoter region and the 18 exons leading to dysfunction LDLR structure and/or function. 
Adapted and modified from Faisal A. Al-Allaf et al. Int Arch Med. 2010; 3: 36. [90] 
 
The promoter region for LDLR is made up of three cis-acting DNA sequences, 
which have been found to allow for the ubiquitous and regulated expression of the LDLR 
gene [91, 92]. Repeats 1 and 3 interact with a general factor, Sp1, to promote transcription 
[91, 92]. Repeat 2 contains a conditional-positive sterol regulatory element (SRE-1) that is 
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necessary for sufficient high-level expression of LDLR. If sterols are absent, SRE-1 
synergizes with the two Sp1 sites to promote LDLR transcription. The presence of sterols 
inactivates SRE-1, suppressing LDLR transcription and hence surface LDLR expression 
[4, 93, 94]. 
Exon 1 encodes a short 21 amino acid signal sequence for the LDLR that is cleaved 
upon translocation to the ER [92, 95]. The ligand-binding domain is encoded by exons 2-
6. This domain is made up of 7 repeats termed the LDLR type A repeat (LR). LR’s 1, 2, 6, 
and 7 are each coded by a single exon while LR’s 3-5 are encoded by a single exon. The 
LR’s are 40 amino acids long and contain 6 cysteine residues that form three intra-repeat 
disulfide bonds [92, 95]. The C-terminus of the LR’s also contain a negatively charged 
repeat of Ser-Asp-Glu that is important for Apo B-100, Apo-E, and calcium binding to the 
LDLR.  Of interest, these LR’s have homology to the C9 protein of the complement 
cascade involved in the immune response. The EGF precursor domain is encoded by exons 
7-14 and is made up of 400 amino acids. This region contains 3-40 amino acid cysteine 
rich repeats or 33% sequence identity to the human EGF precursor gene. These cysteine 
rich repeats are different than those found in the LR of the ligand binding domain. The first 
two repeats, EGFP-A and EGFP-B, are contiguous and are separated from the third repeat 
(EGFP-C) by 280 amino acids. This separation sequence contains 5 copies of a conserved 
YWTD (tyrosine, tryptophan, threonine, and aspartate) repeat every 40-60 amino acids. 
EGFP-A’s role is special in that it interacts in a sequence-specific manner with PCSK9 [28, 
96] leading to the early degradation of the LDLR. Otherwise, these EGFP-domains are 
required for the acid-dependent disassociation of the lipoproteins from the receptor in the 
endosome [92].  Exon 15 encodes for an enriched serine and threonine 58-count amino 
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acid sequence. These act as sites for the attachment of O-linked carbohydrates. Deletion of 
exon 15 has not been shown to have any functional consequences in cultured hamster 
fibroblasts [97]. The 22 hydrophobic amino acids of the transmembrane or anchor domain 
of the LDLR is encoded by exon 16 and the 5’ end of exon 17. The last 50 amino acids 
make up the cytoplasmic domain and are encoded by the rest of exon 17 and exon 18. This 
region contains an NPxY motif necessary for the localization of the receptor into clathrin-
coated pits as well as the sorting of the receptor to the basolateral membrane in polarized 
cells [87].  
In normal cells, the LDLR is transcribed and the mRNA is translated in the ER 
where the newly synthesized protein is properly folded into its immature 120-kDa form. 
The manner in which the domains fold into a functional LDLR is still unclear. Interestingly, 
the LDLR has a structure that is vectorially organized—each domain is sequential to the 
next. Even so, it has been shown that the N-terminal repeats will not attain their native 
conformation until 30 minutes after chain termination [98]. Studies using electrophoretic 
mobility assays in combination with metabolic radiolabeling revealed that instead the 
newly synthesized LDLR polypeptide chains folded rapidly into a compact structure with 
creating random disulfide bond interactions connecting distant regions of the LDLR [99, 
100]. Through isomerization, the random disulfide bonds rearranged themselves, allowing 
extension of the LDLR until the native conformation is formed and the only disulfide bonds 
present are between the cysteine residues within each individual LDLR type A repeat [99, 
100]. Interestingly, even when undergoing the extensive formation of non-native disulfide 
bonds during its folding, the LDLR seldom aggregates [98], which has led to the 
assumption that non-native disulfide bonds isomerization process is originally part of the 
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folding of the LDLR. Calcium also plays a significant role in the proper folding and 
function of the LDLR. The cysteine repeats in both the ligand binding domain and the 
EGFP-A and EGFP-B regions have high affinity for calcium ions. Once the native disulfide 
bonds have formed, calcium binds between distal disulfide bonds. This is especially critical 
in the EGFP regions since the calcium ion stabilizes the linker region between the repeats 
and maintains their fixed orientation to each other [101, 102].  
Of course, the proper folding of the LDLR could not be as efficient as it is without 
the assistance of chaperones. Chaperones are important in maintaining newly synthesized 
proteins in a protected environment until its disulfide bonds are formed. Disulfide bonds 
are usually formed in a vectorial manner unless the N and C-termini are in close proximity 
in their tertiary structure. The most well-known and described is Grp78 for glucose-
regulated protein-78-kDa. This ER-localized Hsp70 family member binds transiently to the 
LDLR to assist in its folding after which LDLR is released for transport to the Golgi [98, 
103, 104]. There is some evidence to suggest that Grp78 may prolong its interaction with 
LDLR mutants to aid in folding unless it is misfolded permanently, causing the mutant 
LDLR to be targeted to the cytosolic 26S proteasome for degradation [98, 105]. Another 
chaperone, the 39-kDa-receptor-associated protein (RAP), has also been shown to facilitate 
folding of the LDLR [98, 106, 107]. RAP interacts specifically with nascent LDLR-like 
family members in the ER, blocking the binding sites of the receptors by binding the LDL-
A repeat of the ligand binding domain, allowing for its folding [98, 106, 107]. Willnow 
and colleagues demonstrated that RAP promotes the receptor folding and maturation by 
preventing formation of intermolecular disulfide bonds and aggregation of LDLR [107]. 
However, this was done in overexpression studies in human glioblastoma U87 cells. Others 
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have shown that RAP-deficient mice had normal LDLR levels in the liver but lower LDLR 
levels in brain indicating that RAP may play a role in folding, but only in particular 
pathophysiological conditions [108, 109]. Even less known is the mesoderm development 
(MesD)’s role in the folding of the LDLR. MesD acts as a chaperone to promote plasma 
membrane localization of LDLR-like family members, LRP5 and LRP6 [98, 110]. In S2 
insect cells expressing human LDLR, the insect homologue of MesD, Boca, facilitated the 
folding of LDLR and other LDLR-like proteins [111]. MesD and Boca appear to act on 
proteins containing EGF-like repeats and B-propeller structures indicating a wide range of 
specificity in their substrates of choice [98, 112].  
After it is properly folded, the LDLR is transported to the Golgi complex where it 
matures to a 160-kDa protein through O-glycosylation. The LDLR is then transferred to 
the cell surface where it will bind LDL-C via Apo-B. Here, the LDLR-LDL-C complex is 
internalized through clathrin-coated pits, which fuse with early endosomes. The acidic 
environment of the endosomes triggers a release of the complex as the LDL-C molecule is 
processed for degradation by the lysosome into its basic components for cell 
regulation/structure, and the LDLR is recycled back to the plasma membrane to wait 
another cycle of internalization until its degradation [4, 113].  
Mutations in exons correspond to mutations in its correlative domain and hence the 
physiological function of the LDLR at any step in its life cycle [92, 98, 113, 114]. Over 
1200 mutations in the LDLR have been identified, and they range from small missense 
mutations like SNPs and indels (58%), nonsense mutations (10.4%), and 
deletions/insertions (22%) to larger rearrangements of splicing defects (9.4%) [95]. About 
half of all mutant LDLR genes produce receptors with partial function due to a point 
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mutation that causes a partial defect in the folding of the LDLR, its transfer to the cell 
surface, or its ability to bind LDL-C [95]. A patient with this kind of mutation has reduced, 
but not null, LDLR activity and is called receptor-defective. The other 50% mutant of 
LDLR genes are true null alleles that fail to produce any detectable LDLR activity [91, 95]. 
The latter is called receptor-negative. Some HoFH patients are genetic compounds with 
two different mutant alleles, referred to as compound heterozygotes. Receptor-deficient 
patients are more likely to respond to drugs like statins since there is some LDLR activity 
to stimulate. HoFH receptor-negative patients usually die prior to age 20 without 
aggressive therapy and can pass as early as 4 years [2, 15, 18]. LDLR mutations have been 
classified into 6 classes.  
Class I mutations are described as null alleles due to the absence of protein caused 
by lack of processed mRNA into the secretory pathway [87, 92, 98]. Some of these null 
alleles produce no LDLR mRNA due to deletions in exons 1 or the promoter. However, 
most Class I null alleles do produce LDLR mRNA but with either rapid mRNA turnover 
due to non-sense mutations in exons 2 and 8 or premature termination codons due to 
deletions in parts of exons 13, 14, or 15 [92]. Class II or transport defective alleles affect 
the transport of the LDLR from the ER to Golgi and will be discussed in further detail 
below (Figure 2). Class III mutant receptors do reach the cell surface but are unable to 
bind LDL-C [92, 98] because of mutations in the LR repeat of the ligand binding domain 
results in the same dysfunction as deleting the entire repeat [92]. Class IV mutations are 
internalization defective alleles in which LDLR will bind LDL-C but the LDLR-LDL-C 
complex cannot be endocytosed [92, 98]. These rare mutations in the cytoplasmic domain 
called 4A or in the transmembrane domain called 4B [95], affect the ability of clathrin-
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coated pits to internalize the complex [92, 98]. Recycling deficient alleles cannot release 
the LDL-C ligand from LDLR and are targeted to the endosome for early degradation 
instead of recycling back to the plasma membrane [92, 98]. The Class V mutations are 
usually the result of mutations in the EGFP domain that is responsible for acid-dependent 
dissociation of the receptor and ligand (Figure 2). The most recently described group of 
LDLR mutants, termed Class VI, contain LDLR’s that mislocalize to the apical instead of 
the basolateral membrane in polarized cells [98, 115]. Over 50% of mutations have been 
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Figure 2. Schematic Representation of Human LDL-Receptor Mediated Endocytosis. 
LDLR is synthesized on the endoplasmic reticulum (ER) and processed into an immature 
120-kDa protein. It is then shuttled to the Golgi for further processing into a mature 160-
kDa LDLR. The mature LDLR is transported and inserted into the plasma membrane where 
it will bind an LDL-C molecule through apoB-100 interaction. This complex will be 
internalized through clathrin-coated pits and fuse with an endosome where a lower pH 
causes the release of the LDL-C from LDLR. The LDLR is recycled back to the plasma 
membrane to repeat this cycle approximately 100 times before it is degraded by the 
lysosome. There are 5 classes of mutations that affect the LDLR life cycle; 1) Lack of 
processed mRNA, 2) transport-defective, 3) LDL-C binding defect, 4) Clustering defect, 
and 5) early degradation defect. Class 2 mutations make up 50% of FH LDLR mutations. 
Promoter adapted and modified from Faisal A. Al-Allaf et al. Int Arch Med. 2010; 3: 36. 
[90] 
 
Class II LDLR Mutation 
   The normal LDLR is synthesized in the ER as a partially glycosylated precursor 
of 120-kDa. Upon reaching the Golgi, N-and O-linked sugars are added yielding a 
molecular weight of 160-kDa. Pulse chase experiments have shown this process to occur 
within an hour after synthesis [116, 117]. This process is delayed or completely abolished 
when LDLR contains class II mutations [92]. Instead, the LDLR doesn’t leave the ER [118] 
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and remains at 120-kDa until it is degraded [92, 98, 119]. Over 50% of FH mutations 
identified have been classified as class II transport defective mutations. Because this 
mutation results in a misfolded LDLR unable to leave the ER, it is commonly referred to 
as a “folding or conformational disease” [98, 120, 121]. 
 Class II defects have been clustered in the exons that encode for the ligand binding 
and EGFP homology domains [92, 114, 117]. Mutations affecting the cysteine-rich repeats 
present in both domains appear to be casually linked to the slowing or halting of the LDLR 
from the ER. Russell’s group was the first to isolate the cDNA sequence of the 12-base 
pair deletion found in the 3rd cysteine-rich repeat of the ligand-binding domain in the FH 
Watanabe rabbit [122]. This in-frame deletion eliminates 4 amino acids and hence disrupts 
the LDLR’s movement from the ER to the Golgi. Although the deletion did not actually 
remove any of the cysteine residues, the change in amino acids present likely altered the 
folding pattern of the protein and prevented proper disulfide bond formation [122].  
Class IIA vs IIB 
Class II mutations can be further divided into two categories depending on the 
percent activity of the LDLR. Mutations that completely block receptor transport out of the 
ER are designated as class IIA mutations [91, 92, 114]. Class IIA mutations have been 
linked to mutations in the EGFP homology domain, sometimes within one of the 3 
cysteine-rich repeats or within the YWTD region between repeats B and C [92]. A 
particular class IIA mutation, p.G565V, is completely retained in the ER as shown through 
co-localization western blot [123, 124] and has no surface LDLR or LDL internalization 
demonstrated by flow cytometry [123]. Jorgensen et al demonstrated two-class IIA mutant 
LDLRs, C646Y and W556S, were totally retained in the ER and bound to Grp78 [125]. A 
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pulse-chase experiment followed by SDS-PAGE  of Class IIA FH429 and FH261 
fibroblasts showed zero mature LDLR compared to normal fibroblasts nearly all-mature 
LDLR [118].  
Class IIB mutations produce LDLRs that are transported at a measurable but 
reduced rate [91, 92, 114]. These mutations appear to change the spacing between the 
highly conserved cysteine residues thereby interfering with disulfide bond formation and 
proper protein folding [92, 114, 122]. Studies in fibroblasts carrying Class IIB mutations 
showed less than 5% conversion of immature to mature LDLR [118]. This extreme case in 
Class IIB is due to the fact that the cell line used was from a HoFH patient. Cases of Class 
IIB mutations that are heterozygous do not have such a significant presence of immature 
LDLR.  
FH Piscataway 
FH Piscataway is named from a young American HoFH patient from Piscataway, 
New Jersey [92]. The mutation, FH563, is localized to the 5th repeat of the ligand-binding 
domain causing a 3-base pair deletion of TGG in exon 4 of the LDLR [117, 122, 126]. This 
removes glycine-197 and results in an in-frame mutation. When Russell’s group was 
identifying if deletions in the cysteine-rich repeats of the LDLR would affect transport, 
they used both the Watanabe rabbit (12 base pair deletion) and human FH563 fibroblast 
cells [122].  
 Pulse-chase experiments with FH563 and normal fibroblasts followed by 
immunoprecipitation with a monoclonal LDLR antibody [122], unsurprisingly 
demonstrated that the normal fibroblasts’ LDLR had been transported to the Golgi for 
processing to the mature 160-kDa proteins within 30 minutes. 95% of the FH563 LDLR 
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remained as 120-kDa after 2 hours. The heterozygous parents’ fibroblasts were also pulse-
chased and showed that after 2 hours, half of their LDLR’s were mature and the other half 
still in precursor form. This indicated FH563 inherited the same mutant allele from each 
parent and was homozygous for a transport-deficient receptor similar to the Watanabe 
rabbit [122].  
 FH563 fibroblasts were also carefully studied through electron microscopy to 
identify the distribution of the intracellular LDLR [118]. Less than 5% of LDLR was 
detectable on the cell surface and in coated pits or vesicles in the endocytic pathway unlike 
normal fibroblast LDLR with almost all LDLR found in coated pits. Instead, most of the 
FH563 LDLR was present in membrane extensions of the rough ER [118]. It’s 
hypothesized that the extensions the mutant LDLR is localized is the site where the ER is 
blocking exit of the LDLR and appeared to be morphologically similar to the transitional 
zone of the ER implicated in transport of secretory proteins to the Golgi [118, 127]. My 
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PART II: GENOME EDITING AND CRISPR/Cas9 
 
Genetic Mutations and Disease 
Genetic mapping is a process that has and is used to link transmittance of a disease 
from parent to child through at least one gene. DNA markers isolated from both the affected 
and normal family members are used to pinpoint the disease-causing gene [128]. Genetic 
mapping has come a long way since the first mapping of a genetic disease marker (found 
in Huntington’s disease on chromosome four) and the first comprehensive genetic map 
produced based on DNA sequencing with restriction enzymes. The first draft of the human 
genome was completed in 2003 and revealed over 20,000 genes [129].  Of those genes, 
3500 have been linked to genetic diseases [130]. Monogenic diseases are usually inherited 
via the classical Mendelian inheritance pattern. These genetic mutations occur in less than 
1% of the population. The most common contributor of genetic variation is due to single-
nucleotide polymorphisms (SNPs). One nucleotide change in the 3.2-billion nucleotide 
pairs can lead to an amino acid conversion altering a protein’s structure or function.   
Understanding the causal link of a disease is necessary to create a treatment plan 
for the patients. Therapies vary across diseases from surgical treatment to dietary 
restrictions, pharmaceuticals, and gene/cell therapy. Some disorders currently have no 
form of treatment and require further studies to understand the disease and identify 
potential treatments. The development of animal models to mimic a mutant phenotype 
has proved beneficial in the research and clinical field in allowing translation of animal 
models in clinical development for patient treatments.  
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History of Genome Editing 
Homologous recombination (HR) is the genome’s natural system to create both 
genetic diversity and repair DNA damage [131-133]. Capecchi and Smithies were the first 
investigators to demonstrate homologous recombination induction in mammalian cells 
between transfected plasmids [134]. Smithies’ lab continued advancing HR in vitro in a 
substantial way: they showed that co-transfection of two non-overlapping exogenous DNA 
mutants into a somatic mammalian cell line would yield neomycin-resistant cells through 
HR [135]. Of importance, this study showed that HR increased 10-fold when a double 
stranded break (DSB) was introduced into one of the input plasmids. This provided the 
foundation for others to work at optimizing HR-DSB repair by modifying cell cycle 
introduction, gene homology length, introduction of double-stranded gaps, and the use of 
linear or circular plasmids [136-140]. This was followed with the correction of a deletion 
in the hypoxanthine-guanine phosphoribosyl transferase (Hprt) gene in a Hprt-/- mouse 
embryonic stem cell (ES) line using the “pre-treated” or cut exogenous DNA [141].  
A major step was taken when two labs that introduced Hprt-/- mouse ES into mouse 
blastocysts through microinjection produced chimeric mice [142, 143].  Further enhancing 
this field, Bradely’s lab observed that HR using an insertion vector targeting Hprt in murine 
ES occurred nine times more frequently than with a replacement vector containing the same 
homologous sequences [144]. Site-directed mutagenesis through the combination of HDR 
and ES cells provided the platform for future development of mouse models to study 
human disease.   
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Gene Targeting 
 Specific gene modification is referred to as gene targeting [145]. Initially, the 
tedious method of genetic manipulation resulted in a low number of cells containing the 
modification. Evidence suggested that adding DSB with an endonuclease occurred during 
metabolic processes such as the production of antibodies [146-150]. In 1995, Jasin et al 
was the first group to introduce DSBs in the genome of mouse cells. They used the yeast 
S. cerevisiae endonuclease, I-SceI [151, 152]. The repair of the DSBs also required the use 
of donor DNA template that contained homology-flanking arms and the mutation of 
interest. This increased targeting efficiency 100-fold compared to no homology-flanking 
arms, providing further evidence that a template containing a certain length of homology 
on either side was necessary for successful gene targeting [153]. Although beneficial, this 
also limited the number of sites for modification.  In addition, the DNA recognition site 
and cleavage function are intertwined into a domain, making it more challenging to modify 
the sites of recognition creating a highly inefficient system.  
 By contrast, zinc-finger nucleases (ZFNs) contain distinct domains for DNA 
recognition and nuclease activity. ZFNs were developed by combining the cleavage 
domain of bacterial FokI-endonuclease and two different zinc finger proteins [154-156]. 
Zinc fingers domains are one of the most abundant DNA binding molecules in mammals, 
containing 4000 binding regions within the genome [145]. A finger is made up of 30 amino 
acids with histidine and cysteine residues coordinating a single zinc atom within a beta-
beta-alpha helix structure. This finger contacts primarily 3 nucleotides and this 3-bp target 
is specific to each finger. In addition, each nucleotide contacts a single amino acid side 
chain projecting from one end of the zinc finger alpha helical structure. This means that 
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multiple zinc fingers could be combined to target multiple sites and amino-acid changes in 
the alpha helix altering specificity of the zinc finger. Flavobacterium okeanokoites or Fok 
bacteria contain an endonuclease with a nonspecific DNA-cleavage activity in its C-
terminal domain. Its N-terminal domain contains a DNA binding domain. Combining the 
endonuclease domain of Fok with a zinc-finger protein, a chimeric restriction enzyme was 
created called the ZFN that will only generate a DSB when dimerized to its target site 
[145]. The zinc finger binds to the DNA by inserting an alpha-helix into the major groove 
of the DNA double helix. Each finger makes its own unique contact with the DNA due to 
variations in the amino acid side chains that make up the ZF. The full structure of the ZFN 
is  N-terminal ZF DNA binding domain, a variable peptide linker, and the C-terminal FokI 
domain. After much optimization, it was demonstrated that inverse orientation, a six base 
pair space between binding sites, and no linker between the ZF and nuclease domain 
produced the most efficient cleavage and recombination. To promote genome editing, a 
pair of ZFNs must bind to a target site, one recognizing the forward strand of a target site 
and the other the reverse strand of the target [131]. Upon binding to their sites, the pair of 
Fok1 domains dimerize and cleave the DNA target, creating a DSB with a 5’ overhang. 
This break is repaired either through non-homologous end joining (NHEJ) or homology-
directed repair (HDR) [131] (Figure 3). The first mammalian cells targeted with ZFNs by 
Porteus and Baltimore integrated a GFP reporter into human embryonic kidney cells 
(HEK293) [157]. Fast forward to more recent work in modifying the human genome in 
CD4+ T-cells with ZFNs. Holmes group shows that ZFNs targeting X-linked severe 
combined immune deficiency (SCID) mutation in IL2RG gene had the ability to modify 
the genetic disease mutation on both chromosomes at a high frequency in human T cells 
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[158].  Despite ZFNs availability, it has proven difficult to engineer ZFNs to bind extended 
stretches of nucleotides with high affinity. An academic consortium developed an open-
source library of ZFNs and protocols to help alleviate this challenge so that others may 
identify ZFNs that bind to desired sequences with high affinity [131, 159].  
 Transcription activator-like effector nucleases (TALENs) use an even simpler 
method for identifying DNA than ZFNs (Figure 3). The TAL effector domain was 
discovered in a plant pathogen, Xanthomonas, and consists of 10-30 tandem repeats. A 
single repeat domain can identify a single nucleotide by using 2 amino acid residues also 
called the repeat variable di-residues (RVDs) [160, 161]. Because of the simplicity in its 
recognition of DNA, TALEN is easily customized for its target DNA and only requires to 
be conjugated to the FokI nuclease domain used with ZFNs. The RVD code can be 
modified resulting in an increased binding affinity to target DNA sequences [131]. 
TALENs are designed similar to ZFNs. The TALE central DNA-binding repeat is fused to 
the FokI catalytic domain through a linker. It’s been shown that TALENs are most 
functional when the spacer length is between 12-30 bp. In addition, TALENs have been 
shown to have fewer context-dependent effects [162]. Another plus of TALENs is the 
ability of the TALE repeat to be designed to target 18-bp of DNA or even longer [163]. 
Because of their ability to be created in a short amount of time and at a high volume, a 
library of TALENs targeting all of the genes in the genome has been created [131]. A 
disadvantage of TALENs is their cumbersome size, at least in comparison to ZFNs [131]. 
The cDNA encoding ZFNs is about 1 kb while the TALEN cDNA is 3 kb making the 
delivery more difficult. 
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The main limitation of both ZFNs and TALENs are their inability to be used in 
high-throughput applications. Because they function through protein-DNA interactions, 
each target site requires engineering and cloning of a new protein [145]. In contrast, 
CRISPR/Cas9 is a RNA-guided nuclease whose sequence specificity is through Watson-
Crick base pairing between its guide RNA and target DNA site [164].  
 
 
Figure 3. Representation of Tools and their Mechanisms for Genome Editing and DSB 
Repair. Zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) and 
CRISPR-associated proteins (Cas) are genome modifying tools that have been utilized to 
induce double stranded breaks (DSBs) in DNA. ZFN and TALEN require the use of 2 
DNA-recognizing proteins conjugated to a nuclease to create a DSB. CRISPR/Cas is an 
RNA-guided system that uses a single nuclease and guide RNA for a DSB. DSBs are 
repaired either through non-homologous end joining (NHEJ) or homology-directed repair 
(HDR). Adapted from Hao Yin et al. Nat Rev Drug Discov. 2017; 16 (6): 387-99. [165] 
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CRISPR 
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-
associated proteins (Cas) are an RNA-mediated immune response mechanism used by 
bacteria to prevent the invasion of foreign DNA like viruses and other bacteria [131, 145, 
166]. The Cas protein can be programmed to target any site by changing its guide RNA 
sequence, providing a platform for high-throughput applications [164]. Before proceeding 
to its mechanism of action, its historical discovery deserves acknowledgement.  
In the early 1990s, Dr. Francisco Mojica characterized the CRISPR locus in an 
archaeal microbe, Haloferax mediterranei, that grew in the extremely salty marshes off the 
coast of Santa Pola near the laboratory where he worked  [131, 167]. Prior to this, Japanese 
researchers had described the presence of short direct repeats interspaced with short 
sequences within the genome of E. coli [168]. Through bioinformatics studies, the CRISPR 
loci would be found in 20 different microbes [169]. However, the function of these repeats 
was still unknown as were the “spacer sequences” between them. He used BLAST to 
analyze the unknown sequences. Eventually, a spacer matched the sequence of a P1 phage 
in an E. coli strain that was also resistant to this infectant [170]. Continuing his BLAST 
work on thousands of bacterial strains, of 88 with similar sequences, he found 2/3 of the 
spacers coding for viruses or conjugative plasmids. It was concluded that the CRISPR loci 
encoded the instructions for an adaptive immune response that protected microbes against 
specific infections [167, 170].  Another group in the French Ministry of Defense had come 
to a similar conclusion after finding identical tandem-repeat loci in closely related isolates 
from a Y. pestis bacterial strain from Vietnam [167, 171]. Instead of an immune response, 
they claimed, “CRISPR may represent a memory of past genetic aggressions” [172].  
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The search went on to investigate if CRISPR was truly an adaptive immune 
mechanism in bacteria. A group of Dutch scientists working in a food laboratory at Danisco 
were interested in the correlation between phage resistance and the spacers in CRISPR 
[167]. They focused on using S. thermophilus, since it’s mainly used in the dairy industry 
to produce yogurt and cheese. It is also phage sensitive and prone to phage attacks during 
yogurt making [173]. They infected the sensitive S. thermophilus until they were able to 
genetically isolate now phage-resistant bacteria [167, 173]. The resistant strains acquired 
phage-derived sequences in their CRISPR loci and the more inserted spacers acquired, the 
increased resistance the bacteria demonstrated giving them immunity against subsequent 
bacteriophage infections [173]. In addition, they discovered that a cas7 gene coding for 
Cas7 protein helped generate new spacer and repeats but not resistance. The cas9 
(originally called cas5) gene coding for Cas9 protein with two catalytic nuclease domains 
was needed for phage resistance [174, 175]; hence, it was actively involved in the now 
confirmed CRISPR adaptive immune response.  
Van der Oost’s group at Wageningen University in Amsterdam took on the task of 
characterizing Cas proteins [167, 176]. His group took a CRISPR deficient E. coli strain 
and transferred into it the CRISPR of another E. coli strain. They knocked out single genes 
and discovered that the whole system was essential to produce a 61-nucletoide long 
CRISPR RNA (crRNA) from a long precursor RNA transcribed from the CRISPR locus 
[176]. They performed a co-immunoprecipitation study of the Cas proteins followed by 
cloning and sequencing of the associated crRNA. This demonstrated that all the Cas 
proteins began with the 8 final bases of the repeat sequences followed by the spacer 
sequence and the start of the next repeat region [176]. It was necessary to verify that crRNA 
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is what confers CRISPR-based resistance. For this, they created a CRISPR array to target 
4 genes in the lambda phage using either anti-sense or sense sequences. The bacteria 
carrying this artificially designed CRISPR conferred resistance to the lambda phage, and 
even more so efficiently in the group carrying the sense strand [176]. This provided 
evidence that CRISPR could be directly programmed and led to a hypothesis of CRISPR 
targeting DNA [176]. 
Marraffini and Sontheimer at Northwestern University studied Staphylococcus’s 
CRISPR system and noticed that the nickase gene (nes) on plasmids from the antibiotic 
resistant S. aureus was also present in the spacer sequence of S. epidermidis. Transfection 
of the S. aureus plasmid into the S. epidermidis bacteria was blocked and unable to be 
transferred. If the nes sequence was disrupted by the plasmid or spacer sequence, the 
plasmid was not blocked from interfering into the S. epidermidis [177]. Utilizing the nes 
gene in the plasmid, they inserted a self-splicing intron in the middle of the sequence. The 
idea was that if mRNA was targeted by CRISPR, the intronic sequence would be spliced 
out, and therefore, the plasmid would not affect interference. If DNA was targeted by 
CRISPR, the intron would prevent the spacer from matching with the plasmid DNA. It 
turned out that the spacer would not match the plasmid DNA and interfered with the 
CRISPR activity, clearly showing that DNA was targeted by CRISPR [177]. It’s important 
to note that there is another CRISPR system that specifically targets RNA [178]. Through 
this discovery, they were the first to state that Cas was a programmable restriction enzyme 
and could potentially be used outside of bacterial systems [167].  
The group at Danisco’s food laboratory continued on working with CRISPR after 
confirming it was a bacterial adaptive immune response [173]. Their next step was to 
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dissect the mechanism by which CRISPR/Cas cleaved DNA. To do this, they transfected 
plasmid free S. thermophilus with vector pNT1, derived from a native S. thermophilus and 
carries a chloramphenicol-resistance gene as its selection marker. These strains were also 
either cas5 or cas7 gene negative. Cas5 (now known as cas9) is involved in interference 
while cas7 plays a role in spacer acquisition [173]. Newly sensitive colonies were screened 
and from the 54, 30 were found to have acquired a new spacer-repeat in their CRISPR loci 
and had also lost the pNT1 vector. Interestingly, 14 different variations of spacers were 
found in these bacteria, all homologous to pNT1 sequences [179]. In addition, consistent 
with previous evidence, no chloramphenicol-sensitive colonies were isolated from the cas5 
deficient bacteria that also retained their pNT1 plasmid. The cas7 deficient bacteria did 
produce chloramphenicol-sensitive colonies; however, none of the colonies had acquired a 
new spacer in their CRISPR loci, indicating pNT1 loss was due to other circumstances. 
Within these two groups, they found strains with CRISPR conferred partial protection 
against pNT1 transformation [179]. One strain even contained a linearized pNT1 plasmid. 
They used this linearized plasmid to study the cutting process of CRISPR and found that it 
was specifically Cas5’s endonuclease protospacer specific and orientation dependent 
activity that cleaved both bacteriophage and plasmid DNA in vitro [179]. In the presence 
of Cas5, the linearized plasmid contained a single blunt end cut event 3 nucleotides 
upstream of the protospacer adjacent motif sequence or PAM site [179]. The PAM site is 
a homologous spacer region in the phage genome that also must be present in the target 
DNA to provide immunity. The PAM site is unique to each CRISPR system in providing 
a sequence recognition pattern for the Cas enzymes to function [173, 180, 181]. Garneau 
also showed that the cuts made were in the same position relative to the PAM site regardless 
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if the positive or negative DNA strand was present or if it was in early or late transcription. 
Altogether, this work showed that Cas9 was the nuclease cutting DNA and at specific 
positions encoded by the crRNAs [167].  
In another collaborative effort to dissect S. pyogenes and its RNAs that could be 
involved in virulence control, another required component of the CRISPR system was 
discovered [182]. Charpentier’s group used differential RNA sequencing of a class II 
CRISPR system. They retrieved data that small crRNAs originally from a 511-nucleotide 
pre-crRNA was the most abundantly expressed. These crRNAs were between 39-42 
nucleotides long and low in primary transcript number indicating they likely were 
processed RNA. The third most expressed transcript present was small trans-activating 
CRISPR RNA (tracrRNA). These were different lengths of 171, 89, 75, and 65 nucleotides. 
The 171 and 89 nucleotide tracrRNA both contained a 25-nucleotide stretch of almost 
identical complementarity to the CRISPR repeats [182]. They hypothesized these 
differences in sizes were likely due to potential base-pairing between tracrRNA and pre-
crRNA that lead to their co-processing and eventual generation of mature crRNA for 
CRISPR function. To test this, they created in frame deletions within either tracrRNA or 
pre-crRNA. Mature crRNA was absent in the mutant tracrRNA and the 75-nucleotide form 
of tracrRNA was not present in the pre-crRNA mutant. The addition of long tracrRNA 
restored pre-crRNA, processing in the mutant tracrRNA bacteria while an 89-nucleotide 
tracrRNA appeared once pre-crRNA function was restored. This indicated that non-coding 
RNAs, tracrRNA and pre-crRNA are required for the function of CRISPR; specifically, it 
is the tracrRNA that directs the maturation of pre-crRNA so that it may target DNA for 
cleavage by Cas enzymes [182]. Of interest, Charpentier’s group also found that it was an 
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RNase III-Csn1 complex that processed the tracrRNA-pre-crRNA to mature crRNA and 
the tracrRNA has the ability to form a stem-loop/inter-molecular RNA structure for pre-
crRNA processing [182].  
At this point, Sapranauskas in Virginijus Siksnys’ lab was working on cloning the 
now well-known CRISPR system of S. thermophilus into a different bacterial genus, E. 
coli. Transfer of the system into E. coli provided protection against bacteriophage infection 
and plasmid transformation [183]. In addition, they found that the Cas9 protein was the 
sole endonuclease necessary for both crRNA maturation and DNA cleavage [183]. 
Gasiunas in Siksnys’ lab continued on to study Cas9-crRNA interaction [184]. Cas9 is a 
large multi-domain protein with 2 catalytic domains, HNH and RuvC [183, 184]. These 
two domains have been shown necessary for interference in vivo [183]. Although Cas9 was 
known to be necessary for the steps of crRNA maturation and DNA cleavage [174, 175], 
it was still unclear which motifs served which purpose. Gasiunas and his colleagues worked 
to isolate the Cas9-crRNA complex, using streptavidin-labeled Cas9 in S. thermophilus 
[184], and confirmed the presence of a 42-nucleotide crRNA that co-purified with the Cas9. 
Using a 55-nucleotide oligoduplex containing a PAM site with flanking identical sequences 
and a protospacer between them, they demonstrated that the Cas9-crRNA complex cleaved 
dsDNA 3-nucleotides away from the terminal end of the protospacer-adjacent to the PAM, 
leaving blunt ends and only in the presence of magnesium ions. This cleavage did not occur 
in the absence of the crRNA and a PAM site. They then went on and mutated each catalytic 
motif to identify each one’s role in the nuclease. The RuvC mutant domain generated 
nicked DNA cutting the positive DNA strand (non-complementary) and the HNH mutant 
cleaved the negative strand only (complementary DNA), indicating each domain is active 
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on opposite strands to produce a DSB. These results clearly demonstrated a mechanism for 
CRISPR’s action [184].  
Charpentier, in collaboration with Jennifer Doudna, also worked on the mechanism 
of CRISPR [167]. After purifying Cas9 from S. pyogenes, they tested its DNA, cleaving 
ability in the presence of mature crRNA, complementary to the target DNA and the absence 
of tracrRNA. No DNA cleavage was present until they added magnesium and tracrRNA, 
which pairs with the repeat sequence of crRNA and allows its maturation. They also found 
that the DNA cleavage occurred 3 base pairs upstream of the PAM sequence, producing a 
blunt cut [185]. After creating point mutations in the catalytic domains of Cas9, they 
demonstrated that each catalytic domain cleaves the opposite DNA strand. Using an 
electromobility shift assay, they also demonstrated that tracrRNA is required for target 
DNA recognition. Then, using different length tracrRNA lacking 5’ or 3’ ends and either 
a full-length mature crRNA or ones lacking the 5’ or 3’ end as well, their group found that 
truncated tracrRNA was still capable of supporting DNA cleavage. Truncation of the 5’ 
end of the crRNA abolished DNA cleavage while truncation of the 3’ end of crRNA still 
allowed DNA cleavage. This indicated to them that there must be a critical structure formed 
between the RNAs to allow this process to occur. Charpentier and Doudna’s group 
describes the PAM sequence as a short sequence motif that allows the recognition of self-
versus non-self in the foreign genome [185]. The PAM sequence of Type II CRISPR 
systems is a NGG consensus sequence. Jinek mutated the PAM site of an oligonucleotide 
and found that the GG was necessary for efficient DNA cleavage and either one’s mutation 
reduced affinity of Cas9-tracrRNA-crRNA to the DNA. At this point, it had been observed 
that crRNA and tracrRNA functioned as individual components; however, whether they 
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combined into a single unit to complete the mechanism of CRISPR was unknown. Jinek et 
al designed a chimeric RNA containing a target recognition sequence at the 5’ end followed 
by a hairpin structure to maintain the base-pairing interaction between the tracrRNA and 
crRNA. Using GFP as the target gene, chimeric guide RNAs targeting GFP were able to 
cleave the DNA efficiently. This was a logical design of chimeric RNA that realistically 
could be programmed for a DNA target-binding sequence similar or more easily than ZFNs 
and TALENs [185].  
  Altering the mammalian genome using CRISPR was the next feat at task. Feng 
Zhang’s lab at MIT proved to be the first group to engineer CRISPR/Cas systems to cleave 
genomic DNA in human and mouse cells [186]. Bacteria cells do not contain a nucleus so 
they began by combining the type II CRISPR locus from S. pyogenes Cas9 (SpCas9) with 
a GFP reporter and different number of nuclear localization signals to guarantee it would 
compartmentalize to the mammalian cell’s nucleus. They transfected 293FT cells and 
observed that an SpCas9 attached to 2 nuclear localization signals had the highest GFP 
expression and hence efficiency of nucleus targeting [186]. After transfecting in the 
different components of CRISPR, they verified that the spCas9, in combination with a 
tracrRNA and pre-crRNA, were enough to facilitate efficient cleavage of the Emx1 locus. 
Then they tested the ability to use a chimeric RNA fusion of a partial tracrRNA to a mature 
crRNA using a synthetic stem loop. They targeted the human PVALB and mouse Th loci 
and found efficient cleavage in both loci with the chimeric RNA [186]. They continued 
their study to explore the specificity of the chimeric RNA for genome editing. To do this, 
they created guide RNAs with single-nucleotide mismatches between the spacer and its 
mammalian protospacer target. A single-base pair mismatch from the 5’ site of PAM up to 
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11 base pairs away fully abrogated SpCas9 cleavage activity. On the other hand, mutations 
upstream in the spacer maintained cleavage of the genomic DNA against the protospacer 
target [186]. To further enhance the mechanism of CRISPR, Zhang’s group went on to 
mutate the RuvC I domain within SpCas9 to convert it to a nickase (Figure 4). As a 
nickase, the SpCas9 should only nick the genomic DNA, which is mediated to repair 
through HDR rather than non-homologous end joining (NHEJ). They also introduced a 
homology repair template to promote the changes desired in the EMX1 locus. After 
transfection and sequencing of the loci, a pair of inserted restriction enzyme sites found in 
the donor repair template were discovered and integrated in the genome demonstrating the 
ability of CRISPR to facilitate targeting genomic insertions [186]. This also showed that 
the Cas9 enzyme, as a nickase, could enable genomic editing with a decrease for off-targets 
[186].  
After this publication, CRISPR research modifying and editing the genome 
skyrocketed [187-191]. It helped tremendously that publications included protocols and 
detailed methodology and results [166, 172, 186, 192]. In addition, many labs deposited 
their vectors for the various CRISPR components into Addgene repository, making it even 
more available for researchers. This collaboration has allowed the reproducibility of 
genome editing both in vitro and in vivo [187, 189-191] and the optimizing of CRISPR to 
work effectively and efficiently, including the use of ribosomal CRISPR and the deadCas9 
[193-197].  
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Figure 4. CRISPR/Cas9 and its Modification for Altering the Genome. The gRNA binds 
through complementarity to the target sequence. Because of the 2 active catalytic domains 
(RuvC and HNH), Cas9 enzyme creates a DSB at the 5’ end of the gRNA that usually 
results in NHEJ for DNA repair. By inactivating one of the catalytic domains a nickase is 
generated that cleaves only the DNA strand that is complementary to it. Pairing 2 nickases 
will increase Cas9 specificity and produce two nicks each with a 5’ overhang that can be 
repaired through HDR when a repair template is provided. Paired nickases also decrease 
the potential for off-target mutations.  Adapted and modified from Jeffry D. Sanders et al. 
Nat Biotechnol. 2014; 32 (4): 347-55. [198] 
 
There are two classes of CRISPR systems that exist across a range of bacteria and 
archaebacterial [164, 199]. The components involved, and the mechanism of action 
determines the class. The class I system requires a large complex of multiple effector 
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protein for RNA-guided target cleavage while the class II system only needs a single RNA-
guided endonuclease for DNA cleavage [199]. Each system is comprised of a distinctive 
array of direct repetitive repeats, non-coding RNAs, and a Cas gene to complete 
recognition and cleavage of DNA [164, 199]. The repeats are interspaced by short variable 
sequences derived from the exogenous DNA targets known as protospacers.  The host 
acquires its protospacer through recognition of fragments of invading phages or plasmids 
[164, 199]. The direct repeats and protospacer is known as the CRISPR RNA (crRNA) 
array [164]. The crRNA is the 20-nucleotide guide sequence that will bind via Watson-
Crick base-pairing to the DNA target. Adjacent to the crRNA-target must be a protospacer 
adjacent motif (PAM). The PAM is essential for crRNA targeting and changes for each 
type of CRISPR system [164]. The target sequence must be preceded by the PAM 
sequence, which will recognize this sequence and allow the target to try and base pair. The 
PAM sequence is absent in the host’s genome to prevent self-cleavage [164].  
The mechanism of action is uniform throughout, though the CRISPR action will be 
dependent on the presence and sequence of PAM [164]. The bacteria’s first step is the 
acquisition phase in which protospacers are acquired and incorporated into the host’s 
CRISPR locus as spacers. In the transcription phase, the CRISPR array is transcribed into 
pre-crRNA, which is cleaved and processed to mature crRNA by the now expressed Cas 
protein. Finally, in the interference stage, the Cas protein recognizes the target sequence 
through the guidance of the crRNA and cleaves the phage/plasmid DNA, defending itself 
from an infection [164, 199].  
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Current Advancements 
There have been many successes and improvements with CRISPR. The most well 
characterized system is the type II CRISPR system. Streptococcus pyogenes (S. Pyogenes) 
contain the type II CRISPR that works by incorporating sequences from the invading DNA 
into its own genome, specifically within the CRISPR repeat sequence set up as an array 
within the bacterial genome [164]. Its PAM conforms to the 3’NGG consensus sequence, 
containing two G:C base pairs that occur one base pair downstream of the crRNA binding 
sequence, within the target DNA [182]. When it cleaves DNA, it creates a blunt ended cut 
3 base pairs away from the PAM site [182]. It is also the most commonly used Cas (Cas9) 
protein for genome editing. The Cas9 has been modified to act as a nickase by mutating a 
nuclease domain, thereby allowing a DSB that has a higher likelihood for HDR with the 
addition of an oligonucleotide while decreasing off-target effects [166, 186]. In addition, 
both of Cas9’s catalytic domains can be mutated to act as a “dead” protein. The protein can 
still be guided and bind DNA, but it will not cut [197]. This allows the protein to be used 
to act as a transporter to deliver other factors to activate or repress the genome and study 
epigenetic modifications [200].   
There are other type II Cas enzymes that have been discovered to mediate DNA 
cleavage and found to be useful in mammalian cells. Cpf1 is a class II type V CRISPR that 
only requires the guidance of a crRNA without a tracrRNA [201]. Although it is very 
similar to Cas9, its PAM sequence is 5’TNN and must be located on the 5’ end of the target 
DNA. Its 2 catalytic residues are found in its singular RuvC domain. Unlike Cas9, if any 
of the catalytic residues in the RuvC domain are mutated, no cleavage activity can occur. 
It creates a 5-base pair- 5’ overhang 18 base pairs away from the PAM site. Some 
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advantages that Cpf1 may provide over Cas9 include sticky ends after cleavage, which 
could allow gene transfer in non-dividing cells that usually cannot be modified through 
HDR. Since its PAM site is 5’TNN rather than the G-rich Cas9, AT-rich regions or 
genomes without 3’NGG could be targeted with Cpf1 [201]. In addition, the single crRNA 
needed would be smaller and easier to deliver in somevectors than Cas9’s about 100-
nucleotide tracrRNA/crRNA hybrid [201, 202]. Finally, the number of off-target effects 
created by Cpf1 is not much smaller than that of Cas9; however, computationally, the 
number of off-target sites predicted for Cpf1 is usually in the 1-12 range while Cas9 is as 
high as 90 sites [202, 203].  
The delivery of CRISPR systems is an essential component in the success or failure 
of a modified genome. After identifying how many components need to be delivered (Cas, 
sgRNA, repair template), the delivery method can be selected. Delivery via transfection, 
viral infection, or even injection as protein, RNA, or DNA is suitable [204]. The expression 
system for efficient cleavage of the genome will be dependent on the end goal. An 
expression vector is appropriate for transient or stable transfection for high efficiency in a 
mammalian cell [204, 205]. Lentiviral transduction is the most commonly used for 
CRISPR genome wide screening and difficult to transfect cell lines and even in vivo [9, 
204]. Adeno-associated viral (AAV) transduction is useful for transient and stable 
expression of only the Staphylococcus aureus Cas9 (SaCas9). An AAV is common for in 
vivo delivery due to its low immunogenicity and ability to preferentially infect specific 
tissues [33, 204]. However, it can only package up to 4.5 kb [33, 204].  
Feng Zhang’s group continues to pave the way in optimizing the use of CRISPR 
by developing a Cas9 that would fit into an AAV. The Cas9 enzyme is large ranging in 
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size from 1000-1300 amino acids [206] and in combination with the chimeric sgRNA (4.2 
kb) cannot be shrunk to fit into the 4.5 kb package. To find a Cas9 enzyme, six different 
sized Cas9 enzymes were transfected into 293FT cells with sgRNAs for specific genes. Of 
the six Cas9 orthologs tested, the Cas9 from the Staphylococcus aureus (SaCas9) had the 
highest cleavage activity [206]. Since another species of Cas9 was being used, various 
sized sgRNA also had to be tested to see if the length of the sgRNA would vary with each 
Cas as well. The highest editing efficiency with SaCas9 turned out to be 21-23 nucleotides 
long. In addition, using deep sequencing, their group identified a strong linear correlation 
between DSB scores and indel levels for each Cas9 and sgRNA pair in 293FT cells 
transfected with the different Cas9s and sgRNAs targeting EMX1 [206]. However, they 
also noticed other genes that were cleaved besides EMX1 due to homology of their 
sequences. These off-target sites were generated both through Watson-Crick base pairing 
and through guide: target heteroduplex formation [206]. The group still proceeded to target 
the Apob gene in vivo in the mouse genome using SaCas9, driven by a CMV promoter, and 
a sgRNA, driven by the U6 promoter, all packaged into an AAV vector. The virus was 
injected intravenously into C57BL/6 mice and after one week, they noticed a 5% indel 
formation in the liver tissue. They extended the wait time to 4 weeks after which dissection 
of the liver tissue demonstrated characteristics of hepatic lipid accumulation in the Apob 
knockout mice with higher oil red staining [206]. They saw the opposite results when using 
the CRISPR system to target the Pcsk9 gene; they observed a 95% decrease in serum 
PCSK9 levels and a 40% decrease in total cholesterol after just the first week of 
administering CRISPR [206]. Of course, it’s necessary to determine if any off-target effects 
occurred within the genome after injection with the Pcsk9 targeting CRISPR. Deep 
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sequencing of DNA extracted from the liver tissue did not reveal significant levels of indel 
formations; the mice did not show any signs of toxicity or any acute immune response to 
the virus or CRISPR [206].  
Other methods of delivery of CRISPR include plasmids containing the gRNA and 
Cas9 mRNA, which can be delivered through electroporation or microinjection [204]. This 
is usually only used when generating transgenic embryos or transient expression [204]. An 
improvement in the delivery of CRISPR has been through the use of Cas9-gRNA 
ribonucleoprotein complexes (RNPs) [204, 207]. The Cas9-RNP, delivered via gold 
nanoparticles in mice with muscular dystrophy, had a high efficiency of gene editing in 
muscle tissue with low toxicity [195].  All in all, the use of CRISPR has only just begun 
and advancements in technology will ensure that CRISPR is utilized far beyond what we 
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PART III: THE ENDOPLASMIC RETICULUM and  
UNFOLDED PROTEIN RESPONSE 
 
Endoplasmic Reticulum, Protein Folding and Chaperones 
 The ER is a large and crucial component of the cell made up of a closed, yet 
interconnected network of tubules and flattened sacs extending from cell membrane to 
form a contiguous connection with the nuclear envelope. Its extensive structure is required 
for all the processes the ER maintains: synthesis and folding of proteins trafficking through 
the secretory pathway, biosynthesis of lipids and proteins, and maintaining a quality control 
process to prevent cell stress [208, 209]. The ER is made up of both the smooth and rough 
ER. Most cell types contain a small volume of smooth ER; however, hepatocytes are rich 
in smooth ER [210]. It is in the smooth ER that enzymes chemically convert toxic 
hydrophobic compounds like pesticides to water-soluble molecules for secretion from the 
body [210].  
 The quality control system of the ER ensures that newly synthesized proteins only 
leave the compartment when their folding criteria have been met [208, 209, 211]. Newly 
synthesized unfolded proteins enter the ER. At the N-terminus of the protein is a signal 
sequence that is recognized by a signal recognition particle (SRP). The protein sequence-
SRP complex binds to an SRP receptor in the ER membrane. This chain is then guided to 
the Sec61 translocon, an integral membrane protein, which acts as a tunnel to allow the 
translocation of the growing amino acid chain across the ER membrane and into the ER. 
Once fully in the ER lumen, the protein completes its folding assembly into its native 
structure with the assistance of ER chaperones such as Grp78 [208, 212, 213]. The protein 
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can undergo further post-translational modifications in the ER though these modifications 
also occur in the Golgi as it does for the LDLR [98]. The properly folded protein is then 
released by the ER chaperone to proceed to its proper cellular compartment via vesicles 
[208, 213].  
The specific factors and molecular mechanisms responsible for LDLR folding and 
maturation is still unclear. Chaperones are expressed in the ER and play a major role in the 
protein folding process [105, 214]. The general chaperone, Grp78, is known to transiently 
bind LDLR and assist in its proper folding under normal conditions [124, 125, 215]. This 
correlates with studies of Grp78 acting selectively in retaining proteins in the ER [215].  
Another chaperone that has been implicated in binding and facilitating the proper folding 
and maturation of the LDLR is the receptor-associated protein (RAP) [216]. The rate at 
which the ER folds proteins is dependent on the physiological and pathological reactions 
occurring within the biological system. The ER folding process can become susceptible to 
aggregation in times of inflammation, diabetes, and cancer [208].  
 Because the ER is responsible for processing of proteins, it requires a strict and 
modulated signaling mechanism to maintain homeostasis and prevent aggregation of 
unfolded or misfolded proteins and even correct misfolded proteins. This quality control 
ensures that only properly folded protein exit the ER for the Golgi, while misfolded 
proteins are retained in the ER. If unable to be corrected, misfolded proteins in the ER 
eventually undergo a process called ER-associated degradation, or ERAD. ERAD is a 
retrograde transport process where the misfolded protein is translocated back through the 
Sec61 tunnel to the cytosol. The protein is ubiquitinated and finally degraded by the 26S 
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proteasome [208, 217]. Otherwise, misfolded proteins can and do lead to cell death by 
apoptosis [213, 217, 218]. 
 
Unfolded Protein Response in FH Class II Mutations 
Before some misfolded proteins can undergo the process of ERAD, the 
accumulation of these proteins leads to condition called “ER Stress” [213, 217, 218]. ER 
stress elicits a coping mechanism of “unfolded protein response (UPR)” [213, 217, 218]. 
The UPR’s major role is to maintain protein homeostasis in the presence of accumulated 
un/misfolded proteins [213]. There are three known signaling pathways in mammals that 
are activated to adapt to the ER stress environment and “fix” the misfolded proteins [213]. 
The 3 major stress sensors of these pathways are IRE1, PERK, and ATF6 [213] and work 
to restore folding capacity in the ER by controlling the expression of transcription factors 
and other downstream factors (Figure 5).  
Inositol-requiring transmembrane kinase/endonuclease (IRE1) is the best-
characterized sensor of the ER stress response pathway. It’s signaling is conserved across 
bacteria, plant, and animal [219, 220]. This serine/threonine protein kinase and 
endoribonuclease catalyzes the processing of transcription factor X-Box binding protein-1 
(XBP1) [213, 221, 222] (Figure 5). The splicing of a 26-nucletoide intron from xbp1 
generates the transcription factor, spliced XBP1 (XBP1s) [213, 221, 223]. XBP1s regulates 
UPR genes for folding, ERAD, autophagy, and organelle biogenesis [213, 224-226]. Of 
interest, XBP1s targets different genes in different tissues and under specific conditions for 
each indicating that this ER stress responder is as unique and in need of dissecting as most 
of the players involved in the UPR [213, 227].  
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PKR-like ER kinase (PERK) is an ER transmembrane protein whose activation 
through phosphorylation mediates UPR by phosphorylating initiation factor EIF2 [213, 
217, 228]. EIF2 phosphorylation renders it inactive; this leads to an inhibition of protein 
translation and a decrease of misfolded proteins. Through its inactivation, EIF2 also 
increases the translation of a transcription factor, activating transcription factor 4 (ATF4) 
[213, 217, 228]. It does this by recognizing an inhibitory upstream open reading frame in 
ATF4’s 5’ untranslated region [218]. ATF4 modulates another subset of UPR genes 
involved in antioxidant response, glutathione biosynthesis, amino acid metabolism, 
autophagy, and apoptosis [229-231] (Figure 5).  
Activating transcription factor 6 (ATF6) is another ER transmembrane protein that 
mediates UPR [213]. Within the ATF6 protein structure is a cytosolic domain that renders 
it inactive in the ER [221, 232]. During ER stress, ATF6 translocates to the Golgi where 
the cytosolic domain is released by two proteases. This segment termed ATF6f (a fragment 
of ATF6) then goes on to act as a transcription factor to upregulate the expression of UPR 
genes involved in protein folding like ER chaperones and degradation like ERAD [221, 
232] (Figure 5). 
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Figure 5. Schematic of the Unfolded Protein Response (UPR). When misfolded or 
unfolded proteins begin to aggregate in the endoplasmic reticulum (ER), Grp78 
disassociates from the three ER stress receptors leading to a sequential activation of the 
receptors and their downstream effectors. Pancreatic ER kinase (PKR)‐like ER kinase 
(PERK) is activated by autophosphorylation and leads to phosphorylation of eukaryotic 
initiation factor 2α (eIF2α) inhibiting translation of proteins except activating transcription 
4 (ATF4). ATF4 acts on genes for amino acid synthesis and antioxidant production.  
Activating transcription factor 6 (ATF6) activation generates a fragmented ATF6 that acts 
as a transcription factor for expression of degradation and apoptotic protein CHOP.  
Inositol‐requiring enzyme 1 (IRE1) regulates the expression of X box‐binding protein 1 
(XBP1), another transcription factor, that is spliced into its active form by IRE1. Spliced 
XBP1 protein (SXBP1) translocates to the nucleus regulates transcription of genes for 
chaperones and protein degradation. Adapted from Eva Szegezdi et al. EMBO Rep. 2006; 
7: 880-85. [233] 
 
To be brief, under stressful conditions the ER utilizes the UPR to regain 
homeostasis. If UPR is prolonged, severe consequences including oxidative stress, 
inflammation, and eventually apoptosis can occur [213, 217, 218, 229]. How does ER 
stress and the UPR relate to class II LDLR mutants in FH?  
Evidence in the literature claims that ER stress does occur due to a class II 
misfolded LDLR [124, 125]. A few studies first confirmed that class II LDLR mutants are 
retained in the ER [118, 124, 125]. For example, Chang cells overexpressing wild type 
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LDLR or mutant W556S or C646Y LDLR were subjected to pulse chase experiments and 
showed wild type LDLR was processed to mature LDLR while the mutants remained in 
the immature form [125].  
Using mass spectrometry and western blot others have demonstrated that Grp78 
binds and retains class II LDLR in the ER [125]. Grp78 is an ER chaperone that binds 
unfolded proteins and also regulates activation of ER stress response [103, 104]. Lysates 
from Chang cells overexpressing class II LDLR mutants co-immunoprecipitated with 
Grp78 and blotted for LDLR showed binding between the two proteins. In fact, Grp78 
transiently interacts with the wild type LDLR as it is processed to its mature form and its 
interaction is prolonged with the mutant LDLRs [125]. Another study by Sorensen and 
colleagues overexpressed other class IIA and class IIB mutant LDLR into Chinese hamster 
ovary cells (CHO) and confirmed prolonged interaction between mutant LDLR and Grp78  
[124]. To test for ER stress, they looked at UPR gene and protein expression markers 
XBP1s and phosphorylated-PERK. Mutant G544V LDLR expressed XBP1s mRNA and 
had a fold induction of phosphorylated-PERK [124]. These two studies indicated that the 
accumulation of misfolded LDLR in the ER increased Grp78 and activated the UPR.  
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CHAPTER II 
CRISPR CORRECTION OF A HOMOZYGOUS LDLR MUTATION IN FAMILIAL 
  





Cardiovascular disease (CVD) is the leading cause of death worldwide. While risks 
include lifestyle choices and environmental factors, a subgroup of the population develop 
early CVD due to inheritable genetic mutations. Familial hypercholesterolemia (FH) is an 
autosomal dominant disease primarily caused by mutations in the low-density lipoprotein 
receptor (LDLR) gene, resulting in supra-elevated low-density lipoprotein-cholesterol 
(LDL-C) that leads to premature CVD [17, 234-236]. Defective LDLR in FH presents in 
two forms; the more common single allele mutation, heterozygous FH (HetFH), 1:250 [1, 
237] and the rare two allele mutation form, which can be a true homozygous or compound 
heterozygous mutations (both referred to as homozygous (HoFH), 1:250,000) [237, 238]. 
Over 1200 LDLR mutations have been identified leading to a wide spectrum of disease 
severity depending on the mutation’s effect on LDLR activity [236, 239]. While HetFH 
patients can generally be treated with standard hypercholesterol therapeutic approaches 
(i.e. lifestyle changes, statins), receptor-defective HoFH patients with <2% LDLR activity 
are generally non-responsive and must rely on more extreme, costly approaches such as 
weekly/bi-weekly lipid apheresis [15]. Transplantation of a normal liver in HoFH patients 
  53 
has been shown to restore normal LDL-C levels, however, the lack of organ donors creates 
a deficit in availability 
[129, 240]. In addition, the most severely affected patients can present as adolescents in 
their first decade of life [17, 236]. By the time these patients are considered for liver 
transplant, they often have already developed severe CVD requiring a heart transplant. 
Therefore, mitigating the effects of genetically induced hypercholesterolemia at the earliest 
time possible is critical for these patients.  
Because of the common donor organ shortage and challenges related to liver 
transplantation, alternative approaches for providing LDL-C regulation have been 
investigated. Hepatocyte cell therapy demonstrates efficacy in animals [41, 42, 45] and 
humans [51]. However, as with solid liver organs, there is a shortage of high quality 
hepatocytes. Since FH is a monogenic disease, it has long been the target of gene therapy 
which has shown promise in animal models [41, 42, 45, 241] but mixed results in humans 
[51]. The discovery of cellular reprogramming to generate patient specific iPSC presents 
the potential for generating unlimited autologous therapeutic cells [242]. The iPSC have 
been generated from FH patients [243-245], but the LDLR mutations are retained and 
require modifications for receptor-mediated LDL-C internalization [244, 245]. The 
genome editing system, clustered-regularly-interspaced-short-palindromic-repeats/Cas-
associated 9 (CRISPR/Cas9) is a relatively simple technology capable of permanent 
genetic modifications and has been used to repair endogenous disease-causing genetic 
mutations in several diseases [187, 192, 246]. Although many cell types are used for 
correction with CRISPR/Cas9, an advantage of correcting at the iPSC level is their 
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theoretical unlimited expansion post-correction without concern for cell senescence. They 
also have the capability of differentiating to the cell source of choice.  
As a proof-of-concept, we reprogrammed FH fibroblasts carrying a homozygous 3 
bp deletion in exon 4 of the LDLR gene (GM03040). This mutation causes a Class II 
mutation and has <5% normal receptor activity. This mutation is referred to as FH-
Piscataway [92]. To introduce a permanent correction, we utilized Cas9 nickase (Cas9n) 
with paired single-guide RNAs (sgRNA) to generate adjacent off-set nicks in the selected 
genomic target. This strategy is reported to reduce off-target mutations [186, 198]. For the 
repair template, we used a single-stranded oligodeoxynucleotide (ssODN) [186, 247]. 
After double positive transfection and magnetic sorting of the final isolated clones, we 
estimate an efficiency of homozygous correction of 0.2% with this approach. The HLC 
derived from the corrected FH-iPSC confirmed restoration of the mature LDLR protein 
and normalization of receptor-mediated LDL internalization compared to non-corrected 
FH-HLC. This demonstrates the feasibility to generate permanently restored endogenous 
LDLR activity in FH-HLC by CRISPR technology. 
 
MATERIALS AND METHODS 
Cell Culture. Human fetal fibroblasts (IMR90; [248]) were cultured in DMEM-
HG (Invitrogen, Carlsbad, CA), 2mM L-glutamine (Invitrogen, Carlsbad, CA), and 10% 
fetal bovine serum (Invitrogen). Cells were maintained at 37 C and 5% CO2. Cells were 
passaged by rinsing the cell monolayer with Dulbecco’s PBS without calcium and 
magnesium (Invitrogen). 0.05% trypsin-EDTA (Invitrogen) was added to the cells and 
incubated at 37 C for 3 minutes. Once detached, complete media was added to cell 
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suspension to inactivate trypsin. A 1:10 split ratio was dispensed into a new culture vessel. 
Skin fibroblasts from an FH patient (GM03040; Coriell Cell Repositories) were cultured 
in FH growth medium comprised of MEM (Invitrogen), 15% FBS, 2mM L-glutamine, and 
0.1 mM Non-Essential Amino Acids (MNEAA) (Invitrogen). Cells were maintained at 37 
C and 5% CO2. Cells were passaged as above. Reprogrammed GM3040 (3040-iPSC) were 
cultured on hESC-Qualified Matrigel coated plates (BD Biosciences, San Jose, CA) in 
mTeSR1 with media changed daily (STEMCELL Technologies, Vancouver, Canada) 
[245].  Cells were passaged using Gentle Cell Dissociation Buffer (GCDB; STEMCELL 
Technologies) with 10 M Rock inhibitor (Selleck Chemical, Houston, TX) and 
maintained at 37 C and 5% CO2 [245]. H1 stem cells (WiCell, Madison, WI) were cultured 
in the same way as iPSC.  
Genotype Analysis by Sequencing, Karyotype Analysis, and DNA 
Fingerprinting. The GM03040 LDLR was genotyped by Ambry Genetics (Aliso Viejo, 
CA) and Sanger sequencing (Genomics Core, Louisville, KY) was used to confirm the 
mutation using a 20 M forward primer for LDLR exon 4 (Integrated DNA Technologies 
(IDT); (5’-CGGCTATAGAATGGGCTGG-3’)). IMR90 fibroblasts were also sequenced 
as a normal LDLR gene control. Corrected clones were sequenced in the Genomics Core 
using the same forward LDLR exon 4 primer, and the results were analyzed in Seqman Pro 
(DNASTAR) to determine homozygous or heterozygous correction. DNA karyotyping and 
fingerprinting on GM03040 fibroblasts and derived 3040-iPSC were performed by Cell 
Line Genetics (Madison, WI) to confirm both were karyotypically normal and preserved 
matching DNA fingerprints. 
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Cellular Reprogramming. GM03040 fibroblasts were reprogrammed using 
Stemgent’s MicroRNA enhanced feeder free synthetic modified mRNA reprogramming 
according to the manufacturer’s instructions (STEMGENT, Cambridge, MA) [245]. 
Immunocytochemistry. 3040-iPSC were fixed with 2% PFA/PBS (10 minutes, 
24° C; Electron Microscopy Sciences, Hatfield, PA), permeabilized when needed with 
0.05% Triton X-100/PBS (5 minutes, 24° C; Sigma Aldrich), and blocked with 5% normal 
goat serum/PBS (Sigma-Aldrich).  A list of all antibodies used for analyses is given in 
Table 1. Primary antibodies were diluted in 5% goat serum/PBS and incubated on cells 
overnight at 4° C. DAPI nuclear stain (1:2000; ThermoFisher) was added (5 minutes, 24° 
C), washed, mounted, and imaged using an Olympus IX81 fluorescence microscope 
(Center Valley, PA).   
Teratoma Formation. 3040-iPSC were cultured in mTeSR1 on Matrigel and 
passaged with trypsin-EDTA five times then subcutaneously injected into NOD/SCID-null 
immunocompromised mice (Jackson Laboratory, Bar Harbor, ME) [245, 249]. Teratomas 
were dissected from the mice after the tumor reached 10 mm in diameter, followed by 
fixing in 4% PFA overnight, paraffin embedded, sectioned, and stained with hematoxylin 
and eosin for histological examination. Tissue identification was performed on the 
Olympus IX81 microscope. All animal procedures were conducted in accordance with an 
approved University of Louisville Institutional Animal Care and Use Committee (IACUC) 
protocol.  
Hepatocyte Differentiation. 3040-iPSC underwent directed differentiation to 
hepatocyte-like cells as reported previously [245, 250]. qPCR analysis for stem cell and 
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hepatocyte markers (Table 2) was performed at the end of each stage (including stage 0) 
and immunocytochemistry at the end of stage 4.  
Quantitative PCR analysis. At the end of each stage, 3040-HLC were lysed using 
250 L of 0.1% -mercaptoethanol in RLT Buffer (Qiagen). The lysates were purified with 
Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions. RNA 
was quantified with a NanoDrop 1000 Spectrophotometer (Genomics Core, University of 
Louisville). cDNA was generated using SuperScript II Reverse Transcriptase kit 
(Invitrogen) and qPCR performed using PCR Supermix (Invitrogen) with primers obtained 
from IDT (Table 2). Amplicons were evaluated via 2% agarose gels (Bio-Rad). 10 L of 
amplicons were added to 2 L TrackIt™ Cyan/Orange Loading Buffer (Invitrogen). Gels 
were run at 120 V for 45 minutes and imaged via ChemiDoc MP Imaging System (Bio-
Rad).  
Indocyanine-Green Assay. Indocyanine green (ICG; Cardiogreen; Sigma-
Aldrich) was used to measure hepatocyte function. We adapted a protocol by Ho et al [251] 
with modifications of dissolving the ICG dry powder at 1mg/mL in sterile water and 
mixing with stage 5 media at a 1:1 ratio to obtain a 0.5 mg/mL stock solution. Cells were 
imaged on the Olympus IX81 microscope at both bright field and phase settings.  
Fluorescence-labeled LDL uptake analysis. Cells were plated in 8 wells of a 24-
well plate and taken through HLC differentiation (see above). At the end of stage 4, LDL 
internalization was quantified as we have previously described [245].  
Western Blot. Cells were starved overnight in 5% lipoprotein-deficient serum 
media (Alfa Aesar, Tewksbury, MA) augmented with 5 M Lovastatin (EMD Millipore) 
or excess sterols (10 g/mL cholesterol and 5 g/mL 25-Hydroxycholesterol; Sigma-
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Aldrich). The following morning, the cells were thoroughly washed Dulbecco’s PBS with 
calcium and magnesium prior to adding 200 L RIPA lysis buffer (ThermoFisher) plus 
protease inhibitor cocktail (ThermoFisher) to collect the cells. The DC Protein Assay (Bio-
Rad) was used for protein quantification and 20 g/sample of total protein was run on a 4-
10% mini-protean TGX precast gel (Bio-Rad) at 80 volts for 2 hours. Proteins were 
transferred onto nitrocellulose membrane (Bio-Rad) then blocked in 5% non-fat dry 
milk/TBST. Membranes were incubated overnight with the LDLR antibody (1:5000; R&D 
Systems, Minneapolis, MN) or Actin (1:500; Santa Cruz Biotechnology, Dallas, TX) 
overnight at 4C. After 3-5 minute washes with 5% milk/TBST, the membranes were 
incubated in either HRP-Rabbit Anti-Goat IgG H+L (Invitrogen) or anti-mouse IgG, HRP-
linked antibody (Cell Signaling, Danvers, MA) the following day for 2 hours. Supersignal 
West Femto Maximum Sensitivity Substrate (ThermoFisher) was used to visualize the 
proteins on the Bio-Rad Imager. Densitometry was performed using Bio-Rad imaging 
software.  
CRISPR Editing Design:  
sgRNA design and cloning. The MIT CRISPR Design Tool (crispr.mit.edu) was 
utilized to design paired guides in close proximity to the 3 bp (TGG) deletion in exon 4 of 
the LDLR gene (Chr19:11,105,170-11,105,650) (5’-
…TTCCACTGCCTAAGTGGCGAGTGCATCCACTCCAGCTGGCGCTGTGATGGT
GGCCCCGACTGCAAGGACAAATCTGACGAGGAAAACTGCGCTGTGGCCAC-
3’). We selected paired guides 1 and 9 to use with Cas9n. The guides were cloned into 
pHL-H1-ccdB-mEFα-RIH (#60601, Addgene, Cambridge, MA) deposited by the Hotta lab 
[192]. Briefly, primers were designed as previously described [172]; for guide specific 
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forward primers, 19 bp (bases 2-20) of MIT sgRNA design were utilized and the first base 
pair was changed to a G to enable H1 Pol III transcription.  Infusion homology arms (in 
blue) (Table 3) were added to the 5’ end of each primer pair to enable cloning into the 
vector when cut with BamH1 and EcoRI. A PCR reaction was performed using Phusion 
Hot Start Polymerase (Thermo Fisher, Walton, MA) and either guide primer paired with 
sgUniversal Reverse primer (Table 3).  The PCR product was cloned into pHL-H1-ccdB-
mEFa-RIH with In-fusion Cloning (Clonetech Laboratories, Inc.).  Clones were sequence 
confirmed with our H1-Fwd primer (5’-GCATGTCGCTATGTGTTCTG-3’). 
Cas9n-GFP design. We obtained a humanized S. pyogenes D10A Cas9 nickase 
plasmid, pHL-EFlα-SphcCas9(D10A)-iP-A (#60600, Addgene), deposited by Hotta lab 
[192].  The puromycin gene, along with a portion of the internal ribosomal entry site 
(IRES), was removed by digesting with KpnI and BamH1.  In-fusion cloning was utilized 
to reinstate the missing IRES sequence and concurrently insert a green fluorescent protein 
(GFP) gene.  The primers for PCR are listed in Table 4, sequences in blue are infusion 
homology arms while underlined sequence is that of GFP.  The Cas9n-GFP clone was 
sequence confirmed. 
ssODN design. A 157 bp anti-sense single stranded oligodeoxynucleotide (ssODN) 
repair template with 50 bp left and right homology arms were designed to insert the missing 
3-nucleotides (CCA) while simultaneously adding silent mutations within the PAM site 
and guide target site (57 bp) to generate a novel XmnI restriction site (GAATGCATTC) 
and prohibit further Cas9n editing by blocking guide recognition sequence (Figure 11). 
The oligo was obtained from IDT (Coralville, Iowa) as a 4nM ultramer oligo and was not 
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HPLC purified. The ssODN sequence has been modified from chromosome 19, gene 
NM_00527.4 corresponding to nucleotides 750-896.  
Transfection and Selection. Electroporation transfection of reprogrammed 
GM03040 (3040-iPSC) was modified from previously described protocols [172, 246, 252]. 
Cells were transfected using a square-wave electroporator, Nepa21 cell electroporator, 
(NepaGene, Ichikawa-City) carried out at 24C at different voltages and time to determine 
optimum electroporation range and cell viability (Table 5).  3040-iPSC were pre-treated 
overnight in 10 M Y-27632 and transfected at 150 V for 5 milliseconds. The transfection 
occurred in 2-millimeter electroporation cuvettes (Bulldog Bio, Portsmouth, NH) with 106 
cells in 90 L Opti-MEM and 20 g nucleic acids (5 g Cas9n, 5 g sgRNA1, 5 g 
sgRNA9, and 5 g ssODN) in 10 L. Transfected cells were cultured in Y-27632-mTeSR1 
media. After two days, we sorted for double fluorescent positive cells via fluorescence 
activated cell sorting (FACS). A week prior to transfection and sorting, used media from 
3040-iPSC was collected, centrifuged, filtered, and stored at -20C.  On the day of sorting, 
conditioned media was prepared by mixing used media and fresh mTeSR1 media in a 1:1 
ratio with 1% penicillin/streptomycin (Invitrogen). Basic sorting buffer was prepared using 
1X DCF-PBS (ThermoFisher), 1 mM EDTA (ThermoFisher), 25 mM HEPES pH 7.0 
(Invitrogen), and 1% knock-out serum replacement (ThermoFisher) and filter sterilized. 
To prepare for sorting, cells were dissociated to single-cells, counted, centrifuged, and re-
suspended at <106 cells per 0.5 mL basic sorting buffer in a 5-mL polypropylene tube on 
ice. Cells were transported to the University of Kentucky FACS facility (Lexington, KY) 
where cells were sorted for positive expression of both red fluorescent protein (RFP) and 
GFP into 35 mm dishes in conditioned:mTeSR1 plus Y-27632 media. Cells were incubated 
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for 48 hours at the University of Kentucky before being transported back to our lab at the 
University of Louisville for continued cell culture. Percent dual positive cells was analyzed 
via FlowJo (Ashland, OR). 
Magnetic Sorting. Transfected cells were incubated overnight in 5% lipoprotein 
deficient serum media supplemented with 5M Lovastatin. Magnetic-activated cell sorting 
(MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) separated LDLR+ 3040-iPSC 
from LDLR- 3040-iPSC. Cells were disassociated into single cells, counted, and re-
suspended at <107 cells/60 L ice cold sorting buffer (DCF-PBS, 0.5% knockout serum 
replacement, and 2mM EDTA filter sterilized, degassed for 15 minutes by keeping the 
vacuum on). 20 L FcR blocking reagent (Miltenyi Biotec) and biotinylated anti-LDLR-
C7 antibody (1:100; Novus Biologicals, Littleton, CO) were added to the cells and rocked 
for 2 hours at 4C. Cells were washed by centrifugation at 200 x g for 4 minutes with 2 mL 
sorting buffer twice. 3040-iPSC were re-suspended in 60 L sorting buffer, 20 L FcR 
blocking reagent, and anti-biotin Microbeads UltraPure (1:4; Miltenyi Biotec) and 
incubated for 45 minutes at 4C with rocking. While cells were rocking, a magnetic 
separation column was set up according to manufacturer’s instructions (Miltenyi Biotec). 
Cells were washed once more and re-suspended in 500 L sorting buffer. Magnetic 
separation was followed according to manufacturer and the column of LDLR+ 3040-iPSC 
was removed from the magnet and eluted with 1 mL sorting buffer and plunger. Cells were 
plated onto 35 mm dishes. An aliquot of the positively collected cells, negative cells, and 
pre-sorted cells were processed further for sorting efficiency. Cells were pipetted into a 5-
mL polypropylene tube, centrifuged, and re-suspended in supernatant left in tube after 
decanting (~50 L) plus 20 L FcR blocking reagent and anti-biotin-FITC antibody (1:5; 
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Miltenyi Biotec). The cells were incubated at 4C for 45 minutes, washed twice with 0.05% 
sodium azide/DCF-PBS, and re-suspended in 300 L 0.05% sodium azide in DCF-PBS. 
FACS analysis grouped cells based on FITC fluorescence. 
Clonal Isolation. Clonal selection was performed based on Rodin et al [253] 
protocol with modifications. Dialyzed albumin was prepared as previously except using 
endo-toxin free bovine serum albumin (A8806; Sigma-Aldrich, St. Louis, MO). 1.6 g/mL 
laminin-521 (ThermoFisher) and 0.2 g/mL E-cadherin-Fc (#CDH1-274H; Creative 
Biomart, Shirley, NY) were mixed at a 9:1 (wt/wt) ratio in di-cationic PBS and 50 L 
coated the inner 24-wells of Sarstedt 96-well tissue culture plates (ThermoFisher) after 
which they were washed twice with 80 L di-cationic PBS followed by addition of 50 L 
mTeSR1:albumin per well. The MACS isolated 3040-iPSCs were prepared in single-cell 
suspension and counted. Serial dilution of the cells to 1 cell/50 L was completed and 50 
L cell suspension added per laminin-521/E-cadherin-coated well. Single-celled colonies 
were selected and expanded into 24-well plates. Confluent clones were collected and 
genotyped using restriction fragment length polymorphism (RFLP).  
Restriction Fragment Length Polymorphism Assay. Genomic DNA was 
extracted from cells following the manufacturer’s protocol (Qiagen Gentra Puregene Cell 
Kit, Germantown, MD). PCR was performed with LDLR exon 4-F (5’-
CGGCTATAGAATGGGCTGGG-3’) and LDLR exon 4-R (5’-
GAATACTTTCTTGGCATGTTGTTG-3’) for 34 cycles, with denaturation at 98C, 
annealing at 62C, and extension at 72C. 5 L of amplicons were run on a 1% agarose gel 
to detect presence of PCR product. 250 ng of PCR product, 0.3 L XmnI enzyme (New 
England Biolabs (NEB), Ipswich, MA), 1.5 L 10X Cut Smart Buffer (NEB, Ipswich, MA) 
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were combined with nuclease free water (Qiagen) for total volume of 15 L and incubated 
at 37C for 2 hours. 3 L TrackIt™ Cyan/Orange Loading Buffer was added to the digested 
sample followed by a 2% agarose gel run at 120 V for 45 minutes. Heterozygous and 
homozygous correction was determined by observation of bands at 576 bp, 384 bp, and 
192 bp on the gel relative to 1 kB ladder (Bio-Rad, Hercules, CA). PCR products were 
Sanger sequenced to verify 3-nucleotide correction of the LDLR.  
Off-Target Analysis. Potential off-target sites that each guide may have was listed 
in the MIT CRISPR Design Tool. The three highest scoring genic and three non-genic sites 
were selected to check for potential off-target effects of the sgRNA (Table 6). PCR primers 
were designed and amplified with 25 cycles, denaturation at 98C, annealing at 62C, and 
extension at 72C. 5 L amplicons were run at 120 V for 30 minutes on 1% agarose gel to 
confirm presence of amplicon. Following this, 10 M forward primer of the selected 
potential off-target sequence was added to PCR product for Sanger sequencing. Analysis 
in SeqMan Pro (DNASTAR, Madison, WI) was performed to identify deletions, indels, 
and SNPs. Control non-corrected 3040-iPSC were first tested to verify sequence followed 
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Table 1 
 
List of Antibodies and Fluorophores  
 
 
Antigen Host Dilution Distributor 
OCT4 Rat 1:200 R&D Systems, Minneapolis, MN 
SOX2 Goat 1:200 R&D Systems 
SSEA4 Mouse 1:200 ThemoFisher, Walton, MA 
SSEA1 Mouse 1:200 EMD Millipore, Billerica, MA 
TRA-1-60 Mouse 1:200  EMD Millipore 
TRA-1-81 Mouse 1:200 EMD Millipore 
StainAliveTM TRA-1-81 
(DyLightTM 488) 
Mouse 1:200 Stemgent, Cambridge, MA 
AFP Mouse 1:200 Invitrogen, Carlsbad, CA 
ALB Rabbit 1:200 MP Biomedicals, Santa Ana, CA 
CYP7A1 Rabbit 1:200 Santa Cruz Biotechnology, Dallas, TX 
CYTOKERATIN-18 Rabbit 1:200 Santa Cruz 
LDLR Goat 1:5000 R&D Systems 
Actin Mouse 1:1000 Santa Cruz Biotechnology 
Biotinylated-LDLR-C7 Mouse 1:100 Novus Biologicals, Littleton, CO 
Alexa Fluor Anti-Goat 
488nm 
 1:500 Invitrogen 
Alexa Fluor Anti-Goat 
594nm 
 1:500 Invitrogen 
Goat anti-Mouse 488  1:1000 Invitrogen 
Goat anti-Rabbit 488  1:1000 Invitrogen 
HRP-Rabbit Anti-Goat IgG 
H+L 
 1:4000 Invitrogen 
Anti-Mouse IgG, HRP-
linked 
 1:1000 Cell Signaling, Danvers, MA 
Anti-Biotin Microbeads  1:4 Miltenyi Biotec (Bergisch Gladbach, 
Germany 
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Table 2 
 
List of Primers to Determine Expression of Hepatocyte Differentiation 
 
 










744 F: 60.03C 
R: 59.97C 
SOX17 CCGCGGTATATTACTGCAACTA CACCCAGGACAACATTTCTTTG 371 F: 58.1C 
R: 58.02C 
HNF4A CCACGGGCAAACACTACGG GGCAGGCTGCTGTCCTCAT 250 F: 61.32C 
R: 62.34C 
AFP GCTGACCTGGCTACCATATTT GGGATGCCTTCTTGCTATCTC 384 F: 57.8C 
R: 58.2C 
ALB GGTGTTGATTGCCTTTGCTC CCCTTCATCCCGAAGTTCAT 502 F: 57.93C 
R: 57.28C 












Cas9n-GFP Clone Primers 
 
   
Guide 1 gagaccacttggatccGGCACTCGCCACTTAGGCAGgttttagagctagaaatagca 




  IRES in-fusion PCR GFP in-fusion PCR 
Forward AAGGATGCCCAGAAGGTAC TAATATGGCCACAACgcgtatgGTGAGCAAGGGCGAGG 
Reverse GTTGTGGCCATATTATCATCGTG CTTAAGCCTAGGATCctaGTACAGCTCGTCCATGC 
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Table 5 
 





Predicted Off-Target Cutting Sites 
 
 
Name Sequence PAM 
Site 
























3MMs [4:10:13]  
4MMs [3:4:5:9]  
3MMs [1:2:16]  
































































100 5 50 2 Y Y 
125 2.5 50 2 Y Y 
125 5 50 2 Y Y 
150 5 50 2 Y Y 
175 5 50 2 Y N 
200 5 50 2 Y N 
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RESULTS 
FH Fibroblasts GM03040 have a Class IIB-FH Piscataway Mutation. We 
acquired the FH skin fibroblasts (GM03040) from the Coriell Cell Repository (Camden, 
NJ) described as homozygous receptor-defective; but no genetic information was provided. 
We initially confirmed the inability of GM03040 to internalize cholesterol by culturing 
them and a normal fibroblast control (IMR90) overnight in 5% lipoprotein deficient serum 
media supplemented with either Lovastatin or excess sterols, followed the next morning 
with incubation in low density lipoprotein labeled with 1,1’-dioctadecyl-3,3,3’,3’-
tetramethyl-indocarbocyanine perchlorate (DiI-LDL) [245]. Lovastatin inhibits 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), blocking 
cholesterol synthesis and leading to an upregulation of LDLR. The excess sterols act 
independent of the LDLR leading to a decrease in LDLR expression. LDL internalization 
by the LDLR-normal IMR90 was robust in response to Lovastatin, that was abrogated in 
the presence of excess sterol treatment (Figure 6A). In contrast, GM03040 showed 
virtually no DiI-LDL internalization, even under the same Lovastatin treatment conditions 
that induced robust internalization in IMR90. We next wanted to know if any LDLR was 
produced by GM03040. Under the same conditions for the LDL internalization assay, we 
collected cell lysates for analysis by western blot (Figure 6B). Lovastatin treatment of 
IMR90 showed strong expression of the mature LDLR protein with low expression of the 
immature proteins. No LDLR protein was detected when IMR90 were exposed to excess 
sterols.  In the GM03040, Lovastatin induced low level LDLR expression with the greatest 
increase in immature LDLR protein and very little mature LDLR (Figure 6B). Though 
GM03040 expresses little LDLR, even with Lovastatin treatment, excess sterols 
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downregulated LDLR indicating these FH fibroblasts are physiologically responsive to 
cholesterol feedback control as described by Brown & Goldstein [235]. Sequencing of the 
GM03040 (and IMR90 control) LDLR identified a pathological, homozygous 3-nucleotide 
deletion in exon 4 (c.654_656delTGG (pG219del)) (Figure 6C). This is a Class IIB 
mutation known as FH-Piscataway, which results in less than 5% LDLR activity and 
misfolding of immature LDLR that is degraded by the proteasome pathway [92, 119]. 
Together these data confirm the FH cell line contains a 3-nucleotide deletion in exon 4 of 
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Figure 6. Mutation Identification in HoFH Fibroblasts. (A) HoFHɸ and control fetal 
IMR90ɸ were treated overnight in 5% lipoprotein deficient serum (LPDS) media 
supplemented with either Lovastatin or excess sterols. A significant amount of fluorescent 
DiI-LDL was visualized in IMR90ɸ treated with Lovastatin that was abrogated with excess 
sterols. GM03040ɸ showed impaired DiI-LDL internalization with Lovastatin treatment 
(Scale bars = 200 M). (B) Western blot for LDLR shows IMR90ɸ upregulate LDLR in 
Lovastatin and suppress LDLR when exposed to sterols. In contrast, HoFH GM03040ɸ 
express comparatively little LDLR under the same conditions. (C) Sanger sequencing 
revealed a homozygous 3-nucleotide deletion in exon 4 of LDLR in GM03040ɸ. (IMR90ɸ: 
IMR90 fibroblasts; GM03040ɸ: HoFH GM03040 fibroblasts). 
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Derivation of 3040-iPSC and Differentiation into Hepatocyte-Like Cells. 
Before reprogramming the parental GM03040, we confirmed the normal karyotype 
(Figure 7A) and DNA fingerprinting (not shown). We reprogrammed the fibroblasts to 
3040-iPSC using a modified synthetic mRNA cocktail containing OCT4, SOX2, KLF4, C-
MYC, and LIN-28 [245] and began seeing colonies that were morphologically compact 
and refractile at approximately day 16. Manually picking of stem cell positive expressing 
TRA-1-81+ colonies was initiated around day 20 for expansion into feeder-free culture 
(Figure 8A). 3040-iPSC demonstrated immunoreactivity with pluripotence markers TRA-
1-81 and UEA1 (Figure 8B), TRA-1-60, SSEA4, Oct4 and Sox2, while being negative for 
SSEA1 (Figure 8C). We confirmed that the reprogrammed cells were still karyotypically 
normal (Figure 7B) and DNA fingerprinting (not shown) established the 3040-iPSC 
originated from the parent GM03040 fibroblasts. Histological examination of harvested 
teratomas confirmed 3040-iPSC pluripotence with differentiation into derivatives of all 
three germ layers in vivo (Figure 8D).  
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Figure 7. GM03040 are Karyotypically Normal. (A) Parent GM03040 fibroblasts and (B) 
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Figure 8. Reprogrammed 3040-iPSC are Pluripotent. (A) An iPSC colony is visible post 
reprogramming, characterized by its small, clustered appearance at Day 16 (Scale bar = 
100 μm) and live staining with pluripotent marker TRA-1-81 at Day 18 (Scale bars = 200 
μm). (B) Assessment of expanding 3040-iPSC pluripotence is seen with positive TRA-1-
81 and UEA1 immunostaining. (C) Micrographs further confirmed expression of 
pluripotent markers TRA-1-60, SSEA4, Oct4 and Sox2, while being negative for mouse 
SSEA1. (D) Teratoma generated in immunocompromised mice from 3040-iPSC (i) 
differentiated into the 3 germ layers: endoderm-respiratory epithelium (ii), mesoderm-
muscle (iii), and ectoderm-nerve ending (iv).  
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Most LDLRs are found on liver hepatocytes and are responsible for most LDL 
regulation [235]; therefore, we wanted to confirm 3040-iPSC capability to differentiate 
toward hepatocyte-like cells (HLC). Following a previously described five stage protocol 
[245, 250], 3040-iPSC showed expression of stage specific markers after completion of 
each differentiation stage as demonstrated by qPCR (Figure 9A; Table 2). As we have 
shown previously [245], 3040-iPSC undergo differentiation, as demonstrated by 
progression of expression of pluripotence marker octamer-binding transcription factor 4 
(OCT4)  at stage 0, definitive endoderm marker sex determining region Y box 17 (SOX17) 
[250], in stage 1, hepatic lineage specification as indicated by expression of hepatocyte 
nuclear factor 4a (HNF4A) in stages 2-5, the early hepatocyte marker alpha fetal protein 
(AFP) [250] beginning in Stage 2, and standard albumin (ALB) [250] expression initiated 
during stage 3. To examine protein expression, we differentiated 3040-iPSC to the end of 
stage 4 and used immunocytochemistry (ICC) for detection of commonly associated 
hepatocyte markers, albumin, AFP, CYP7A1, and cytokeratin 18 (Figure 9B)  [245, 250]. 
Finally, we tested 3040-HLC functionality via an indocyanine green (ICG) exclusion assay, 
demonstrating 3040-HLC could take up and clear the green dye within 24 hours (Figure 
9C). These data confirm that the reprogrammed GM03040 FH fibroblasts are pluripotent 
and can specifically differentiate to functioning HLC.   
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Figure 9. Hepatocyte-Like Cells (HLC) can be Derived from 3040-iPSC. (A) Stage-
specific markers were tested at both mRNA expression level (POU4F1, SOX17, HNF4A, 
AFP, and ALB) by PCR (n=3) and (B) protein level (AFP, ALB, CYK18) by 
immunocytochemistry (n=2) in 3040-HLC (Scale bars = 50 μm). (C) HLC function was 
tested by uptake and exclusion of indocyanine green dye (ICG) over 24h (Scale bars = 50 
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CRISPR Correction of Homozygous 3-nucleotide Deletion in the LDLR in 
3040-iPSC. Our lab has previously restored physiological function of the LDLR in FH-
iPSC using an episomal transgene; however, plasmid retention is compromised without 
continuous antibiotic selection [245]. We opted to use CRISPR/Cas9 to permanently 
correct the 3 bp pathogenic deletion in the 3040-iPSC. A schematic outline of our genome 
editing approach is presented in Figure 10. Using the MIT CRISPR Design Tool 
(crispr.mit.edu), we input the exon 4 LDLR sequence of the FH patient for identification 
of sgRNA. Thirteen possible sgRNA were found that could be used with wildtype Cas9 
that were arranged in suggested pairs for use with Cas9n. We utilized the Cas9n with a pair 
of offset sgRNA since this grouping had previously been successful in facilitating specific 
genome editing in human cells [246]. The double offset nicking approach has also shown 
a higher likelihood of forcing HDR to improve specific repair and reduce off-target 
mutations. Our guide pairs (sgRNA1 and sgRNA9) were selected based on Ran et al criteria 
[246, 252]. The guides generate 5’ overhangs with a +2 offset and create at least one nick 
within 6 bp of the target mutation site to increase the probability of HDR [186, 246]. HDR 
requires a repair template for the DNA to utilize and precisely modify the genome [186, 
198, 246, 247].  We designed an anti-sense ssODN template with right and left 50 bp 
homology arms flanking the deletion in exon 4 of LDLR. The repair template contained 
the deleted 3-nucleotides for inserting the missing 3 bp (ACC) and silent mutations in the 
protospacer adjacent motif (PAM) of sgRNA 1 within the first 10 bp upstream of the PAM 
site in sgRNA 9 to minimize rebinding after genome repair and to introduce a novel XmnI 
restriction site (Figure 11A,B) [186, 198, 246, 247].   
  76 
 
Figure 10. CRISPR Correction Strategy Methodology Schematic. (1) 3040-iPSC were 
transfected with 5 g Cas9n, 5 g sgRNA1, 5 g sgRNA9, and 5 g ssODN using (2) a 
NEPA21 square-wave electroporator. (3) Double positive (GFP+/RFP+) cells were selected 
for expansion via fluorescence sorting. (4) LDLR+ cells were enriched by magnetic sorting 
and expanded in culture. (5) Clones were isolated on laminin-521 + E-cadherin-Fc 
substrate then (6) analyzed for correction of the LDLR via RFLP, sequencing, western blot, 
and LDL internalization. 
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Figure 11. CRISPR ssODN Design. (A) Diagram of the CRISPR/Cas9 design to target the 
mutation site of the LDLR. Paired single-guide RNA (target 1 and target 9) were selected 
to target the mutation site, and a single-stranded oligodeoxynucleotide (ssODN) template 
was created to mediate HDR. The ssODN contains a 10-nucleotide sequence (underlined) 
as a novel XmnI restriction enzyme site, additional silent mutations (red nucleotides) at the 
PAM for sgRNA 1 or within 10 bp upstream of the PAM for sgRNA 9 to prevent re-binding 
of guides and cleavage with Cas9n following repair, and the 3 bp insertion (purple). (B) 
157 bp single-stranded oligodeoxynucleotides (ssODN) repair template sequence. 50 bp 
left and right homology arms (blue) surround the sequence target (57 bp). Silent mutations 
(red) were inserted to prevent further re-binding of Cas9n post-correction and create a 
novel XmnI site (underlined). 3 bp (CCA) insertion (purple) for correction was built into 
the sequence. 
 
We obtained Cas9n and sgRNA plasmids (Addgene # 60600 and 60601, 
respectively) deposited by the Hotta lab [192] and cloned in our selected sgRNA (Figure 
10, Step 1). The sgRNA plasmid contains a red fluorescent reporter (RFP) that can be used 
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to select for cells positively transfected with the sgRNA. We opted to use double 
fluorescence cell sorting post-transfection rather than antibiotic selection to potentially 
maximize selection of transfected cells. The Cas9n plasmid deposited by Hotta was 
modified to incorporate GFP into the vector.  Before transfection, we optimized 
electroporation voltage necessary for highest transfection efficiency, referencing NEPA21 
electroporator conditions by the Hotta lab [192] (Table 5). We then transfected the 3040-
iPSC with 20 g total nucleic acids (5 g Cas9n, 5 g sgRNA1, 5 g sgRNA9, and 5 g 
ssODN) (Figure 10, Step 2). After 48 hours, we sorted for dual positive (i.e. GFP & RFP) 
cells to subculture only cells transfected with both Cas9n and guide plasmids (Figure 10, 
Step 3). We collected 2.4% of the 13.1% population expressing both RFP and GFP (Figure 
12A). Because we used 2 plasmids for each guide, we could not guarantee that sorted cells 
contained both guide plasmids for correction. To enrich the population of double-positive 
transfected cells that actually contained the 3 bp insertion, we treated the culture with 
Lovastatin to upregulate LDLR expression and targeted the cell surface receptor for 
magnetic-activated cell sorting (MACS) (Figure 10, Step 4).  Using a biotinylated-C7-
LDLR antibody, we enriched for LDLR+ cells within the bulk of transfected cells. We 
analyzed the percentage of LDLR+ cells collected (green dots) after MACS by FACS. 
FACS analysis showed a mix of LDLR+ (green dots) and LDLR- (red dots) before sorting 
(left box). After MACS, we confirmed a collection of 19.1% LDLR+ cells, or corrected 
cells, with a clear shift of green dots to the right (Figure 12B). After expanding the bulk 
LDLR+ cells we adopted the clonal isolation protocol developed by the Tryggvason lab 
utilizing laminin-521 and E-cadherin-Fc substrates in mTeSR1-albumin media (Figure 10, 
Step 5) [253]. Using a clonal dilution approach, we plated 120 cells and after 7 days of 
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culture, identified 16 wells with single colonies (empty and multi-colony wells were 
counted as null clones) for a cloning efficiency of 13%. The clonal colonies were expanded 
for analysis and cryopreservation. 
 
 
Figure 12. CRISPR Positive Sorting. (A) After transfection, 3040-iPSC were sorted for 
double positive RFP and GFP cells via FACS. 13.1% of cells were dual positive and 2.4% 
of the population was collected and expanded to increase specificity of positively 
transfected cells. (B) Magnetic-activated cell sorting (MACS) was performed on the FACS 
sorted 3040-iPSC to enrich for LDLR+ expressing cells. Pre-MACS sorted cells had a mix 
of both positive (green dots) and negative (red dots) LDLR+ cells. After MACS sorting, a 
clear shift to the right showed 19.1% LDLR+ cells were collected. 
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Since we created a donor repair template that contains a unique XmnI restriction 
site (Figure 11), we could use restriction fragment length polymorphism (RFLP) analysis 
to check for potential correction of the 3040-iPSC clones. Additionally, we could see if it 
was a homozygous or heterozygous clone by band size (Figure 10, Step 6). The expected 
LDLR PCR product without any enzyme or correction is 576 bp as indicated by 3040-iPSC 
non-transfected control (Figure 13A). A homozygous corrected clone would have two 
bands at 384 bp and 192 bp while a heterozygous clone would also retain the 576 bp band. 
RFLP of the first clone (3040-C) tested indicated homozygous correction by the presence 
of only 2 bands of the correct size (Figure 13A). RFLP analysis of the other clones showed 
an additional 9 homozygous corrections and 6 heterozygous corrections (Figure 13B). To 
confirm the RFLP results, we performed Sanger sequencing on all PCR positive clones. 
Four clones were found to be homozygous corrected by sequencing; however, RFLP 
demonstrated retention of the 576 bp band (Clone 2, 3, 4, 11). We presumed these were 
not clonal and removed them from consideration.  For 12 clones, the RFLP and Sanger 
sequencing results agreed. Interestingly, sequencing indicated that not only did the 
heterozygous corrected clones (C12 and C14) only correct a single allele, but they also 
obtained different indels in the non-corrected allele proximal to sgRNA1’s target sequence. 
In addition, our selected clone (3040-C) was determined to be heterozygous in 2 silent 
mutation points denoted by the green box (Figure 13C).  From these successfully isolated 
clonal colonies, our efficiency of homozygous correction from the final isolation of 10 
(from 12) homozygous corrected clones is 83%. Since sgRNA can target multiple regions 
within the genome [198], we analyzed for off-target mutations. We selected 3 non-genic 
and 3 genic regions identified by the CRISPR Design Tool for both sgRNA1 and sgRNA9 
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with the highest potential for off-targeting (Table 6). Sequencing of 3040-C compared to 
non-corrected 3040-iPSC indicated no changes in the selected regions of the genome (not 
shown). While we were fortuitous in not detecting off-targets within the highest selected 
regions, this may not be the case with other targeted mutations. These results illustrate that 
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Figure 13. Genetic Analysis 3040-iPSC LDLR Correction by CRISPR/Cas9. (A) RFLP 
analysis was used to determine 3040-iPSC correction status by restriction digest with 
XmnI. Non-transfected 3040-iPSC showed no XmnI cleavage (576 bp) in the presence or 
absence of enzyme. 3040-iPSC clone 1 (3040-C) contained two bands at 384 bp and 192 
bp in the presence of XmnI, which remained uncut (576 bp) without enzyme. (B) RFLP 
analysis confirmed the presence of 9 homozygous (two bands 384 bp and 192 bp) and 2 
heterozygous clones (additional band at 576 bp). (C) Sanger sequencing of 3040-C 
confirmed the permanent insertion of 3-nucleotides in exon 4 of the LDLR in both alleles 
(purple box). Silent mutations (red line) including the novel XmnI site (blue box) were also 
integrated into the gene. Bold letters beneath red lines indicate original native nucleotide. 
Two silent mutations (green box) were introduced in only one allele. Ho= homozygous, 
Het= heterozygous, C= clone.  
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Genetic Correction Leads to Normalized LDLR Function in 3040-C-HLC. 
Genomic mutations of the LDLR in FH patients can vary from a single nucleotide change 
to large deletions that will denote the patient into a certain class [234, 235, 254]. The 3 bp 
deletion in 3040-iPSC are classified as Class IIB FH-Piscataway since the LDLR does not 
reach maturity and instead is retained in the ER as an immature protein that eventually is 
degraded by the proteosomal pathway [92, 119, 254]. After treatment with Lovastatin, we 
observed a robust induction of LDLR expression that was primarily in the form of 
immature protein in the non-corrected 3040-iPSC, but very little mature protein being 
detected (Figure 14i, ii & iii).  Excess sterols downregulated LDLR protein production in 
these cells as expected.  In contrast, Lovastatin treatment of the corrected 3040-C-iPSC 
showed a dramatic shift from predominantly immature protein to predominantly mature 
protein (Figure 14i, ii & iii).  Again, as expected excess sterol treatment of the corrected 
cells downregulated LDLR protein expression.  When comparing the ratio of 
mature/immature LDLR with Lovastatin treatment, the corrected cells were greater than 
30-fold higher than the non-corrected cells (Figure 14iv) suggesting the CRISPR 
modification restored the normal LDLR structure which would allow LDLR to proceed to 
the Golgi for processing and movement to the plasma membrane. Comparing DiI-LDL 
internalization under the same conditions with the hESC line H1, non-corrected 3040-iPSC 
internalize very little DiI-LDL even with Lovastatin treatment (perhaps indicating the 
function of “mature” LDLR in these cells is questionable) (Figure 14A).  Confirming the 
results of the western blot, corrected 3040-C-iPSC internalized DiI-LDL when exposed to 
Lovastatin and this receptor-mediated endocytosis was abrogated by excess sterols to a 
similar level as normal H1.  These data strongly support the conclusion that there was 
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complete genetic correction of the LDLR pathological mutation and normalization of LDL-
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Figure 14. Protein Analysis 3040-iPSC LDLR Correction by CRISPR/Cas9. 3040-C-iPSC 
and 3040-iPSC were incubated overnight in Lovastatin (Lova) or excess sterols (XS). 
Western blot (representative image, i) showed 3040-iPSC respond with an upregulation of 
an immature LDLR after treatment with Lovastatin that is reduced with excess sterols. 
3040-C-iPSC had almost no immature LDLR with Lovastatin and increased mature LDLR. 
Quantification (n=2 independent experiments) showed a 2-fold increase of mature LDLR 
in 3040-C treated with Lovastatin compared to 3040 (ii). Immature LDLR was highly 
expressed in 3040 that was almost lost in 3040-C (iii). Mature/immature LDLR was over 
30 times greater in 3040-C than 3040 in Lovastatin that was abrogated in excess sterols 
(iv). Bars shown as mean  S.E.M. 
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Figure 15. LDLR-Mediated Endocytosis is Restored in Corrected 3040-iPSC and HLC. 
(A) LDL internalization showed 3040-C-iPSC respond with an increased DiI-LDL 
internalization similar to control H1 cells that is almost non-existent in non-corrected 
3040-iPSC. LDL uptake is decreased with excess sterols. (B) DiI-LDL uptake was restored 
in 3040-C-HLC after treatment with Lovastatin that was not obvious in 3040-HLC. H1-
HLC was used as a control for normal LDLR function. Bar graph (n=2 independent 
experiments) shows measured fluorescence intensity of DiI-LDL that correlates a 4-fold 
increase in DiI-LDL uptake in 3040-C-HLC relative to 3040-HLC. Excess sterols were 
normalized to 1 and Lovastatin normalized to excess sterols. Bars shown as mean  S.E.M. 
(Scale bars = 50 μm). 
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The hepatocyte is responsible for production and metabolism of cholesterol which 
is defective in FH; therefore, we differentiated non-corrected and corrected FH-iPSC to 
HLC to determine if receptor- mediated endocytosis is corrected and functional in HLC. 
After differentiation, HLC were treated overnight with either Lovastatin or excess sterols. 
Fluorescence microscopy of 3040-C-HLC is consistent with 3040-C-iPSC indicating an 
upregulation in DiI-LDL endocytosis relative to 3040-HLC. H1-HLC control was similar 
to 3040-C-HLC (Figure 15B).  Quantification of DiI-LDL fluorescence intensity showed 
3040-C-HLC contained a substantially increased fluorescence intensity compared to 3040-
HLC (Figure 15B) that was comparable to H1-HLC.  For all three cell lines, excess sterols 
reduced DiI-LDL internalization to a basal level. Taken together, these data demonstrate 
our CRISPR/Cas9 design successfully corrected the 3bp deletion in the homozygous FH 
cells, restoring LDLR protein and LDLR-mediated endocytosis.  
 
DISCUSSION 
The novel and important findings of this study are that we have used CRISPR/Cas9 
genome editing to permanently correct a homozygous pathological mutation in patient-
specific iPSC. We have targeted a Class IIB 3 bp deletion in exon 4 of the LDLR that 
causes a reduction in receptor activity to less than 5% of normal. The successful insertion 
of the missing 3 bp has permanently corrected the genetic mutation and restored the 
physiological feedback control of receptor expression and cholesterol metabolism. We 
developed a stepwise enrichment protocol to enhance the probability of isolating corrected 
clones. The placement of the guides with respect to the mutation site likely made our cells 
more amenable to correction. Double-positive sorting with GFP and RFP improved 
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selection of dual transfected cells while MACS sorting increased the yield of LDLR 
expressing cells. Our systematic stepwise enrichment protocol allowed for the final 
isolation of 10 (from 12) homozygous corrected clones (83%). This procedure is likely 
adaptable to identifying any corrected surface protein and is a proof-of-concept that 
CRISPR technology can successfully repair LDLR mutations causing FH. 
The estimated prevalence of FH is 1:250 and 1:250000 for heterozygous and 
homozygous FH, respectively [1, 237, 238]. It is not uncommon that receptor-defective 
HoFH patients will present with clinically symptomatic CVD in the first decade of life 
[18]. A critical issue for these patients is early identification and therapeutic intervention 
[237]. Because FH is considered underdiagnosed, screening has been proposed for 
newborns. For rare HoFH patients, life-style changes and statin/ezetimibe therapy may be 
insufficient to achieve target LDL-C levels [1]. This requires more aggressive treatment 
including newly approved pharmacologics (i.e. Mipomersen, Lomitapide), lipid apheresis 
and even a liver transplant [15, 129, 240], all of which have their own potential 
complications. It is also important to recognize that newly approved PCSK9-inhibitors rely 
on LDLR expression and have a questionable effect on receptor-negative HoFH patients 
[23]. This supports the need to develop alternative approaches for treating HoFH. 
Gene and cell therapies, amenable to monogenic deficiencies [239], to restore 
cholesterol metabolism homeostasis in FH have been investigated for decades [255]. Gene 
therapy to deliver an LDLR transgene to the liver has evolved from retrovirus [256] and 
adenovirus [47] to adeno-associated virus containing liver-specific promoters [241]. The 
first gene therapy clinical trial using ex-vivo LDLR-transduced autologous hepatocytes 
showed some benefit to lowering LDL-C, but was halted due to variable metabolic results, 
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in particular, in receptor-defective homozygotes [50, 51]. A Phase 1/2 clinical trial using 
AAV-based vector to deliver LDLR is currently approved (NCT02651675). Virus-based 
gene therapy has demonstrated a capacity to lower cholesterol levels in 
hypercholesterolemic animal models [257], but issues remain including transgene 
persistence, vector delivery efficiency, and lack of LDLR expression regulation because of 
vector size limitations [245]. With regards to cell-based therapy for FH, multiple reports 
of liver transplantation demonstrate the effectiveness of providing sufficient LDLR-normal 
hepatocytes to resolve FH hypercholesterolemia [129, 240]. However, liver availability is 
limited, as are quality hepatocytes. Additionally, transplanted hepatocyte engraftment is 
very poor unless major insult to the liver is first performed [258]. Together, this 
demonstrates that issues of transgene and cell delivery for treating HoFH have not been 
completely solved. 
CRISPR/Cas9 genome editing has been demonstrated to be a straight forward 
methodology for creating mutations and for endogenous mutation repair. It has specifically 
been used in animal models to repair mutations in the dystrophin gene Dmd which causes 
Duchene muscular dystrophy [192, 259].  Pankowicz and colleagues used CRISPR/Cas9 
in a mouse model of hereditary tyrosinaemia type I to delete hydroxyphenylpyruvate 
dioxygenase (Hpd), which converted the animal to an asymptomatic tyrosinaemia type III 
[260]. Jarrett, et al [187] delivered CRISPR/Cas9 in an adeno-associated virus to disrupt 
the LDLR and cause hypercholesterolemia. They co-administered CRISPR/Cas9 to also 
disrupt the Apob gene, which rescued the hypercholesterolemic phenotype. In a Chinese 
clinical trial directed by Lu You, CRISPR was used to inactivate the T-cell PD1 gene, then 
delivered back to the patient as a treatment for metastatic non-small cell lung cancer [257]. 
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NIH has now approved a Phase I trial for using CRIPSR modified T-cells in cancer patients 
[261]. Certainly, the immediate benefit of CRISPR genome editing is rapid genetic 
modification for molecular modeling. Long-term it may also prove of even greater value 
for therapeutic applications. 
CRISPR technology has also been used to modify iPSC [172, 252]. It can knock-in 
reporters to specific loci, create knockout models and repair pathological mutations, as we 
have demonstrated here. The significance of combining CRISPR genome editing with 
patient specific iPSC is the ability to generate a completely repaired autologous cell source 
with the potential to differentiate to any cell lineage. It is widely recognized that lack of 
therapeutic cell sources is one of the major barriers to cell-based therapies and this includes 
hepatocytes to treat liver diseases [262]. Here, we demonstrate the ability to correct a 
homozygous deletion in the LDLR and normalize receptor-mediated endocytosis in 
patient-derived-HoFH-HLC.   
The FH-iPSC used in our study is considered a Class IIB FH-Piscataway mutation. 
This 3 bp in frame deletion results in a missing Gly197 in the highly-conserved binding 
domain in exon 4 of the LDLR and is highly prevalent in the Ashkenazi Jewish community 
originating from Lithuania [92]. A class II mutation leads to an improperly folded LDLR 
since the spacing between cysteine residues becomes abnormal. The immature LDLR is 
retained in the endoplasmic reticulum and eventually degraded by the proteasome pathway 
[119]. Once corrected, it is expected that the immature LDLR expression will decrease 
since the LDLR will properly fold and transition from the endoplasmic reticulum to the 
Golgi for glycosylation to a fully mature LDLR before it is transferred to the plasma 
membrane. Our western blot with fibroblast cells (Figure 6B) shows a very low level of 
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mature LDLR protein in IMR90 and no immature LDLR in GM03040. This could be due 
to the fact that these are fibroblast cell lines and do not express LDLR as hepatocytes do. 
Our western blot data indicates that non-corrected FH-iPSC have a very small 
mature/immature ratio of LDLR that is normalized in the corrected FH-iPSC. The total 
LDLR protein (immature + mature) was less in the corrected cells (Figure 14i).  The 
precise reasons for this are unclear, but is likely the result of restoration of feedback 
regulation, increased receptor recycling, and more efficient LDL-C processing. In non-
corrected cells, expression is high and the immature LDLR expression appears to be 
uncontrolled protein production. Further investigation would be needed to determine if this 
is unique to a class II mutation.   
What we’ve shown is an efficient way to fully correct a genetic mutation. By using 
Cas9n the number of off-target mutations is reduced and using specific sgRNA mediates 
specific on-target cleavage. Intriguingly, only the heterozygous corrected clones 
introduced indels into their gene. It is known that other off-target modifications may occur 
in places not predicted in the candidate list (Table 6) due to a variety of reasons including 
genomic and epigenomic properties that may affect cleavage frequency; therefore, 
unbiased detection of off-target cleavage such as whole genome sequencing is 
recommended and would be required before any corrected cell would be delivered to a 
human patient [263]. Although the CRISPR correction of HoFH-HLC does not solve all 
cell/gene-based therapy technical hurdles, it provides a platform for autologous cell 
replacement with a permanent genetic correction to the underlying pathology. CRISPR 
corrected HoFH-HLC could provide an unlimited source of autologous hepatocytes that 
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could be delivered directly to the liver or engineered into a functional liver-like tissue with 
sufficient cell mass to have a significant effect or even restore LDL-C homeostasis.   
To conclude, these data validate the feasibility of using Cas9n, dual sgRNA, and a 
repair template to correct a genetic mutation in a homozygous FH cell line, which can be 
differentiated into functional HLC that mediate LDLR endocytosis. In the future, the use 
of CRISPR-edited iPSC could be tested in patients as is currently being performed in the 
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CHAPTER III 
MAMMALIAN SPECIES WNT3A DIFFERENTIAL  
 





Liver dysfunction is caused by a variety of diseases including FH, alpha-1 
antitrypsin deficiency, non-alcoholic fatty liver disease, hepatitis B, cancer, and cirrhosis 
[264]. Although the liver has an innate ability to regenerate itself, the only successful 
approach to curing any liver disease is through organ transplantation, especially when the 
damage overtakes regeneration [265]. There are currently over 17,000 patients in the US 
waiting for a liver transplant [264]. A major problem is the limited amount of donor livers 
and quality hepatocytes available for patients. Many issues tend to arise post-liver 
transplantation including donor-host incompatibility, requiring lifelong 
immunosuppressing medications, causing an increased susceptibility and recurrence of 
infections [266, 267]. Other problems that may occur include a reversal back to the disease 
state after transplantation. In patients with FH, long term post-liver transplantation has 
shown that within 6 months to 2 years, many patients develop cholesterol levels above 200 
mg/dl, requiring high statin therapy [240, 268, 269].  
Hepatocytes are the major cell component of the liver [270]. Culturing and expanding 
primary hepatocytes has proven difficult since their survival depends on the liver 
microenvironment [271, 272]. Because of this, cultured hepatocytes begin to 
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dedifferentiate and lose their polarity over a short time. An additional key factor that has 
limited the application of hepatocyte transplantation is the significant cell loss post-
transplantation [266, 267, 273-279]. Without immunosuppressive drugs, transplanted 
allogeneic hepatocytes survive for only 7 to 10 days [258, 267, 280].  Other experimental 
approaches to address the lack of therapy in diseases like FH have included the delivery of 
normal LDLR transgenes via viral vectors [51, 244, 245, 281-284]. A clinical trial with 
HoFH patients utilized ex vivo liver-directed gene therapy and engrafted 3-9 x 109 
retrovirus-transduced autologous hepatocytes to treat FH [51]. Three of five patients had a 
decline in LDL-C levels and none developed antibodies to either the LDLR or retroviral 
proteins. However, HoFH receptor negative or defective patients did not respond to this 
treatment. Alternative treatment strategies using induced pluripotent stem cells (iPSC) has 
become one of the leading research fields for treatment of liver disease and dysfunction 
[270].  
  Transcription factors, specifically 4 including Oct4, Sox2, Klf4, and cMyc, are 
introduced into a differentiated somatic cell to reprogram it into a pluripotent stem cell 
[242]. The result is an unlimited supply of self-renewable stem-like cells. There are debates 
as to whether or not iPSC are equivalent to embryonic stem cells (ESC), especially at the 
RNA and microRNA level [285, 286]. However, there are many advantages to utilizing 
iPSC derived from patient cells including their immunological compatibility, limitless 
supply, and their ability to be differentiated into other cell types like hepatocytes [242, 287, 
288].  
 The Deng lab developed a stepwise protocol for differentiation of iPSC into 
hepatocyte-like cells (HLC) [250]. This protocol used a 5-stage protocol that involved 
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endoderm induction, hepatic specification, hepatoblast expansion, hepatic maturation, and 
matured hepatocytes. Their process required the sequential use of growth factors for the 
gradual progression from endoderm to mature hepatocyte. The critical factors were Activin 
A (AA), bone morphogenetic protein 2 (BMP2), fibroblast growth factor 4 (FGF4), 
hepatocyte growth factor (HGF), and Oncostatin M (OSM). These 5 factors were included 
among 8 (keratinocyte growth factor, Dexamethasone, N2) different components necessary 
in the 5-stage, 21-day protocol for differentiation of iPSC to HLC [250]. By the end of 3 
weeks of differentiation, the HLC expressed hepatic markers including immature 
hepatocyte marker alpha-fetoprotein (AFP), mature hepatocyte marker albumin, and 
hepatocyte plasma membrane marker cytokeratin 18. In addition, the cells exhibited 
activity of hepatocytes including glycogen and urea synthesis and albumin secretion [250].  
 Duncan and colleagues modified this protocol [289, 290] so that only 4 stages were 
needed but more importantly, the growth factors required were decreased to 5 (AA, BMP2, 
FGF4, HGF, and OSM). In addition, the environmental conditions were modified to a 
hypoxic state (4% oxygen, 5% carbon dioxide). At the end of this differentiation, 70% to 
90% of cells expressed albumin with a decrease in AFP expression indicating these human-
derived HLCs when injected into mouse livers integrated into the existing mouse 
parenchyma [289]. Both of these differentiation protocols were successful in 
differentiating human iPSC to HLC [289, 290].  
As mentioned in the previous chapter, ESC/iPSC can differentiate into 3 germ 
layers: endoderm, mesoderm, and ectoderm. The proper development of the primitive 
ventral endoderm that forms the liver requires Wnt3a [291]. Wnt3a is a member of highly 
conserved glycoprotein family members that are necessary in normal development [292]. 
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Knockout of Wnt3a resulted in mouse ESC that failed to express mesoderm and endoderm 
genes suggesting the inability to generate a primitive streak [293].  
 Bearing this in mind, the lab of Dr. David Hay designed an HLC-differentiation 
protocol that mimicked the developing embryo resulting in a homogenous differentiation 
HLC population [294]. Eventually they developed a 3-stage protocol that used AA and 
Wnt3a in stage 1, no growth factors in stage 2, and HGF and OSM in stage 3 [295]. This 
yielded 90% albumin-expressing HLC.  
 Our lab has previously differentiated iPSC to HLC [189, 245] using the 5-stage 
Song protocol [250]. This resulted in efficient generation of HLC as shown in Figure 9. 
However, the cell yield was low. Differentiation to definitive endoderm is considered the 
critical stage to HLC production. It is here that will decide the fate of whether or not cells 
differentiate to hepatocytes and if they do so in an efficient manner. Therefore, we 
investigated which protocol was the most efficient at producing endoderm.  
 
MATERIALS AND METHODS 
Cell Culture. H1 (WiCell, Madison, WI) were cultured on hESC-Qualified 
Matrigel coated plates (BD Biosciences) in mTeSR1 with media changed daily 
(STEMCELL Technologies) [245].  Cells were passaged using Gentle Cell Dissociation 
Buffer (GCDB; STEMCELL Technologies) with 10mM Rock inhibitor (Selleck 
Chemical) and maintained at 37C and 5% CO2 [245].  
Hepatocyte Differentiation. H1-ESC underwent directed differentiation to 
definitive endoderm as outlined in Figure 16 below.  
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Figure 16. Hepatocyte-Like Cell (HLC) Differentiation Protocol.  H1 stem cells underwent 
differentiation to the end of stage 1 or definitive endoderm. Song stage 1 has been modified 
for use of commercially available StemDiff (STEMCELL Technologies, Vancouver, 
Canada) for 4 days. Duncan requires the use of AA, BMP4, FGF2, HGF, and OSM. Hay 
utilizes AA and Wnt3a in the definitive endoderm stage and only adds OSM and HGF in 
the final stage.  
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Fluorescence Activated Cell Sorting (FACS). After differentiation to definitive 
endoderm, cells were dissociated to single-cells, counted, centrifuged, and re-suspended at 
<106 cells in 100 L stain buffer and kept on ice. The same was done with control HepG2 
and non-differentiated H1 cells. The cells were incubated in their appropriate isotype 
controls or antibodies (Table 7) for 30 minutes at 4 C protected from light. After 30 
minutes, cells were washed twice with stain buffer. Cells were re-suspended in 300 L 
stain buffer. The cells were run through the BD LSRII Cytometer (BD Biosciences) and 
analyzed via FlowJo (BD Biosciences).   
mWnt3a and hWnt3a Dose Course. H1-ESC were differentiated to definitive 
endoderm following Hay’s stage 1 protocol (Figure 11). Mouse Wnt3a (mWnt3a; 
Peprotech) or human Wnt3a (hWnt3a; R&D) were added to definitive endoderm media at 
various concentrations [0, 10, 25, 50 ng/mL]. After 5 days, cells were collected and 
analyzed via qPCR for definitive endoderm markers.  
mWnt3a and hWnt3a Time Course. H1-ESC underwent directed differentiation 
to definitive endoderm following Hay’s stage 1 definitive endoderm (Figure 11). 50 ng/mL 
of mWnt3a or hWnt3a were added to definitive endoderm media. Cells were collected at 
time point 0, 1, 3, and 5 days and analyzed via qPCR for definitive endoderm markers.  
Quantitative PCR analysis. At the end of stage 1, H1 cells were lysed using 100 
L of 0.1% -mercaptoethanol in RLT Buffer (Qiagen). The lysates were purified with 
Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions. RNA 
was quantified with a NanoDrop One Spectrophotometer (ThermoFisher). cDNA was 
synthesized using 1g RNA with SuperScript IV reverse transcriptase (Invitrogen) in a 20 
L volume. The qPCR was performed using Fast SYBR Green Master Mix 
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(ThermoFisher) with primers obtained from Integrated DNA Technologies (IDT) (Table 
8). Reactions were run on the StepOnePlus Real-Time PCR System (ThermoFisher). Raw 
data was analyzed in Microsoft Excel and graphs produced in GraphPad’s Prism 8.  
Table 7 
List of Antibodies for FACS  
Tube Particle/Cell APC AF700 
Bead (+) (+) bead/ (+) IgG bead -- -- 
Bead Tra-1-81 
(+) bead/ (+) IgG bead + 
Tra-1-81-APC in 1ml SB 




(+) bead/ (+) IgG bead + 
CXCR4-AF700 in 1ml SB  
-- 
5 l CXCR4 AF700 
(R&D) 
Control H1 Tra 1-81 APC CXCR4 AF700 
Control H1 





Hay DE, Duncan DE, 
Song DE 
Tra 1-81 APC CXCR4 AF700 
 
Hay DE, Duncan DE, 
Song DE 
IgM APC IgG AF700 
 
Table 8 
List of Primers Used for qPCR Analysis of Definitive Endoderm  
Gene  Primer 1 (5’ → 3’) Primer 2 (5’ → 3’) Product 
Size 
(bp) 
Oct4 TGATCCTCGGACCTGGCTAA AACCACACTCGGACCACATC 180 
Sox17 CCGCGGTATATTACTGCAACTA CACCCAGGACAACATTTCTTTG 152 
Hnf4a GGCCAAGTACATCCCAGCTT TCATTGCCTAGGAGCAGCAC 170 
P0 TCGACAATGGCAGCATCTAC ATCCGTCTCCACAGACAAGG 200 
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RESULTS 
Activin A and Wnt3a increase CXCR4+ Definitive Endoderm Cells. We began 
by investigating which of the 3 endoderm differentiation protocols would deliver the 
highest rate of this cell type. Efficient production of endoderm requires expression of the  
endoderm markers Sox17 and CXCR4 [296]. Markers for ESC/iPSC like Tra-1-81 can 
distinguish cells that have yet to begin differentiation [297].  We plated H1-ESC onto 35 
mm dishes and began each of the differentiation processes according to Figure 16. To note, 
we did not have a chamber available to maintain cells at 4% oxygen prior to or throughout 
the course of differentiation as suggested by Duncan [289]. Instead, we focused on treating 
H1 with only Activin A for the 5-day differentiation. We observed significant cell death at 
day 2 with the Song/StemDiff and at day 3 with Duncan and Hay. However, cells grew in 
most of the plates at the end of stage 1. We collected the cells for analysis of Tra-1-81 and 
CXCR4 expression by FACS. 
Our H1 non-differentiated control expressed only Tra-1-81 (Figure 17A) and no 
cell-surface CXCR4. In contrast, all 3 endoderm differentiation procedures resulted in 
expression of CXCR4 (Figure 17B, C, D, bottom right panel). However, there also 
appeared to a substantial number of Tra-1-81 expressing cells present in all 3 cell cultures 
(Figure 17B, C, D, bottom center panel). Compiling the data for Tra-1-81 and CXCR4 
into single graphs indicated that indeed for all the differentiation protocols there were many 
Tra-1-81 expressing cells, indicating they are still stem cells (Figure 18). In comparing 
each protocol, Song/StemDiff appeared to have lowest expression of Tra-1-81 and an 
increase in CXCR4 (Figure 18, blue). The Hay protocol resulted in a shift to the right for 
both Tra-1-81 and CXCR4 compared to Song/StemDiff (Figure 18, green). Cells in 
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Duncan’s modified protocol had the largest shift to the right in both Tra-1-81 and CXCR4 
expressing cells indicating that while a large population were differentiating to endoderm, 
a large population were still stem cells too (Figure 18, yellow). Although more cells 
expressed CXCR4, the Tra-1-81 expression was greater than that of H1 control non-
differentiated cells. Since Hay’s protocol resulted in the greatest number of CXCR4 
expressing cells, we used this protocol for the rest of this study.  
Wnt3a species and dose impact differentiation of cells to definitive endoderm.  
The Hay protocol calls for the use of 50 ng/mL of recombinant mouse Wnt3a (mWnt3a) 
purchased from Peprotech [295]. Other sources have used human Wnt3a at lower 
concentrations [298] although it has been shown that recombinant mouse Wnt3a (mWnt3a) 
exhibited higher Wnt signaling activity than hWnt3a [299]. We began by investigating 
whether mWnt3a or hWnt3a would be most efficient for endoderm. H1 cells were plated 
and differentiated using Hay’s protocol (Figure 16) with the modification of either hWnt3a 
or mWnt3a at concentrations of 0, 10, 25, and 50 ng/mL. After 5 days, the cells were 
collected and qPCR was done to assess mRNA transcript levels for Oct4, Sox17, and 
Hnf4a, which are common markers for distinguishing stem cells from definitive endoderm 
(Figure 19).  
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Figure 17. Differentiation for Endoderm. H1 stem cells were differentiated using 3 
different protocols and analyzed for expression of stem cell or definitive endoderm markers 
by FACS. In the top panels, control IgM and IgG2b are not expressed in the cell (A) Control 
H1 non-differentiated stem cells bottom panels: H1 express no CXCR4 and are all Tra-1-
81 positive. (B) Hay protocol for definitive endoderm: bottom panels: some cells still 
express Tra-1-81 and there is clear expression of CXCR4 positive cells; most cells are 
alive. (C) Song/StemDiff protocol for definitive endoderm: bottom panels: expression of 
CXCR4 positive cells is greater than Tra-1-81 but there is also increased cell death. (D) 
Duncan protocol for definitive endoderm: bottom panels: CXCR4 positive cells present but 
a larger number of Tra-1-81 cells still present in culture. (n=1) 
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Expression of octamer-binding transcription factor 4 (OCT4) is an indicative 
pluripotence marker while sex determining region Y box 17 (SOX17) is a definitive 
endoderm marker [250]. Hepatic lineage specification is indicated by expression of 
hepatocyte nuclear factor 4a (HNF4A) [250]. Oct4 expression was highest in non-
differentiated cells in both groups. Noticeably, hWnt3a treated cells had low expression of 
Oct4 across all doses that was only present with Activin-A in the mWnt3a treated culture 
(Figure 19A). Expression of Sox17 was upregulated in mWnt3a treated culture and 
appeared to decrease with increased dose (Figure 19B). hWnt3a treated culture had 
reduced Sox17 expression, while its Hnf4a transcript levels were elevated compared to 
mWnt3a treated culture in all doses (Figure 19C). Of interest, Oct4 expression levels were 
10 times higher than Sox17 and Hnf4a levels. Graphs depicting this indicate just how low 
expression of definitive endoderm and hepatic markers can be in a mixed cell culture 
(Figure 19D, F).  
Because definitive endoderm differentiation occurs over 5 days, we examined a 
time course for changes in expression of iPSC markers recession and endoderm marker 
appearance. Similar to the dose curve data (Figure 19), Oct4 expression was higher in 
mWnt3a treated culture than hWnt3a treated culture. Still, Oct4 decreased greatly by day 
3 in both cultures (Figure 20A). Sox17 expression was 10-fold higher in mWnt3a treated 
culture than hWnt3a treated cells, particularly by day 3 across all doses in mWnt3a treated 
cells. Hnf4a transcripts were also upregulated in mWnt3a treated culture as the dose days 
progressed. This was surprising in that hWnt3a treated culture had an increased Hnf4a at 
day 5 across all doses in Figure 14C. This was completed with a sample of 1 and requires 
repeating.  
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Figure 18. All Protocols Result in a Mixed Population of Tra-1-81 and CXCR4. Control 
(red) non-differentiated cells expressed only Tra-1-81. StemDiff/Song (blue) showed lower 
Tra-1-81 and higher CXCR4 expression but an overall smaller population of total cells. 
Duncan (yellow) had the highest number of cells expressing both Tra-1-81 and CXCR4. 
Hay (green) had a lower number of Tra-1-81 positive cells than Duncan and similar levels 
of CXCR4.  (n=1) 
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Figure 19. Human Wnt3a Causes Increased Hnf4a Expression Compared to mWnt3a. 
Stage-specific markers were tested at the mRNA expression level (POU4F1, SOX17, 
HNF4A). (A) Oct4 expression was highest in non-differentiated cells. (B) Sox17 definitive 
endoderm was increased in 10 ng/mL mWnt3a cells. (C) Hnf4a had high expression in 
hWnt3a culture across all doses. (D,E) Sox17, Hnf4a expression modified to fit Y-axis of 
Oct4 to distinguish the low expression of these 2 markers.  
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Figure 20. Hnf4a Expression Occurs by Day 5 in Endoderm Differentiation. (A) After time 
course of 5 days, Oct 4 expression was highest in mWnt3a at all doses but began to decrease 
by day 3 in culture. The same pattern was observed in hWnt3a culture. (B) Sox17 was 
elevated at day 3 in both mWnt3a and hWnt3a at all doses and begins to decrease at day 5. 
(C) Hnf4a had high expression in m Wnt3a at day 5 as did hWnt3a.   
 
DISCUSSION 
 There are many factors to consider when beginning the differentiation process of 
cells. The starting confluence, the plating of single cells over clumps/colonies of cells, and 
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even the logarithmic phase of the ESC/iPSC growth prior to passaging for differentiation 
must all be scrutinized to reliably generate healthy HLC [289, 300]. A protocol described 
in one paper effectively producing functional HLC does not mean that this will occur 
universally in all labs. These protocols are like recipes that must be examined and 
optimized for in your own kitchen. With this in mind, we sought optimize conditions for 
differentiation of our ESC to HLCs. 
  The main finding of this report is that 25 ng/mL and 50 ng/mL of hWnt3a and 
mWnt3a with the Hay protocol both upregulate expression of endoderm and hepatic 
markers (Sox17 and Hnf4a) reaching similar levels [295]. This indicates that both may be 
sufficient in producing definitive endoderm. To confirm this result, the experiment needs 
additional replication. In addition, differentiation to HLC would provide evidence, if 
favoring one or the other was optimal.  
We observed that Duncan’s protocol yielded higher numbers of H1-CXCR4 
expressing cells; however, the number of ESC Tra-1-81 positive cells was just as high 
(Figure 18D). We did not follow the protocol precisely since we did not have access to a 
cell chamber to maintain hypoxic oxygen levels. This may be the key to reducing the 
number of non-differentiated cells. It has been demonstrated that hypoxic oxygen levels at 
1% significantly increase Activin A-induced definitive endoderm cells compared to 21% 
normoxia in mouse ESC [301]. With a controlled chamber for oxygen, we could determine 
if Wnt3a is necessary for differentiation of our iPSC to HLC.  
Despite this work, it is known that HLCs derived from iPSC will still present an 
immature hepatocyte phenotype, which would limit their use in clinical therapy. The 
extracellular matrix (ECM) is regarded as the foundation that can make or break derived 
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hepatocytes potential of becoming fully functioning mature hepatocytes. Matrigel is the 
main ECM used for both stem cell culture and differentiation [290, 299, 302]. Matrigel, 
unfortunately, varies from batch to batch and is still undefined with respect to various 
components [303]. It also contains animal derivatives that would make it difficult to use in 
clinical work.  An alternative to Matrigel could be the use of laminins. Laminins (LN) are 
glycoproteins that are part of the ECM. They are found in the ECM of the embryo. Hay’s 
lab utilized two laminins, LN521 and LN111, to derive HLC from iPSC [304]. These two 
laminins are present in the liver stem cell niche and have been shown to drive endoderm 
and liver stem cell differentiation [305, 306]. LN521 and LN111/LN521 mixture increased 
the number of cells with morphological appearance of HLC compared to the use of 
Matrigel. Additionally, staining for bile canaliculi organization demonstrated a functional 
bile canaliculi on the LN521 and LN111/LN521 mix that was present on Matrigel [304].    
The use of patient-specific iPSC for studies in disease modeling, drug toxicity, and 
organoid transplantation would require a highly pure culture of definitive endoderm in the 
initial stage of differentiation. Taking into consideration these factors involved can help us 
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CHAPTER IV 
STATIN-INDUCED ACCUMULATION OF CLASS II IMMATURE LDL-RECEPTOR  
IN FAMILIAL HYPERCHOLESTEROLEMIA DOES NOT ACTIVATE  





Familial hypercholesterolemia (FH) is an autosomal dominant disease primarily 
caused by mutations in the LDL receptor (LDLR) gene leading to premature cardiovascular 
disease (CVD) [17, 234-236]. LDLR activity ranges with disease severity and is based on 
the mutation within the LDLR [92]. There are over 1200 LDLR mutations identified that 
are categorized into six classes [236, 239]. As of 2012, greater than 50% have been 
described as class II or transport defective mutations [92, 98]. After translation, a newly 
synthesized and unfolded LDLR is processed in the ER as a partially glycosylated 
precursor of 120-kDa [98], aided by ER chaperones glucose-regulated protein 78 (Grp78),  
receptor associated protein (RAP) [98, 106, 307] and Mesoderm Development (MESD) 
[110]. The LDLR is then transported to the Golgi where N-and O-linked sugars are added, 
increasing the molecular weight to 160-kDa [116, 117]. Class II mutations are commonly 
referred to as a “folding or conformational disease” [98, 120, 121] because these mutations 
result in a misfolded LDLR that is either unable or has a less than 5% rate of leaving the 
ER for the Golgi [92].  
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The molecular mechanisms responsible for LDLR folding and maturation is still 
unclear. The quality control system of the ER ensures that newly synthesized proteins only 
leave the compartment when their folding criteria have been met [208, 209, 211]. 
Chaperones expressed in the ER play a significant role in the protein folding process  [105, 
214]. General chaperone Grp78 transiently binds the LDLR and aids in its proper folding 
under normal conditions [124, 125, 215]. This correlates with studies of Grp78 acting 
selectively in retaining proteins in the ER [215].  This quality control ensures that only 
properly folded proteins exit the ER for the Golgi, while misfolded proteins are retained in 
the ER for further processing. If unable to be corrected, misfolded proteins in the ER can 
accumulate and cause ER stress, activating the unfolded protein response (UPR) [213, 217, 
218]. The UPR’s major role is to maintain protein homeostasis in the presence of 
accumulated un/misfolded proteins. The 3 major stress sensor pathways in UPR activation 
are inositol-requiring transmembrane kinase/endonuclease (IRE1), PKR-like ER kinase 
(PERK), and activating transcription factor 6 (ATF6) [213]. The UPR works to alleviate 
ER stress by upregulating the folding capacity through controlling expression of 
transcription factors and other downstream targets that specifically mediate protein folding, 
ER-Golgi trafficking, organelle biogenesis, and ER-associated degradation (ERAD) [213].  
Also classified as a misfolded protein disease [98], there is very limited research 
into class II LDLR misfolding, primarily because of the accelerated devastating effect FH 
has on the cardiovascular system. Evidence presented in the literature suggests that ER 
stress occurs in FH class II mutations because of accumulating misfolded LDLR [124, 
125]. We reprogrammed class II FH fibroblasts with a homozygous 3 bp deletion in LDLR 
exon 4 (GM03040) with <5% receptor activity to iPSC [189]. We utilized the genome 
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editing tool, clustered-regularly-interspaced-short-palindromic-repeats/CRISPR-
associated 9 (CRISPR/Cas9), to permanently correct the 3 bp deletion in the LDLR. The 
successful correction restored physiological feedback control of receptor expression [189].  
C-iPSC confirmed restoration of the mature LDLR protein and normalization of receptor-
mediated LDL internalization compared to NC-iPSC. Prior to correction, we observed a 
significant accumulation of immature LDLR protein upon treatment with statin in NC-
iPSC [189]. Understanding that ER stress activates UPR due to accumulation of misfolded 
proteins and that overexpressed class II LDLR mutants express ER stress markers, we 
questioned how statin therapy affects FH class II LDLR function. Using our FH class II 
LDLR corrected and non-corrected model as a tool, we hypothesized that class II FH cells 
differentiated to hepatocyte-like cells (HLC) activate UPR when treated with statins and 
this effect is diminished with correction of the LDLR.  
 
MATERIALS AND METHODS 
 
Cell Culture and Hepatocyte Differentiation. Reprogrammed human induced 
pluripotent stem cells (iPSC), 3040-iPSC and 3040-C-iPSC (derived from Coriell Cell 
Repository GM03040 fibroblasts) [Add Omer et al here], were cultured on hESC-Qualified 
Matrigel coated plates (BD Biosciences, San Jose, CA) in mTeSR1 with media changed 
daily (STEMCELL Technologies, Vancouver, Canada) [245].  Cells were passaged using 
Versene (ThermoFisher, Waltham, MA) with 10 M Rock inhibitor (Selleck Chemical, 
Houston, TX) and maintained at 37C and 5% CO2 [245]. H1 cells (WA01/NIH 0043, 
WiCell, Madison, WI) were cultured as the iPSC.  
All three cell lines underwent directed differentiation to hepatocyte-like cells as 
reported previously [308]. Briefly, iPSC were plated on hESC-Qualified Matrigel coated 
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60mm plates at 5 x 105 cells. The next day, stage 1 definitive endoderm differentiation was 
initiated by replacing stem cell media with stage 1 differentiation media (RPMI1640 
(Invitrogen, Waltham, MA) with B27 (1X, Invitrogen)) supplemented with human Activin 
A (100 ng/mL, Peprotech, Rocky Hill, NJ) and human Wnt3a (50 ng/mL; R&D Systems, 
Minneapolis, MN). Media was changed daily for 5 days. This was followed with a 5-day 
culture in stage 2 hepatoblast media (Knock Out Dulbecco’s Modified Eagle’s medium 
(KO-DMEM, Invitrogen), 20% knockout serum replacement (KSR, Invitrogen), 0.5X 
GlutaMAX (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM -
mercaptoethanol (ThermoFisher), and 1% DMSO (v/v) (ThermoFisher) with media 
replacement every other day. Cells were finally cultured in stage 3 hepatocyte maturation 
media for 11 days (HepatoZYME (Invitrogen) with 10 M hydrocortisone 21-
hemisuccinate (Sigma-Aldrich), 0.5X GlutaMAX supplemented with human hepatocyte 
growth factor (HGF, 10 ng/mL, Peprotech) and human Oncostatin M (OSM, 20 ng/mL, 
Peprotech)). The media was changed every other day.  
Quantitative PCR analysis. The iPSC or HLC were starved overnight in 5% 
lipoprotein-deficient serum (LPDS, ThermoFisher) media supplemented with 5 M 
Rosuvastatin (EMD Millipore, Burlington, MA) or excess sterols (10 g/mL cholesterol 
and 5 g/mL 25-hydroxycholesterol; Sigma-Aldrich). Positive control cells were also 
treated with 5 g/mL Tunicamycin (Invitrogen) for 4 hours. Control cells were treated with 
DMSO overnight. At the end of treatment, iPSC and HLC were lysed using 150 L of 
0.1% -mercaptoethanol in RLT Buffer (Qiagen, Valencia, CA). The lysates were purified 
with Qiashredder and RNeasy kits (Qiagen) according to the manufacturer’s instructions. 
RNA was quantified with a NanoDrop One Spectrophotometer (ThermoFisher). cDNA 
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was synthesized using 1 g RNA with SuperScript IV reverse transcriptase (Invitrogen) in 
a 20 L volume. qPCR was performed using Fast SYBR Green Master Mix 
(ThermoFisher) with primers obtained from Integrated DNA Technologies (IDT) (Table 
9). Reactions were run on the StepOnePlus Real-Time PCR System (ThermoFisher). Raw 
data was quantified in Microsoft Excel and statistics performed in GraphPad’s Prism 8 (La 
Jolla, CA). Polymerase chain reaction (PCR) was carried out for spliced-XBPI and XBPI 
expression with PCR Supermix (Invitrogen). Amplicons were evaluated via 2% agarose 
gels (Bio-Rad). 10 L of amplicons were added to 2 L 6X Loading Buffer (Invitrogen). 
Gels were run at 80 V for 60 minutes and imaged via ChemiDoc Imaging System with 
Image Lab Touch Software (Bio-Rad, Hercules, CA).   
Western Blot. The iPSC or HLC were treated as described above. Following 
treatment, the cells were thoroughly washed with PBS+/+ prior to adding 200 L RIPA lysis 
buffer (ThermoFisher) plus protease inhibitor cocktail (ThermoFisher) for cell collection. 
Lysates were rocked overnight at 4C, followed by centrifugation for 15 minutes. 
Supernatants were used for protein quantification by DC Protein Assay (Bio-Rad). 10 
g/sample of total protein was run on a 4-10% mini-protean TGX precast gels (Bio-Rad) 
at 200 volts for 40 minutes. Proteins were transferred onto PVDF (Bio-Rad) then blocked 
in 3% milk/PBST. Membranes were probed overnight with the LDLR antibody (1:1000 in 
5% BSA/PBST; R&D Systems) or -actin (1:1000; Santa Cruz Biotechnology, Dallas, TX) 
overnight at 4C. The membranes were incubated in either HRP-Bovine anti-goat IgG H+L 
(Jackson ImmunoResearch, West Grove, PA) or anti-mouse IgG (Cell Signaling, Danvers, 
MA), HRP-linked antibodies (1:5000 in 3% milk/PBST) the following day for 1 hour at 
room temperature. Clarity Max Western ECL Blotting Substrate (Bio-Rad) was used to 
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visualize the proteins on the Bio-Rad Imager. Densitometry was performed using Bio-Rad 
imaging software. A list of all antibodies used for analyses is presented in Table 10.  
Cellular Cholesterol Replenishment. Cells were plated on 35 mm tissue culture 
dishes and differentiated until day one of stage three, as described above. Cells were treated 
with LPDS media supplemented with 5 M Rosuvastatin for 48 hours. After 48 hours, cells 
were treated with LPDS media supplemented with 5 M Rosuvastatin and 10 mM methyl-
-cyclodextrin (Sigma-Aldrich) for 45 minutes [309]. After 45 minutes (timepoint 0-hour), 
cells were collected as described below. The remaining dishes were cultured with LPDS 
media supplemented with 5 M Rosuvastatin and 10 g/mL LDL-C (ThermoFisher). Cells 
were collected at 6 and 24 hours.   
Cells were collected by incubating in TrypLE Express (ThemoFisher) for five 
minutes then gently scraping and transferring cells to a 15 mL tube. After centrifugation 
(200 x g, 4 minutes), the cell pellet was re-suspended in 200 L chloroform/methanol (2:1 
v/v) mixture, vortexed, and centrifuged (14,000 x g, 5 minutes) to allow separation into 
three layers. A micropipette was used to carefully discard the top aqueous layer containing 
RNA. Next, a micropipette was used to gently push past the interphase layer (a thin 
membrane of protein) to reach the organic phase layer containing the lipids. This bottom 
lipid layer was transferred into a new microcentrifuge tube. The lipid solution was dried 
using the Savant SpeedVac Plus vacuum (ThermoFisher) for 30 minutes. The dried lipids 
were re-suspended in 1X reaction buffer supplied in the Amplex Red Cholesterol Assay 
kit (ThermoFisher). The middle protein layer was re-suspended in RIPA lysis buffer, 
incubated overnight at 4° C, and processed the day next day for protein analysis.  
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Collected lipid content was analyzed with the Amplex Red Cholesterol Assay Kit 
per the instructions. Readings were measured on the Synergy4 spectrophotometer (BioTek, 
Winooski, VT) with Gen5 software (BioTek) at an excitation of 560 nm and emission 
detection at 590 nm. Lipid content was normalized to total protein level as measured by 
the DC protein assay. 
Fluorescence-labeled LDL uptake assay. NC-iPSC and C-iPSC were plated in 3 
of 4 wells of a 4-well chamber slide and differentiated to HLC (see above). Three wells 
were treated overnight in LPDS media supplemented with 5 M Rosuvastatin. The 
following day, two wells in Rosuvastatin were treated with 10 g/mL low density 
lipoprotein labeled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine 
perchlorate (fluorescently labeled DiI-LDL) (ThermoFisher) for either 6 or 24 hours while 
the remaining well did not receive any DiI-LDL. Cells were fixed with 2% PFA/PBS (10 
minutes, 24° C; Electron Microscopy Sciences, Hatfield, PA) and mounted with 
VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories, 
Burlingame, CA). Slides were imaged using Olympus IX81 fluorescence microscope 
(Center Valley, PA) at 20X magnification.  
Immunocytochemistry and Image Analysis. Following Rosuvastatin treatment 
overnight in LPDS media, HLC were fixed with 2% PFA/PBS (10 minutes, 24° C), 
permeabilized with 0.05% Triton X-100/PBS (10 minutes, 24° C; Sigma Aldrich) and 
washed with PBS. Cells were then blocked with 5% normal donkey serum/PBS (Jackson 
ImmunoResearch) for 1 hour followed by blocking with an avidin/biotin blocking kit 
(Vector Laboratories). Primary antibodies were diluted in 5% donkey serum/PBS and 
incubated on cells overnight at 4° C. Secondary antibodies diluted in 5% donkey 
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serum/PBS (1:1000) were added to the cells (2-hour, 24° C) followed by washing and 
mounting with VECTASHIELD Antifade Mounting Medium with DAPI. Slides were 
imaged using Olympus BX61WI confocal microscope with Fluoview (FV10-ASW 4.1, 
Olympus). The four channels were merged into a single image using AMIRA software 
(ThermoFisher) [310]. Using Fluoview (FV10-ASW 4.1), confocal image stacks were 
analyzed utilizing the colocalization processing tool to both visualize overlapping of 
images as well as quantification of overlap. A list of all antibodies used for analyses is 
listed in Table 10. 
Statistical Analysis. Data from three independent experiments were analyzed via 
one or two-way ANOVA with a post-hoc using Tukey multiple comparison test in 
GraphPad Prism 8 and expressed as mean  SEM. Figure legends contain further details.  
Table 9 
PCR Primers for LDLR and ER Stress  
Gene  Primer 1 (5’ → 3’) Primer 2 (5’ → 3’) Product Size (bp) 
LDLR GCAGTGTGACCGGGAATATGA GTTGGTCCCGCACTCTTTGA 115 
Grp78 CCGTTCAAGGTGGTTGAAAAGAA TGGCGTTGGGCATCATTAAAA 200 
(S) XBP1 CCTGGTTGCTGAAGAGGAGG GGCAGGCTGCTGTCCTCAT 150; 124 
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Table 10 
List of Antibodies and Fluorophores for WB and ICC 
Antigen Host Dilution Distributor 
LDLR Goat 1:100 (ICC), 1:1000 
(WB)  
R&D Systems, Minneapolis, MN 
Calnexin Mouse 1:100 EMD Millipore, Billerica, MA 
Biotinylated-Wheat 
Germ Agglutinin 
- 1:200  Vector Laboratories, Burlingame, CA 
Actin Mouse 1:1000 Santa Cruz Biotechnology, Dallas, TX 
gIgG Goat 1:100 Novus Biologicals, Littleton, CO 
mIgG2b Mouse 1:100 Invitrogen, Carlsbad, CA 
Alexa Fluor Donkey 
Anti-Goat 488nm 
 1:1000 Invitrogen 
Alexa Fluor Donkey 
Anti-Mouse 546nm 
 1:1000 Invitrogen 
Streptavidin-649   1:1000 Vector Laboratories 
HRP-Bovine Anti-Goat 
IgG H+L 









LDL-C Internalization is Restored in Corrected Hepatocyte-Like Cells  
Our previously published work was focused on iPSC and the restoration of LDL-C 
internalization in FH-iPSC using CRISPR/Cas9 [189]. This is potentially important for 
studying the effects of statins on pregnant FH patients. The hepatocyte is responsible for 
cholesterol regulation and is the cell making up the liver parenchyma. After CRISPR/Cas9 
correction of cells, we saw an internalization of LDL-C was restored in HLC [189]. We 
wanted to examine a time course for replenishment of LDL-C and whether or not the NC-
HLC could recover over a 24-hour period by non-receptor mediated mechanisms. We 
treated HLC overnight in LPDS media with Rosuvastatin (0h), then added 10 g/ml DiI-
LDL for 6 (6h) or 24 (24h) hours. As expected at the 0h, no DiI fluorescence was detected 
in either NC or C-HLC. After 6h, NC-HLC still had not internalized a detectable level of 
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DiI-LDL as evidenced by lack of fluorescence signal.  After 24 hours, a minimal DiI 
fluorescence signal was detected suggesting internalization by non-receptor mediated 
mechanism or through the expected 5% LDLR activity of this mutation (Figure 21A, top 
panels). In contrast, the C-HLC presented a far greater capacity for DiI-LDL 
internalization over this time frame (Figure 21A, bottom panels). At 6h, the C-HLC 
showed bright DiI fluorescence that qualitatively increased over 24h (Figure 21A). This 
indicates that the corrected cells are capable of internalizing LDL via receptor mediated 
mechanisms and that statin treatment produces a time dependent LDL internalization 
increase. 
We next asked what is the ability of NC and C-HLC to restore cellular cholesterol 
after depletion with methyl--cyclodextrin. HLC were incubated in LPDS media 
supplemented with Rosuvastatin overnight for 48 hours as described, then treated with 10 
mM methyl--cyclodextrin for 45 minutes to extract any cholesterol stored within the cell 
[309]. Samples collected after 45 minutes and designated as time point zero or basal 
cholesterol levels. At t0, unlabeled LDL-C was added to the remaining cells for 6 and 24 
hours after which samples were also collected. Cholesterol content was measured using 
Amplex Red quantification [311] and normalized to total protein (Figure 21B). At t0 after 
cyclodextrin treatment, the starting cellular cholesterol content for both NC and C-HLC 
were 15.7 and 11.6 M/(g/L) with no statistical difference, indicating the starting 
cholesterol content was equivalent for both cell populations. Six hours after cyclodextrin 
treatment the NC and C-HLC cholesterol content was 10.6 and 14.5, respectively, which 
was still not significantly different between the cell groups at this time point nor different 
from the t0 starting time point. It was only after 24h that a statistically significant difference 
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was quantified. At 24h, the NC-HLC contained 21 cholesterol/unit protein, which 
statistically was equivalent to t0 and t6h. When the LDLR is corrected, C-HLC contained 
statistically significant (p < 0.05) increase in cellular cholesterol of 61 with treatment 
compared to t0 and t6h as well as NC-HLC. This demonstrates a quantitative increase in 
the corrected HLC’s ability to internalize cholesterol and the receptor corrected cells have 
the ability to overcome cyclodextrin inhibited endocytosis [312]. Together this data 
supports the normalization of LDLR mediated LDL-C endocytosis in FH differentiated 
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Figure 21. LDLR-Mediated Cholesterol Internalization is Restored in C-HLC. (A) NC- 
and C-HLC were treated overnight in 5% lipoprotein deficient serum media (LPDS) 
supplemented with Rosuvastatin. This was followed by incubation with DiI-LDL for 6h or 
24h. NC-HLC did not show any DiI fluorescence from LDL uptake until 24h. C-HLC 
internalized DiI-LDL by 6h, which increased after 24h. Scale bars = 100 μm (B) HLC were 
treated with LPDS media and Rosuvastatin for 48h followed by incubation in methyl--
cyclodextrin (MBC) for 45 minutes when time point 0h samples were collected. Cells were 
further incubated for 6h or 24h with unlabeled LDL then analyzed for cellular cholesterol 
concentration with respect to protein. NC-HLC showed no statistical difference in cellular 
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cholesterol for all three time points demonstrating the dysregulation of cholesterol 
metabolism in FH HLC. Corrected cells did not have statistically different cholesterol 
content after 6h demonstrating the effect of MBC treatment and plasma membrane 
cholesterol chelation on receptor-medicated endocytosis. After 24h exposure to LDL-C, 
receptor corrected HLC were able to increase cellular cholesterol to a statistically 
significant level (61 M/(g/L) compared to t0 11.6 M/(g/L). There was no 
difference in cholesterol concentration at t0 between NC- and C-HLC.  The graph values 
represent the mean  SEM (n = 3) per treatment, per cell type. Statistics were performed 




Distribution of LDLR in FH and LDLR Corrected HLC  
The normal LDLR is synthesized in the ER as a partially glycosylated precursor of 
120-kDa. Upon reaching the Golgi, N-and O-linked sugars are processed for a molecular 
weight of 160-kDa. This process is delayed or completely abolished in class II mutations, 
trapping the misfolded LDLR in the ER [92]. Previous work using fibroblasts containing 
the same homozygous 3 bp deletion in the LDLR as our patient FH cells were studied 
through electron microscopy to identify the distribution of the intracellular LDLR [118]. 
Unlike normal fibroblasts where most all LDLR was found in coated pits, the class II 
mutant cells had less than 5% of LDLR detectable on the cell surface, in coated pits or 
vesicles in the endocytic pathway. Instead, most of the class II LDLR was present in 
membrane extensions of the rough ER [118]. We sought to examine if NC-HLC retained 
the LDLR in the ER and if correction allowed proper movement of the LDLR to the 
membrane.  
Situated within the ER is calcium-binding Calnexin [313]. Calnexin interacts with 
newly synthesized proteins, acting to retain misfolded proteins in the ER [313]. Wheat 
germ agglutinin (WGA) is a lectin that binds to N-acetylglucosamine found in the plasma 
membrane of different cell types including hepatocytes [314, 315]. After differentiation, 
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HLC were treated overnight in LPDS and Rosuvastatin after which we examined protein 
localization using immunocytochemistry for Calnexin, LDLR, and WGA. Stacking of 
images into a 3D rendering presented the appearance of class II LDLR localizing with ER-
Calnexin in NC-HLC (Figure 22A). Using Fluoview Program software, images were 
further analyzed utilizing the colocalization processing tool to both visualize overlapping 
of images as well as quantification of overlap. In Figure 22B, a slice from a 3D stack is 
presented. To aid in visualization, for NC vs. C-HLC, we focused on two channels at a 
time and pseudo-colored Calnexin or WGA red so that colocalization with LDLR (Green) 
will display as yellow. NC-HLC detection of the class II LDLR shows a compact 
localization that when combined with Calnexin, illustrates colocalization in the ER (top 
row, left panel). When NC-HLC LDLR is combined with plasma membrane WGA (bottom 
row, left panel), no colocalization as represented by yellow is detected. In contrast, C-HLC 
present a smaller amount of merging of LDLR with ER-Calnexin (Figure 22B, top row, 
right panel) while demonstrating a significant colocalization of LDLR with WGA-plasma 
membrane (bottom row, right panel). Quantification of overlap confirmed NC-HLC have 
almost twice the amount of LDLR colocalizing to the ER-Calnexin (0.34) than WGA-
plasma membrane (0.16) and the difference was statistically significant by one-way 
ANOVA with Tukey post-hoc test (p < 0.05) (Figure 22C). In C-HLC, there was 
significant variability between samples and though a slight increase in WGA-plasma 
membrane and LDLR colocalization compared to ER-Calnexin was calculated, this was 
not significant (Figure 22C). This data confirms that NC-HLC retains the LDLR in the 
ER, but in spite of other evidence clearly demonstrating a function LDLR at the plasma 
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Figure 22. LDLR Colocalizes with Calnexin-ER in FH-HLC. (A) After differentiation, 
HLC were treated overnight in LPDS media supplemented with Rosuvastatin followed by 
ICC and confocal imaging, 100x oil immersion objective. AMIRA software was used to 
stack slices and merge channels to present an overview of localization of the LDLR (green) 
Calnexin-ER (red), WGA-plasma membrane (magenta), and nucleus (DAPI). (B) 
Fluoview software was used to visualize overlap between the LDLR-Calnexin-ER or 
LDLR-WGA-plasma membrane. The channel for WGA-plasma membrane was changed 
to red for visualization on overlap. Overlap is shown in yellow. NC-HLC appear to have a 
greater amount of yellow with the LDLR-Calnexin (left, top row) compared to LDLR-
WGA (left, bottom row). C-HLC appear to have an increase in colocalization of LDLR-
WGA (right, bottom row) compared to LDLR-Calnexin (right, top row). (C) Quantification 
of colocalization using Fluoview software indicated that NC-HLC did have a significantly 
greater colocalization of the LDLR with Calnexin than WGA. C-HLC showed a slight 
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increase in LDLR-WGA colocalization compared to LDLR-Calnexin though it was not 
significant. The graph values represent the overlap index  SEM (n = 5) per cell type. 
Statistics were performed using a one-way ANOVA Tukey post-hoc test. *p<0.05 of NC-
HLC LDLR-Calnexin to NC-HLC WGA, C-HLC WGA, and C-HLC Calnexin.  
 
 
Rosuvastatin Upregulates LDLR Transcript and Protein Levels in FH and Corrected Cells 
In our previously published work, we used Lovastatin in our studies and found that 
NC-iPSC expressed immature LDLR compared to C-iPSC that converted its protein to all 
mature LDLR [189]. We confirmed this once more in our iPSC cells after treatment with 
Lovastatin in LPDS media. Lovastatin did increase LDLR protein expression in all 3 cell 
types (Figure 23A), and the NC-iPSC presented both the mature and immature form of 
LDLR similar to control recombinant human LDLR (rhLDLR). Lovastatin inhibits HMG-
CoA reductase, preventing cholesterol synthesis leading to an upregulation of LDLR. In 
addition, Lovastatin has been cited to inhibit or modulate the 20 S proteasome pathway 
[316-318]. The LDLR receptor class II mutants have been reported to be degraded via the 
26 S proteasome-pathway [119]. To ensure the accumulation of immature LDLR that we 
observed was not due to effects on the proteasomal pathway, we opted to use a 
contemporary drug, Rosuvastatin.  
  To confirm the form of LDLR protein in NC, C, and control H1 stem cells, we 
treated the iPSC with Rosuvastatin or excess sterols in LPDS media overnight. Excess 
sterols act independently of the LDLR and enter the cell via pinocytosis to decrease LDLR 
expression. NC-iPSC demonstrated a major accumulation of the immature LDLR not seen 
in the C-iPSC or H1-ESC (Figure 23A), suggesting the CRISPR modification restored the 
normal LDLR structure allowing LDLR to proceed to the Golgi for processing and 
movement to the plasma membrane. Quantification and of total LDLR indicated a 
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significantly greater total LDLR in NC-iPSC than in C-iPSC and H1-ESC (Figure 23B). 
Two-way ANOVA with a Tukey post-hoc test determined significance of total LDLR in 
all 3 iPSC/ESC lines treated with Rosuvastatin compared to excess sterols (***p<0.001, 
**** p<0.0001) and NC-iPSC Rosuvastatin compared to C-iPSC and H1-ESC with 
Rosuvastatin (#p<0.001).  
We differentiated the iPSC/ESC to HLC, and after treatment with Rosuvastatin, we 
observed an induction of LDLR expression primarily in immature form in NC-HLC and 
very little mature LDLR (Figure 23C). C-HLC and H1-HLC expressed solely mature 
LDLR (Figure 23C). Excess sterols downregulated LDLR protein synthesis in all the cells 
as expected. Quantification and two-way ANOVA with a Tukey post-hoc test confirmed 
an upregulation of total LDLR protein mainly in NC-HLC compared to NC-HLC in excess 
sterols and H1-HLC in Rosuvastatin (**p<0.01, #p<0.01) (Figure 23D).  
To investigate if total LDLR protein and increase in immature LDLR (Figure 23B, 
D) was due to differential transcriptional regulation of the LDLR between NC and C cells 
in the presence of statins, qPCR analysis was used on both iPSC and HLC post-treatment 
with control carrier DMSO, Rosuvastatin, and excess sterols. For both iPSC and 
differentiated HLC, Rosuvastatin increased LDLR transcript levels across all the cell types 
compared to excess sterols or DMSO control (Figure 23E, F), which two-way ANOVA 
with a Tukey post-hoc test showed to be significant (**p<0.01, ****p<0.0001). However, 
there was no difference in transcript levels when comparing statin treatment across cell 
lines or differentiation state, which is to be expected with statin treatment. 
Taken together, this shows that both iPSC and HLC can be induced to express 
LDLR with statin treatment and while the NC generally has more total LDLR that 
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accumulates predominately in the ER, this is not due to any difference in transcription. 
This suggests the accumulating misfolded LDLR may be due to an issue with protein ER 
processing or degradation. 
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Figure 23. Rosuvastatin Increases Total LDLR Protein Levels and an Accumulation of 
Immature LDLR in NC-cells. (A) iPSC were treated overnight in LPDS media 
supplemented with either Lovastatin (Lova), Rosuvastatin (RS), or excess sterols (XS). 
Western blot analysis for LDLR shows NC-iPSC upregulate immature LDLR in Lovastatin 
while C-iPSC and H1-ESC express mature LDLR.  Rosuvastatin treatment shows the same 
response and LDLR is suppressed when exposed to sterols. Recombinant human LDLR 
protein (rhLDLR) was used as detection control. (B) Quantification of total LDLR 
demonstrated that statin-treated-NC-iPSC had a significantly greater total LDLR than C-
iPSC and H1-ESC treated with Rosuvastatin. All 3 statin-treated cell types were 
significantly greater compared to their excess sterol treated counterparts. (C) iPSC/ESC 
were differentiated to HLC. Under the same conditions of RS or XS treatment, NC-HLC 
express greater total LDLR, predominately as immature protein, that is converted to all 
mature in C-HLC and H1-HLC. LDLR levels decreased with sterols treatment. (D) 
Quantification of total LDLR presented a significant increase in total LDLR in statin-
treated-NC-HLC compared to its excess sterols. In addition, statin-treated-NC-HLC had a 
significantly larger amount of LDLR compared to statin-treated H1-HLC. (E) qPCR 
analysis of LDLR shows Rosuvastatin (RS) treatment significantly increases LDLR 
transcript levels statistically equivalently in NC-and C- iPSC like that of H1-ESC 
compared to DMSO (DM) control and excess sterol (XS) treatment. (F) Similarly, HLC 
showed consistent results with significantly upregulated LDLR mRNA levels with RS 
treatment and no difference between cell type. The graph values represent the mean  SEM 
(n = 3) per treatment, per cell type using a two-way ANOVA Tukey post-hoc test. 
**p<0.01, ***p<0.001, ****p<0.0001 #p<0.05 between RS-treated cell type 
 
Treatment of Cells with Rosuvastatin Does Not Induce ER Stress 
Two studies reported that class II LDLR mutants are retained in the ER causing ER 
stress and activating the UPR. Since statins cause an accumulation of immature protein in 
NC FH-iPSC and HLC, we investigated statin treatment induced ER stress in class II 
iPSC/HLC and if it was normalized in the corrected cells. ER chaperone Grp78 is a major 
factor involved in maintaining ER homeostasis. It is also the first component activated in 
the UPR. Little is known about the ER stress responses in iPSC or derived HLC, therefore, 
we used the ER stress inducer, tunicamycin as a positive control. Tunicamycin functions 
by inhibiting glycoprotein synthesis, inducing protein unfolding and activating the UPR. 
iPSC/HLC were treated with either Rosuvastatin, excess sterols, and control DMSO 
overnight or tunicamycin for 4.5 hours. We specifically looked at Grp78 mRNA transcript 
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levels since it has been documented that Grp78 mRNA levels increase quickly in responses 
to ER stress. In addition, in an overexpression class II LDLR mutant model, Grp78 mRNA 
and protein levels are upregulated [124, 125]. After treatment with Rosuvastatin, both iPSC 
and HLC did not produce any quantifiable increase in Grp78 expression in any of the cell 
types (Figure 24A, B). There was no difference in transcripts between statin treatment and 
control DMSO or excess sterols. However, tunicamycin significantly increased Grp78 
transcript levels across all cell types in both iPSC and HLC demonstrating that UPR 
pathways were capable of being activated (Figure 24A, B). Two-way ANOVA with a post-
hoc Tukey test confirmed a significant upregulation of Grp78 mRNA with tunicamycin 
treatment (***p<0.001, ****p<0.0001). 
X-box binding protein 1 (XBP1) is a transcription factor that becomes activated in 
response to accumulation of unfolded proteins [218]. The splicing of a 26-nucletoide intron 
from XBPI generates the transcription factor, spliced XBP1 (SXBP1) [213, 221, 223]. 
SXBP1 regulates UPR genes for folding, ERAD, autophagy, and organelle biogenesis 
[213, 224-226]. The SXBP1 isoform can be detected through PCR and after tunicamycin 
treatment, our cells exhibited the SXBP1 isoform (Figure 24C, D) in the iPSC/ESC or 
HLC. However, no XBP1 splicing was detected with any other treatment in the NC or C 
iPSC and HLC. Though H1 hESC did not show XPB1 splicing other than Tunicamycin, 
curiously H1 HLC had a basal level of SXBP1 which was statistically equivalent to 
Tunicamycin treatment. Quantification of SXBP1 to total XBP1 confirmed that 
Rosuvastatin treatment did not activate SXBP1 or the UPR in NC, C, or H1 cells (Figure 
24C, D). Two-way ANOVA with a Tukey post-hoc test showed that only tunicamycin 
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treatment significantly activated the splicing of XBP1 in all iPSC/ESC (****p<0.0001) 
(Figure 24C). No significance was found in HLC treated with tunicamycin.  
We further evaluated the activation of the UPR through western blot. During ER 
stress, ATF6 is cleaved and releases a 50-kDa fragment termed ATF6f that continues on to 
act as a transcription factor and upregulate expression of UPR genes involved in protein 
folding and degradation [221, 232]. CHOP is a protein downstream of the PERK pathway. 
Its activation signifies the cell’s response towards an apoptotic state due to an 
overwhelming amount of ER stress. We ran a western blot for ATF6, CHOP, and Grp78. 
Across all HLC, Rosuvastatin and excess sterol treatment did not change the levels of 
ATF6 (Figure 24E). HLC treated with tunicamycin had a decrease in expression of the 
ATF6 protein; however, we could not detect the ATF6f (Figure 24E). The expression 
pattern of decreased ATF6 with only tunicamycin was indicative that this was specific to 
some sort of stress response that was not present with statin or excess sterol treatment. 
CHOP was not present until HLC were treated with tunicamycin in NC, C, and H1 (Figure 
24E). Grp78 levels were upregulated in all HLC treated with tunicamycin (Figure 24E) 
correlating with qPCR data (Figure 24B). Altogether, this data shows that although FH 
NC and C cells as well as normal H1 controls can be induced to activate ER stress and 
UPR with Tunicamycin treatment, exposure to statins that cause downstream LDLR 










Figure 24. FH-NC Cells Do Not activate the UPR Following Rosuvastatin Treatment. 
Following treatment with either carrier DM, RS, XS, or tunicamycin (TM; 5 μg/mL for 4.5 
hours), cells were tested for ER stress and UPR markers at both mRNA and protein levels 
in iPSC/ESC and HLC. (A) qPCR analysis in iPSC indicated Grp78 mRNA levels do not 
change with RS treatment compared to DM/XS controls across the 3 cell groups. TM 
significantly increased Grp78 mRNA in NC-, C-, and H1 stem cells. (B) HLC presented 
the same trend with TM significantly upregulating Grp78 transcripts while RS did not. (C) 
PCR for spliced-XBP1 (SXBP1) visualized on a 2% agarose gel indicated TM treatment 
induced splicing of XBP1 that was not present in RS treated iPS/ES cells. Quantification 
of SXBP1/XBP1 shows significant SXBP1/XBP1 activation in TM-treated cells across all 
3 cell types. (D) HLC presented similarly to iPSC/ESC for SXBP1/XBP1. Quantification 
of SXBP1/XBP1 did not show any significance. (E) Western blot analysis showed a 
decrease in ATF6 levels in TM-treated HLC only while RS- and XS-treated HLC did not 
change. CHOP was expressed only in TM-expressed HLC. Grp78 protein levels were 
upregulated in TM-treated HLC while staying closer to basal level in RS-and-XS-treated 
HLC.  The graph values represent the mean  SEM (n = 3) per treatment, per cell type 
using a two-way ANOVA Tukey post-hoc test. ****p<0.0001 of TM-treatment to all other 




The novel and important findings of this study are that LDL-C internalization was 
restored in corrected hepatocyte-like cells and that statin did not induce ER stress in non-
corrected hepatocyte-like cells. This data provides proof of concept that these FH-corrected 
cells are functioning and could be useful in the future as models to compare mutant to 
corrected cellular response, drug testing or even cell-based therapy work. Overexpression 
studies have provided evidence that class II LDLR mutants activate the ER stress UPR 
pathway. Our model served as a tool to determine if a physiologically relevant statin-
induced LDLR expression would cause ER stress and if correction would alleviate the 
response. We did not observe ER stress.  
It has been hypothesized that class II mutations change the spacing between the 
highly conserved cysteine residues which interferes with disulfide bond formation and 
proper LDLR folding [92, 114, 122]. Retention of the class II mutant in the ER as an 
immature protein suggests it is a transport problem [122] or a protein folding disease [98]. 
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We demonstrated previously that modification of the genomic mutation permanently 
corrects the defect and allows for proper processing to the mature LDLR and receptor-
medicated endocytosis [189]. We also showed that statin treatment differentially caused 
accumulation of more total LDLR in the FH class II mutant (predominantly immature) 
compared to CRISPR corrected (predominantly mature) [189]. This led us to question why 
the mutant FH cells are retaining more total protein with statin treatment.   
Since most of our previous work was performed in cells in the pluripotent state, we 
initially investigated if receptor-medicated endocytosis was also normalized in 
differentiated HLC. A time course of internalization of DiI labeled LDL-C showed that 
even after 24h, very little DiI could be detected in the mutant HLC, while robust 
fluorescence is detected in the corrected HLC at both 6h and 24h. When cellular cholesterol 
is depleted by statin and methyl--cyclodextrin, even at 6h neither FH or corrected HLC 
showed a quantifiable change in cholesterol restoration. Even after 24h, no statistical 
change in cellular cholesterol was quantified in FH-HLC. However, in corrected HLC, 
between 6h to 24h, LDLR activity appears to have been sufficient to restore cellular 
cholesterol levels likely including within the plasma membrane [312, 319]. 
Since the class II LDLR mutant is misfolded, we next asked if we could detect a 
statin mediated accumulation of mutant LDLR in the ER that was resolved in the LDLR 
corrected cells. We observed NC-HLC LDLR colocalized with calnexin-ER (Figure 22). 
Previous work with Class II FH563 fibroblasts were also carefully studied through electron 
microscopy to identify the distribution of the intracellular LDLR [118]. Less than 5% of 
LDLR was detectable on the cell surface and in coated pits or vesicles in the endocytic 
pathway. Instead, most of the class II LDLR was present in membrane extensions of the 
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rough ER [118]. It is hypothesized that the extensions at which the mutant LDLR is 
localized is the site where the ER is blocking exit of the LDLR and appeared to be 
morphologically similar to the transitional zone of the ER implicated in transport of 
secretory proteins to the Golgi [118, 127]. This correlates with our observation in the 
internalization assays (Figure 21) in which very minimal LDL was internalized by the NC-
HLC. This small number may represent non-receptor mediated pathways of cholesterol 
internalization, such as pinocytosis, in addition to the receptor-mediated pathway resulting 
from the few functional, mature LDL receptors. 
One possibility for the accumulation of misfolded LDLR with statin treatment was 
the statin used. We originally used Lovastatin. Lovastatin was the first FDA approved statin 
drug and has since been found to also inhibit the proteasome, which is reported to be the 
mechanism of FH class II LDLR degradation [74, 316, 317]. However, this effect is only 
seen in the closed-ring -lactone-form and does not inhibit HMG-CoA reductase [317].  
When we compared the effect on mutant LDLR accumulation of Lovastatin to 
Rosuvastatin, we detected the same increase in total protein levels of LDLR in NC-cells as 
well as similar total mature protein between corrected LDLR and wild type control, which 
demonstrates that Lovastatin proteasome inhibition was not the culprit causing misfolded 
protein accumulation (Figure 23). The presence of immature LDLR in FH cells has been 
demonstrated in past studies [122]. A pulse-chase study comparing unaffected and class II 
FH fibroblasts (the same patient cell type we derived our iPSC from) found that normal 
fibroblasts’ LDLR had been transported to the Golgi for processing to the mature 160-kDa 
proteins. 95% of the class II LDLR remained as 120-kDa [122]. The accumulation of 
mutant LDLR compared to the corrected LDLR was not the result of differential 
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transcriptional control, which is what we expected since the cells were treated with statins 
to inhibit HMG-CoA reductase and upregulate LDLR. We also found that a similar 
accumulation of mutant LDLR occurs in FH-iPSC and differentiated FH-HLC, indicating 
mutant LDLR accumulation is a post-translational regulation mechanism. FH class II 
LDLR proteins are reported to be degraded by two mechanisms, 1) proteasome [119, 320] 
and 2) lysosome [7, 28, 321]. It is possible that one or both of these systems is overwhelmed 
by the statin mediated expression induction allowing misfolded protein to accumulate, but 
then one would expect this to cause ER stress and UPR induction [217, 231]. 
It has been demonstrated that ER chaperones retain misfolded class II LDLR in the 
ER. Two-class II mutant LDLRs, C646Y and W556S, were retained in the ER and bound 
to Grp78 when overexpressed in model Chang cells shown through mass spectrometry and 
western blot [125]. This was confirmed in CHO cells overexpressing another 2 class II 
LDLR mutations where there was prolonged binding of Grp78 to mutant LDLR [124]. In 
addition, ER stress activation in CHO overexpressing mutant G544V LDLR was observed. 
Spliced XBP1 mRNA was present in the Class II LDLR mutant and absent in 
overexpressed WT LDLR. Class II mutant LDLR overexpression resulted in a fold 
induction of phosphorylated-PERK [124]. In contrast, we did not observe an increase in 
Grp78 expression (Figure 24A, B) in NC-cells treated with Rosuvastatin. We did not detect 
ER stress activation after Rosuvastatin treatment either (Figure 24C, D, E). Our study 
specifically used iPSC and derived HLC rather than an overexpression model. It is possible 
that statins are causing a low-grade chronic ER stress that we were unable to detect. A 
study of liver samples from untreated patients with chronic hepatitis identified “ER-
stressed hepatocytes” in clusters scattered in the liver parenchyma [322]. These same 
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samples showed protein expression of ATF-6, IRE1, and PERK. However, qPCR of UPR-
genes did not show induction of ER stress; instead, genes involved in inflammation and 
apoptosis were significantly upregulated in these patient samples [322].  Another case 
study dissected whether liver hepatoxicity was due to statins or another cause [323].  
Prolonged latency was seen in patients taking Atorvastatin, Simvastatin, Fluvastatin, and 
Rosuvastatin, and they presented both hepatocellular and cholestatic patterns of liver 
injury. Many of these cases resolved after discontinuation of statins. It appeared that statin-
induced liver injury takes months to years to instigate [323]. It is possible that our cells are 
expressing ER stress through a non-canonical inflammatory response that we were unable 
to detect with our methods. 
Another chaperone that’s been implicated in binding and facilitating the proper 
folding and maturation of the LDLR is RAP [106]. Mesoderm D (MesD) has also been 
associated in binding LDL-like receptor proteins [98, 110]. Using this NC and C-HLC 
model could connect whether or not RAP or MesD are involved in retaining or transporting 
class II LDLR mutants into or out of the ER. It could also be interesting to investigate if 
the accumulation of the immature LDLR has an effect on MesD and LDL-like receptor 
protein interactions and regulation.  
It is known that the UPR’s purpose is not only to increase folding capacity of the 
ER, but to also eliminate misfolded proteins by ERAD [324]. The proteasomal degradation 
pathway also plays a significant role in the degradation of class II LDLR mutants [119]. 
The 26 S proteasome is the main protein involved in the ERAD pathway of the cell and 
degrades misfolded proteins translocated from the ER. Class II LDLR proteins 
overexpressed in CHO cells were degraded through the 26 S proteasome and MG132 
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inhibited LDLR degradation [119].  We observed both accumulation of immature LDLR 
(Figure 23) and no UPR activation (Figure 24). It is possible that degradation is occurring, 
rather slowly, yet, quickly enough to avoid wholesale UPR. It is also possible the 
proteasome is not involved in what we are observing. Studies using MG132 proteasome 
inhibitor can help begin answering these questions.   
Our study currently has several limitations. First, differentiation of cells to HLC 
must be modified to have a monoculture of hepatocytes. Our cells appear to still be a 
mixture of hepatoblast and hepatocyte, which may answer for the variation in experiments. 
In addition, our ER stress data must be extended with protein analysis via western blot to 
assess inflammatory UPR elements like phosphorylated-JNK. Finally, more functional 
studies for restoration of cholesterol metabolism should be assessed including HMG-CoA 
reductase activity. To conclude, this data validates that an FH-corrected cell line can 
physiologically mediate LDLR endocytosis and presents a suitable model to study class II 
LDLR. In addition, we have determined that the UPR is not activated in a physiological 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
 In this project, we proposed to correct a class II LDLR mutation and follow with 
further modifying the LDLR and finally create a pre-vascularized liver organoid for 
implanting these cells. Instead, we were able to create a familial hypercholesterolemia 
model of non-corrected class II LDLR and corrected LDLR to study cholesterol 
metabolism and investigate statin-induced immature LDLR accumulation effect on the 
cell’s ER stress system.  
 We were able to use the CRISPR/Cas9 tool to target a 3-nucleotide deletion in 
exon 4 of the LDLR of a homozygous patient-derived iPSC. We analyzed LDLR protein 
levels at the iPSC and HLC level and found a mature LDLR expressed and at lower 
levels than NC-cells. LDLR-mediated cholesterol internalization was restored in C-HLC 
as was localization of the LDLR at the plasma membrane. These data provide proof of 
concept that these FH-corrected cells are functioning and could be useful in the future for 
cell-based therapy work. 
 We also are optimizing differentiation of these cells to HLC. There is currently an 
array of protocols for differentiation of iPSC/ESC to HLC. However, there is no 
universal standard set because each lab has taken note that what differentiation works for 
their cells may not work as well in another lab’s cells. Efficiency of differentiation can be 
severely affected by the quality of growth factors and reagents 
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used, the type of plastic plate and the amount of cells plated, and the confluence of the 
cells prior to passaging  [290]. Additionally, the growth factors concentration can be 
variable, as well as species specific. Mouse hepatocyte growth factor is active in mouse 
cells but not human cells, but human hepatocyte growth factor works well in both human 
and mouse cells. We are currently in the process of creating a protocol to achieve a high 
percentage of mature hepatocytes for our studies and definitive endoderm is the primary 
stage of differentiation. We have observed that both mouse and human Wnt3a are active 
in our culture for differentiation to definitive endoderm with high expression of Sox17 
and HNF4a. Further studies are necessary to verify these results.  
 We also investigated the role of ER stress in the non-corrected and corrected FH 
cell lines. We hypothesized that when treated with statins ER stress would be activated in 
class II LDLR mutant, but not in mutation corrected FH cells. Overexpression studies 
have provided evidence that class II LDLR mutants activate the ER stress UPR pathway. 
Our model served as a tool to determine if a physiologically relevant statin-induced 
LDLR expression would cause ER stress and if correction would alleviate the response. 
We could not detect ER stress in the statin treated cells.  
Our findings have resulted in many more questions to answer. To begin with, we 
observed an accumulation of immature LDLR in NC-cells that was not correlative with a 
greater increase in LDLR transcript levels. Regulation of the cholesterol-LDLR feedback 
loop is modulated by a set of membrane bound transcription factors called sterol 
regulatory element binding proteins (SREBPs) [325].  A study using homozygous class II 
LDLR FH patient fibroblast cells found that the SREBP-2 induced de novo cholesterol 
synthesis and upregulation of scavenger receptor class B type I (SR-BI) for cholesterol 
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uptake [325]. SREBP also plays a role in intracellular lipid accumulation during ER 
stress [326]. SREBP is usually retained in the ER by Insig. However, during ER stress, 
Insig translation rapidly declines allowing SREBP to escape the ER and activate 
transcription of genes for lipid synthesis and uptake. We did not check the expression of 
SREBP or its associated genes. In addition, changes could be occurring at the epigenetic 
level. It would be interesting to evaluate through microarray which genes are up or 
downregulated in an FH and corrected HLC cell line. This could be followed with a 
CHIP assay to determine if SREBPs interaction with LDLR promoter is modified.   
  Statins are the most prescribed medication worldwide. Many studies have 
evaluated the risks associated with short-and-long term use of the drug. Generally, statins 
are well-tolerated. However, up to 15% of patients develop adverse effects to statins, 
including myalgia. Even scarcer are reports of stain induced liver injury. A case study 
dissected whether liver hepatoxicity was due to statins or another cause [323].  Prolonged 
latency was seen in patients taking Atorvastatin, Simvastatin, Fluvastatin, and 
Rosuvastatin, and they presented both hepatocellular and cholestatic patterns of liver 
injury. Many of these cases resolved after discontinuation of statins. One patient who 
died also had pre-existing alcoholic cirrhosis. Another patient who had restarted on 
statins rapidly redeveloped acute injury. It also appears that statin-induced liver injury 
takes months to years to instigate [323]. HoFH patients can begin treatment on statins as 
young as 6 years old. Can a patient with a liver disease like FH be more susceptible to 
statin-induced liver injury and not know it until it has become severe? 
Statins are classified category X, meaning the drug should not be taken during 
pregnancy [327, 328] because of studies that have shown problems in the fetus of animals 
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or pregnant women who mistakenly took the medication without being aware of their 
pregnancy. Human iPSC/ESC are useful tools in studying early human development and 
could be a useful source to determine what, if any, effects occur with statin exposure in 
NC versus C-iPSC. A study treating iPSC long and short-term with statins before forming 
them into embryoid bodies could reveal an array of information on which genes are 
changed because of treatment.  
To conclude, we have established a cell line model to study class II LDLR 
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